



אוניברסיטת בן-גוריון בנגב
Ben-Gurion University of the Negev

מדינת ישראל • משרד הבריאות

BARZILAI
MEDICAL
CENTER
ASHKELON



המרכז
הרפואי
ברזילי
אשקלון

www.barzilaimc.org.il

ברזילאי - למען קטן ביופון הבא


BARZILAI MEDICAL CENTER
FACULTY OF HEALTH SCIENCES
BEN-GURION UNIVERSITY OF THE NEGEV

RESEARCH & PUBLICATIONS

2005-2010

SHIMON SCHARF, MD, MPH

GILLES LUGASSY, MD



Dear Colleagues,

I am happy to present you to the second edition of the Barzilai Medical Center Research & Publications Report.

This Research directory summarizes information on the activities in basic and clinical sciences at Barzilai Medical Center Between 2005-2010.

As an academic institution whose departments are affiliated with the Faculty of Health Sciences at Ben Gurion University of the Negev, we feel an acute responsibility to constantly advance research studies, both on the basic and clinical levels.

This report stands witness to the varied and intense academic efforts of our staff and picture the high quality and breadth of scientific research. Those keep Barzilai at the forefront of medical science.

Recognizing the many hours that were required to make this possible, I wish to thank the entire Barzilai Medical Center community for the effort they have invested in producing the studies found within this book. A particular expression of gratitude is due to Ms. Ornit Cohen and Professor Gilles Lugassy who are most responsible for the notion and edit of this text.

I hope this report will strengthen cooperation among research staff, and develop further collaboration with others from Israel and abroad. I believe research is a significant component of our mandate and we are therefore committed not to rest on these already impressive accomplishments.

Dr Shimon Scharf. MD, MPH.

C.E.O and Medical Director

Barzilai Medical Center



Executive Summary

The Barzilai Medical Center (BMC) was established in 1961 and it is the only hospital in the Lachish region, located in the city of Ashkelon 35 miles south of Tel-Aviv and only six miles from the boarder of Gaza. It has the major task of serving the 500,000 inhabitants of the area including a substantial number of immigrants who came to Israel in the past 15 years from the former USSR and from Ethiopia.

In case of a major confrontation, Barzilai is now a Front Line Hospital as well, equipped with its own helicopter landing pad.

A 500 bed licensed medical center, Barzilai provides high quality, cost sensitive advanced health services to 100000 residents in an area of 502 sq miles.

Concern academic prosperities, BMC have its own School of Nursing and is a teaching hospital affiliated with the Ben Gurion University of the Negev approved by the Israeli Medical Council for full residency program.

The hospital treated several thousand patients with Acute and Post Traumatic Stress Disorders and Stress Diseases as well as over 500 physically injured as results of over 7000 rockets missiles fired directly into our area.

Our Emergency Department is receiving over 100,000 admissions in a year using the same infrastructure as it did 50 years ago before the amount of the population grew.

However, it is important for me to emphasize that Barzilai continues to maintain its regular policy in spite of the fact that the hospital is under constant threat. Our center continues to accept ill Arabs from within the Palestinian Authority. Whether for the treatment of illnesses or intervention for injuries incurred while fighting Hamas or from Palestinian missile aggression we continue to provide high level health services to those who need us on both sides of our border.

The hospital services and capabilities remain the same straining under the rapidly growing demand in times of routine and events of mess casualties.

FOREWORD

The Barzilai Medical Center/Campus is proud to publish the Second Research and Publication Issue, for the period 2005-2010.

In terms of academic and research activities, the BMC has demonstrated a constant progression over the years: basic scientific research has become an important part of the Center's efforts, while clinical studies, both local and multicenters, have grown to above 100 new proposals a year.

This publication is the witness of the impressive accomplishments by the Medical Departments of the Barzilai Medical Center/Campus, and of their excellency.

Prof Gilles Lugassy, MD

Chairman, Division of Hematology

Chairman, Helsinki Committee



Table of Contents

Administration

Assistant Director General	<i>Dr Emile Hay</i>1-2
Regional Health Research Unit	<i>Dr Michael Gdalevich</i>3-10

Institutes

Nephrology and Hypertension	<i>Prof Yoram Yagil</i>12-25
Hematology	<i>Prof Gilles Lugassy</i>26-30
Oncology	<i>Dr Frida Barak</i>31-38
Rheumatology	<i>Dr Tatiana Reitblat</i>39-41
Gastroenterology & Hepatology	<i>Dr Jorge- Shmuel Delgado</i>42-46
Pulmonology	<i>Dr Zeev Weiler</i>47-51
The Israeli Forum	
Prevention of Cardiovascular Disease	<i>Prof J. Reuven Viskoper</i>52-55

Departments

Psychiatry	<i>Prof Gabriel Schreiber</i>57-62
Neurology	<i>Dr Ron Milo</i>63-81
Cardiology	<i>Prof Amos Katz</i>82-109
Medicine C	<i>Dr Dov Gefel</i>110-111
Obstetrics and Gynecology	<i>Prof Eyal Anteby</i>112-123
In Vitro Fertilization	<i>Prof Raoul Orvieto</i>124-137
Pediatric	<i>Prof Haim Bibi</i>138-145
Pediatric Dentistry	<i>Dr Uri Zilberman</i>146-151
General and Vascular Surgery	<i>Prof Boris Yoffe</i>152-157
Urology	<i>Dr Shmuel Cytron</i>158-164
Ophthalmology	<i>Prof Shmuel Levartovsky</i>165-181
Pharmacy Services	<i>Mgr Ahuva Lustig</i>182- 186
Allergy & Clinical Immunology	<i>Dr Eli Magen</i>187-191

Emile Hay, MD

Assistant Director General

Emergency and Internal Medicine

Barzilai Medical Center

תמונת איש



תמונת איש

Emile Hay, MD

Lecturer of Medicine Ben-Gurion University

emileh@barzi.health.gov.il

List of Publications

1. **Hay E**, Boksenbojm P, Peer BarYosef E: Errors, Patient Safety and Risk Management in Emergency Medicine. Israeli Journal of Emergency Medicine 2005; 5(4):65-68.
2. Zamir D, Weiler Z, Kogan Y, Ben-Valid E, **Hay E**, Reitblat T, Polychuck I: Single dose quinolone treatment in acute gastroenteritis. J Clin Gastroenterol. 2006 Mar; 40(3):186-90.
3. **Hay E**, Boksenbojm P, and Peer BarYosef E: Errors, Patient Safety and Risk Management in Emergency Medicine: Wrong drug delivery. Israeli Journal of Emergency Medicine 2006; 6(1):67-71.

4. **Hay E**, Boksenbojm P, Peer BarYosef E: Patient safety bulletin. Suppl. Israeli Journal of Emergency Medicine 2006; 6(1):72.
5. **Hay E**, Boksenbojm P, and Peer BarYosef E: Errors, Patient Safety and Risk Management in Emergency Medicine: Fleet enema in the renal patient: Case report. Israeli Journal of Emergency Medicine 2006; 6(2):49-51.
6. **Hay E**, Boksenbojm P, Peer BarYosef E: Patient safety bulletin. Suppl. Israeli Journal of Emergency Medicine 2006; 6(2):51.
7. Blaer Y, Shlykhover V, Gabzo R, **Hay E**, Katz A: Unusual hazard of outdoor CPR on a very hot day. Resuscitation 2008; 77:293. (Case report)
8. **Hay E**, Blaer Y, Katz A, Jafari J: Acute transient phlebitis during eptifibatide intravenous injection. Heart and Lung 2010; 39(3):235-236.

Active Participation in Scientific Meetings

1. **Hay E**, Boksenbojm P, Peer BarYosef E: Event report, quality control and risk management software. The 17th Annual National Forum on Quality Improvement in Healthcare, Orlando, USA, December 2005.
2. **Hay E**, Boksenbojm P, Peer BarYosef E: The use of Microsoft Access software as a database of event reports, risk management and quality control. The 13 Annual Conference of the Israeli Association for Quality in Medicine, Tel-Aviv, Israel June 2006.
3. **Hay E**, Peer BarYosef E, Cohen T: Gentamicin overdose in a two weeks old infant. The 2nd International Patient Safety Congress, Antalya, Turkey, March 2008.
4. **Hay E**, Peer BarYosef E, Cohen T: Promethazine and papaverine ampoules: Look alike but differ in action. The 2nd International Patient Safety Congress, Antalya, Turkey, March 2008.

BARZILAI MEDICAL CENTER

RESEARCH INSTITUTE



Director, BMC Research Institute

Regional Health Officer, Ashkelon District Health Office

Dr Michael Gdalevich, MD, MPH

Senior Lecturer, Department of Epidemiology, Ben-Gurion University.

michaelg@barzi.health.gov.il

Research Team

Michael Hartal (Huerta), MD, MPH

Senior Lecturer

Department of Epidemiology

Ben-Gurion University

Description

Main goals

- Support for BMC staff – research methodology and analysis
- Study of air pollution associated health effects.
- Application of diverse research/study methodology in a range of topics within the fields of epidemiology, preventive medicine and public health.

Up to date, the research led by Dr Gdalevich has dealt with the study of the epidemiology of infectious diseases, sero-epidemiology, vaccine-preventable diseases and the study of health behaviors of children, adolescents and young adults. Methodology that was applied in research projects included case-reports,

reviews, cross-sectional studies, simple and nested case-control studies, survival analyses, cohort studies, clinical trials, and meta-analytic systematic reviews. The work has involved collection of original data, as well as analysis of existing databases, either as a primary investigator or the epidemiology/research methodology advisor for other researchers.

During the last five years Dr Gdalevich and Dr Hartal begun to investigate the area of environmental epidemiology and environmental health. The main item of their interest is the study of the health effect of air pollution in Israel, where the subject has not been approached systematically, yet claims more and more of both the public's and the decision makers' attention.

Ongoing research projects in this field include:

- Pollutant dispersal mapping
- Dispersal model validation
- Historical-cohort studies of the association between pollutant exposure and community- and hospital-oriented health outcomes among children, adolescents and adults.

Michael Gdalevich, MD, MPH

*Regional Health Officer, Ashkelon District Health Office
Minister of Health
BMC Research institute*

תמונתו



תמונתו

List of Publications

A - Original Articles

1. Hodak E, Klein T, Gabay B, Ben-Amitai D, Bergman R, **Gdalevich M**, Feinmesser M, Maron L, David M. Familial mycosis fungoides: report of 6 kindred's and a study of the HLA system. J. Am Acad Dermaotol 2005 Mar; 52 (3 Pt 1):393-402
2. Gemer O, Lurian M, **Gdalevich M**, Kapustian V, Piura E, Schneider D, Lavie O, Levy T, Fishman A, Dgani R, Levavi H, Beller U. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol. 2005; 31(9):1006-10
3. Huerta M, Scharf S, Haviv J, Bibi H, **Gdalevich M**. Parental smoking and education as determinants of overweight and obesity in Israeli schoolchildren. Prev Chronic Dis 2006; 3(2):A48
4. Huerta M, **Gdalevich M**, Haviv J, Bibi H, Scharf S. Ten-year trends in obesity among Israeli schoolchildren: 1990-2000. Acta Paediatr 2006; 95(4):444-9

5. Huerta M, **Gdalevich M**, Telshadze A, Scharf S, Schlezinger M, Efrati O, Bibi H. Appropriateness of US and international BMI-for-age reference curves in defining adiposity among Israeli school children. *Eur J Pediatrics* 2007; 166(6):573-8.
6. Gemer O, Ben Arie A, Levy T, **Gdalevich M**, Lorian M, Barak F, Anteby E, Lavie O. Lymphovascular space involvement compromises the survival of patients with stage I endometrial cancer: Results of a multicenter study. *Eur J Surg Oncol.* 2007; 33(5):644-7.
7. Katz LH, Zelazny A, Scharf S, Hourvitz A, Asor N, Arbeli Y, Yust-Katz S, Smollan-Fredman G, **Gdalevich M**. Mass antibiotic treatment to stop an outbreak of meningococcal disease: a molecular analysis. *Clin Microbiol Infect.* 2007;13(9):943-6
8. Lavie O, Uriev L, **Gdalevich M**, Barak F, Peer G, Auslender R, Anteby E, Gemer O. The outcome of patients with stage I endometrial cancer involving the lower uterine segment. *Int J Gynecol Cancer.* 2007
9. Mimouni D, Bar H, **Gdalevich M**, Katzenelson V, David M. Pemphigus – analysis of epidemiological factors in 155 patients. *Journal of the European Academy of Dermatology and Venereology.* 2008;22:1232-5.
10. Gemer O, Uriev L, Voldarsky M, **Gdalevich M**, Ben-Dor D, Barak F, Anteby E, Lavie O. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. *European Journal of Surgical Oncology.* 2009;35:247-51
11. Gemer O, **Gdalevich M**, Voldarsky M, Barak F, Ben Arie A, Schneider D, Levy T, Anteby EY, Lavie O. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometrioid endometrial cancer: results of a multicenter study. *European Journal of Surgical Oncology.* 2009;35:865-9.
12. Gemer O, **Gdalevich M**, Ravid M, Piura B, Rabinovich A, Gasper T, Khashper A, Voldarsky M, Linov L, Ben Shachar I, Anteby EY, Lavie O. A multicenter validation of computerized tomography models as predictors of non- optimal primary cytoreduction of advanced epithelial ovarian cancer. *European Journal of Surgical Oncology.* 2009;35:1109-12.

13. 47. Anteby EY, Kruchkovich J, Kapustian V, **Gdalevich M**, Shenhav S, Gemer O. Short-term effects of closure versus non-closure of the visceral and parietal peritoneum at cesarean section: A prospective randomized study. *J Obstet Gynaecol Res.* 2009; 35:1026-30.
14. Huerta M, Zarka S, Bibi H, Haviv J, Scharf S, **Gdalevich M**. Validity of childhood adiposity classification in predicting adolescent overweight and obesity. *International Journal of Pediatric Obesity.* 2010;5:250-5.
15. Mimouni D, Bar H, **Gdalevich M**, Katzenelson V, David M. Pemphigus, analysis of 155 patients. *J Eur Acad Dermatol Venereol.* 2010;24:947-52.

B – Review

1. Marva E, Markovics A, **Gdalevich M**, Asor N, Sadik C, Leventhal A. Trichinellosis outbreak. *Emerg Infect Dis.* 2005 Dec;11(12):1979-81

Active Participation in Scientific Meetings

1. Huerta M, **Gdalevich M**, Haviv J, Bibi H, Scharf S. Ten-year trends in obesity among Israeli schoolchildren: 1990-2000. American Public Health Association 133rd Annual Meeting, Philadelphia, Pennsylvania, December 10-14, 2005
2. Huerta M, **Gdalevich M**, Haviv J, Bibi H, Scharf S. Ten-year trends in obesity among Israeli schoolchildren: 1990-2000. American Public Health Association 133rd Annual Meeting & Exposition, Philadelphia, Pennsylvania, December 10-14, 2005.
3. **Huerta M**, Haviv J, Bibi H, Scharf S, **Gdalevich M**. Socioeconomic determinants of overweight and obesity among Israeli schoolchildren. American Public Health Association 133rd Annual Meeting & Exposition, Philadelphia, Pennsylvania, December 10-14, 2005.
4. Huerta M, **Gdalevich M**, Scharf S, Haviv J, Bibi H. Research methods in the study of health effects of air pollution in the Ashkelon District. Annual Conference of the Israel Center for Disease Control, Tel Hashomer, December 22, 2005.
5. Huerta M, Bibi H, Haviv J, Scharf S, **Gdalevich M**. Socioeconomic determinants of overweight and obesity among Israeli schoolchildren. Annual Scientific Conference of the Association of Public Health Physicians in Israel. Haifa, January 5-6, 2006.

6. Huerta M, Tlachadze A, **Gdalevich M**, Scharf S, Schlesinger M, Bibi H. BMI-for-age reference curves for elementary schoolchildren in the Ashkelon District of Israel. Annual Scientific Conference of the Association of Public Health Physicians in Israel. Haifa, January 5-6, 2006.
7. Huerta M, Bibi H, Haviv J, Scharf S, **Gdalevich M**. Parental smoking, education and socioeconomic status and the risk of childhood overweight. Annual Conference of the Israeli Ambulatory Pediatric Association. Tel Aviv, June 7, 2006.
8. Huerta M, **Gdalevich M**, Haviv J, Bibi H, Scharf S. Ten-year trends in obesity among Israeli schoolchildren: 1990-2000. Annual Conference of the Israeli Ambulatory Pediatric Association. Tel Aviv, June 7, 2006.
9. Huerta M, Tlachadze A, **Gdalevich M**, Scharf S, Schlesinger M, Efrati O, Bibi H. Appropriateness of US and international BMI-for-age reference curves in defining adiposity among Israeli schoolchildren. Annual Conference of the Israeli Ambulatory Pediatric Association. Tel Aviv, June 7, 2006.
10. N. Asur, Y. Arbeli, M. Huerta, S. Scharf, **M. Gdalevich**. Epidemic rash after exposure to dicyclohexylmethane-4, 4'-diisocyanate during an art class. Poster presentation at the 11th scientific seminar, European Programme for Intervention Epidemiology Training, Mao, Menorca, Spain, 12-14 October 2006
11. Huerta M, Zarka S, Bibi H, Haviv J, Scharf S, **Gdalevich M**. Validity of childhood BMI in predicting adolescent overweight and obesity. American Public Health Association 134th Annual Meeting & Exposition, Philadelphia, Pennsylvania, November 4-8, 2006.
12. Huerta M, Bibi H, Haviv J, Scharf S, **Gdalevich M**. Short-term effects of ambient nitrogen oxides on emergency department cardiac patient load. American Public Health Association 134th Annual Meeting & Exposition, Philadelphia, Pennsylvania, November 4-8, 2006.
13. **Gdalevich M**, Huerta M, Leventhal A, Arbeli Y, Scharf S. Israeli disengagement from Gaza and public health: one year after. American Public Health Association 134th Annual Meeting & Exposition, Philadelphia, Pennsylvania, November 4-8, 2006.
14. Gemer O, Kruchkovich, J Kapustian V, **Gdalevich M**, Shenhav S, Volach V, Anteby E. Short term affects of peritoneal closure at cesarean: A randomized controlled study. 27th annual meeting of the society for maternal fetal medicine. San Francisco USA, 2007.
15. **M Gdalevich**, D Broday, R Bassal, H Bibi, Scharf S, M Huerta. Acute cardio-respiratory effects of SO₂ and NO₂ exposure in southern Israel. American Public Health Association 135th Annual Meeting & Exposition, Washington, DC, November 3-7, 2007.
16. **M Gdalevich**, R Lobel, Scharf S, M Huerta. Treatment of Palestinian patients in an Israeli hospital: No prejudice, no politics. American Public Health Association 135th Annual Meeting & Exposition, Washington, DC, November 3-7, 2007.

17. **M Gdalevich**, D Broday, Yuval, Scharf S, M Huerta. Designing a methodology to measure the health effects of air pollution in Southern Israel: estimation of attributable morbidity, mortality and healthcare consumption. International society for environmental epidemiology & International society of exposure analysis, 2008 Joint Annual Conference, Pasadena, California, USA, October 12-16, 2008.
18. **M Gdalevich**, D Broday, Yuval, H Bibi, Scharf S, M Huerta. Acute cardio-respiratory effects of SO₂ and NO₂ exposure in southern Israel – a case-control design for data collection and analysis. Poster presentation. International society for environmental epidemiology & International society of exposure analysis, 2008 Joint Annual Conference, Pasadena, California, USA, October 12-16, 2008.
19. **M Gdalevich**, Nissan E, Kordova-Biezuner L,† Itamar Grotto, Yuval, Scharf S, M Huerta. Measuring the acute health effects of dust storms: a matched analysis. Poster presentation. International society for environmental epidemiology, 2009 Annual Conference, Dublin, Ireland, August 25-29, 2009.
20. **M Gdalevich**, D Broday, Yuval, Scharf S, H Bibi, M Huerta. Air pollution and community health: acute cardio-respiratory events attributable to SO₂ and NO₂ exposure. International society for environmental epidemiology, 2009 Annual Conference, Dublin, Ireland, August 25-29, 2009.
21. **M Gdalevich**, Nissan E, Kordova-Biezuner L, Itamar Grotto, Yuval, Scharf S, M Huerta. Measuring the acute health effects of dust storms: a matched analysis. International Symposium on Stochastic Models in Reliability Engineering, Life Science and Operations Management, Beer Sheva, Israel, February 8-11, 2010.
22. **M Gdalevich**, D Broday, Yuval, Scharf S, H Bibi, M Huerta. Air pollution and community health: acute cardio-respiratory events attributable to SO₂ and NO₂ exposure. International Symposium on Stochastic Models in Reliability Engineering, Life Science and Operations Management, Beer Sheva, Israel, February 8-11, 2010.

Competitive and Non- Competitive Research Grants

- | | |
|------|---|
| 2007 | Association of Towns for Environmental Protection, 600,000 NIS
Gdalevich M (PI), Huerta M (PI), Bibi H, Scharf S
Measuring the effects of air pollution from the Rotenberg power plant on the morbidity, mortality and healthcare consumption of the population in the Ashkelon region. |
| 2008 | National Institute for Health Policy Research, 168,000 NIS / 1 year
Gdalevich M (PI), Huerta M (PI), Bibi H, Scharf S, Levin H
Health effects of air pollution in the Ashkelon District – Analysis of costs |
| 2008 | Ministry of Environmental Protection, 381,000 NIS / 3 years
Gdalevich M (PI), Huerta M (PI), Broday D, Bibi H, Scharf S
Air Pollution acute health effects in Ashdod population – a quantitative analysis |

Current clinical studies

In progress

1. Side effects of Human Rabies Immune Globulin administration. Partners: Hay E, Scharf S.
2. Prediction of BMI at young adulthood by BMI measurements at primary school. Huerta M, Bibi H, Haviv J, Scharf S
3. Epidemiology of pemphigus in Israel. Partners: Partners: Mimouni D, David M.
4. Geo-meteorological air pollutant mapping and validation in the Ashkelon District. Partners: Huerta M, Bibi H, Haviv J, Scharf S, Dubnov J, Barchana M, Kordova L, Yuval, Broday D.
5. Effects of air pollution on the morbidity, mortality and healthcare consumption of the population of southern Israel. Partners: Huerta M, Bibi H, Haviv J, Yuval, Broday, Scharf S.
6. Treatment of Palestinian patients in Israeli hospital- epidemiological characteristics Partners: Lobel R, Huerta M, Scharf S.

Institutes

DEPARTMENT OF

NEPHROLOGY & HYPERTENSION

מרכז הרפואי

Head of Department

Prof Yoram Yagil, MD

Professor of Medicine Ben-Gurion University

yoramy@barzi.health.gov.il ; labmomed@bgu.ac.il

Clinical Staff

- | | |
|--------------------------|---|
| ▪ Rosa Schneider, MD | Head, Outpatient Dialysis Unit
& Deputy Head of Department
<i>Lecturer in Medicine, Ben-Gurion University</i> |
| ▪ Luiz Griffel, MD | Head, Inpatient Consult Service
<i>Instructor in Medicine, Ben-Gurion University</i> |
| ▪ Marina Sapojnikov, MD | Head, Peritoneal Dialysis Unit
<i>Lecturer in Medicine, Ben-Gurion University</i> |
| ▪ Alexander Wechsler, MD | Head, Inpatient Unit and Outpatient Clinic
<i>Instructor in Medicine, Ben-Gurion University</i> |
| ▪ Larissa Lebedev, MD | Head, Intensive Care Dialysis Unit
<i>Instructor in Medicine, Ben-Gurion University</i> |

Research Staff

Clinical Research

- | | |
|-----------------------|-------------------------------|
| ▪ Daniel Pinhas, B.Sc | Clinical Research Coordinator |
| ▪ Zoya Goldberg, B.Sc | Clinical Research Coordinator |

Basic Research

- Chana Yagil, D.M.D, M.Sc Head, Laboratory of Molecular Medicine
Head, Israeli Rat Genome Center
Professor of Molecular Genetics Ben-Gurion University

- Marina Grinyok, M.Sc Research Associate

- Svetlana Rosenblum, M.Sc Research Associate

- Gurion Katni, M.Sc Research Associate

- Ira Agranovitz Supervisor, Animal Facility

Yoram Yagil, MD

Department of Nephrology & Hypertension

ନିରନ୍ତରତା



ନିରନ୍ତରତା

Research Activities

Clinical Research

- Active participation in multiple multinational multicenter studies

Basic Research

- Genomic investigation of the pathophysiology of salt-sensitive hypertension in the Sabra rat model of glomerulosclerosis
- Genomic investigation of the pathophysiology of proteinuria in the Sabra rat model of glomerulosclerosis
- Genomic investigation of the pathophysiology of diet-induced type 2 diabetes in the Cohen Diabetic rat
- Genomic investigation of the pathophysiology underlying diabetic nephropathy in the Cohen Diabetic rat model
- Generation of consomic and congenic strains for hypertension, proteinuria and diabetes-related quantitative trait loci
- Investigation of the role of ACE2 in an experimental rodent model of pre-eclampsia

List of Publications

Refereed articles in scientific journals (2006-2011)

A- Original Articles

1. **Yagil Y**, M. Hessner, Schulz H, Gosele C, Lebedev L, Barkalifa R, Sapojnikov M, Hubner N, Yagil C. "Geno-transcriptomic dissection of proteinuria in the uninephrectomized rat uncovers a molecular complexity with sexual dimorphism." *Physiol Genomics* 42 (4): 301-16, 2010.
2. Barkalifa R, **Yagil Y**, Yagil C. "Sex-specific genetic dissection of diabetes in a rodent model identifies Ica1 and Ndufa4 as major candidate genes." *Physiol Genomics* 42(3): 445-55, 2010.
3. Mazor R, O Itzhaki, Sela S, **Yagil Y**, Cohen-Mazor M, Yagil C and Kristal B.I. "Tumor necrosis factor-alpha: a possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension." *Hypertension* 55(2): 353-62, 2010.
4. **Yagil Y** and Yagil C. "Genomic research in rat models of kidney disease." *Methods Mol Biol* 597: 427-44, 2010.
5. Levy A, **Yagil Y**, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. *Am J Physiol Regul Integr Comp Physiol* 295(6): R1953-61, 2008
6. Landau D, Chayat C, Zucker N, Golomb E, Yagil C, **Yagil Y**, Segev Y. Early blood pressure independent cardiac changes in diabetic rats. *J Endocrinol* 197: 75-83, 2008
7. Weksler-Zangen S, Raz I, Lenzen S, Jorns A, Ehrenfeld S, Amir G, Oprescu A, **Yagil Y**, Yagil C, Zangen D.H, Kaiser N. Impaired glucose stimulated insulin secretion in exocrine pancreatic lesions in the Cohen diabetic rat. *Diabetes* 57: 279-287, 2008.
8. Mazor R, Kristal B, Cohen-Mazor M, Yagil C, **Yagil, Y.** and Sela S. The polymorphonuclear white blood cell contributes to the development of hypertension in the Sabra rat. *J Hypertens* 25: 2249-2256, 2007.

9. Yagil C, R Barkalifa, M Sapojnikov, A Wechsler, D Ben-Dor S. Weksler-Zangen, N. Kaiser, I. Raz and **Y. Yagil**. Metabolic and genomic dissection of diabetes in the Cohen rat. *Physiol Genomics*. 29:181-92, 2007.
10. Yagil C. and **Yagil Y**. PPAR α - friend or foe? *Hypertension* 50: 847-50, 2007.
11. **Yagil Y**, Yagil C. Integration--a key to success in the genetic dissection of complex diseases? *Trends CardiovascMed*. 16: 35-8, 2006.
12. Yagil C, Sapojnikov M, Wechsler A, Korol A, **Yagil Y**. Genetic dissection of proteinuria in the Sabra rat. *Physiol Genomics*. 25: 121-133, 2006.
13. **Yagil Y**. and C. Yagil. Adducin and microalbuminuria: a complex association. *J Hypertens* 24: 819-20, 2006.
14. Hubner N, Yagil C. and **Yagil Y**. Novel integrative approaches to the identification of candidate genes in hypertension. *Hypertension* 47(1): 1-5, 2006.

Description of the Israeli Rat Genome Center (IRGC)

The Israeli Rat Genome Center (IRGC) was established in the early 90's by Prof. Yoram Yagil and Prof. Chana Yagil, two scientists from the Ben-Gurion University Faculty of Health Sciences, who decided to dedicate their research activities to the study of human disease. Their focus was the investigation of complex diseases, including cardiovascular, metabolic and renal diseases. Searching for experimental animal models that would fulfill their research aspirations, they recognized the rat as a species which physiology has been studied extensively over the years and that would serve as an excellent model for the investigation of the physiology and pathophysiology of disease in humans. Seeking appropriate models, they soon became aware of a number of unique rat models of disease that had been developed in Israel by Israeli researchers and that were solely available in Israel. As these models were dispersed throughout the country, they realized that there was a need to create one central repository of experimental rat models of disease in Israel. This consideration and their intent to apply genomic tools to their research led them to establish the Israeli Rat Genome Center, dedicated to hosting exclusively genetically derived rat models of human disease.

The Israeli Rat Genome Center, a non-profit academic organization, was established within the compounds of the Barzilai Medical Center campus of the Ben-Gurion University Faculty of Health Sciences in Ashkelon, Israel. The Center consists of the Zootechnic Laboratory and the Laboratory for Molecular Medicine. The Zootechnic Laboratory is an animal facility that hosts genetically inbred rat strains that were developed in and that are available solely in Israel. It is staffed by a veterinarian and technicians who are highly qualified in animal care. The Laboratory for Molecular Medicine, which is operated by technical staff and post-graduate students, provides phenotyping and genomic services. It is also directing independently genomic projects seeking to unravel the genetic basis of disease, using rat models.

The stated aim of the Israeli Rat Genome Center is to provide the scientific community in Israel and worldwide full access to the animal resources that are available through the Center. Its intention is to promote thereby continuing scientific research and international collaboration that will forward the understanding of normal physiology in mankind and pathophysiology of human disease, using the rat as an experimental model simulating complex diseases in humans.

The Israeli Rat Genome Center currently hosts several genetically inbred rat models of human disease. The first animal model that was donated to the Israeli Rat Genome Center was the Sabra rat model of salt-sensitive hypertension. This model was founded in the early 70's by Professor Drori Ben-Ishay from the Hebrew University in Jerusalem, Israel. Ben-Ishay et al. (1-4) developed a genetically and phenotypically distinct line of salt-sensitive (SBH) and salt-resistant (SBN) rat strains.

The SBN and SBH substrains were available for many years solely from the original breeding colony at the animal facility of the Hebrew University Medical Center in Jerusalem. When the genetic homogeneity of that colony and its suitability for



Prof. D. Ben-Ishay

genetic studies became an issue with the appearance of reports pointing to genetic contamination of other experimental models, a nucleus from the original colony was transferred to the Israeli Rat Genome Center in 1992. Renewed selective inbreeding was initiated and an extensive effort for genetic purification of the sub-strains was undertaken and. Inbreeding has proceeded so far for over 55 generations. The products of the renewed inbreeding were designated SBH/y and SBN/y, to distinguish from the original breeding colony.

The phenotypic feature that render SBH/y and SBN/y a unique model of salt-sensitive hypertension consists of total dependence of blood pressure on dietary intake of salt. The salt-sensitive and the salt-resistant animals are normotensive at baseline, when fed regular diet with "normal" salt content. When salt-loaded, the salt-sensitive SBH/y substrain invariably develops systolic and diastolic hypertension. In contrast, the salt-resistant SBN/y substrain remains normotensive throughout its lifetime, irrespective of the amount of salt in diet. The hypertensive SBH/y substrain develops left ventricular hypertrophy and renal damage consistent with nephrosclerosis. The cardiovascular phenotypes of SBH/y or SBN/y are not affected by age, gonads or maternal environment (5).

Genome screening with microsatellite markers has demonstrated full homozygosity of the two sub-strains, qualifying them as genetically inbred (6). The presence of a large number of polymorphic markers renders these sub-strains highly suitable for genetic studies. The two sub-strains have in fact been crossbred several times, generating F₁ and F₂ generations, which phenotype has been determined (7;8). Congenic and consomic strains, introgressing part or entire rat chromosomes from SBH/y or SBN/y onto the genetic background of the reciprocal strain, have been constructed and are available at the Israeli Rat Genome Center (7-11). The genomes of the two sub-strains are currently being sequenced, as part of an ongoing international collaborative effort. The Genomic distribution of single nucleotide polymorphisms (SNPs) has been studied; details are available on the RGD website (<http://rgd.mcg.edu/>). The transcript-tome of the two sub-strains has been studied under normal diet and during salt-loading and is available for public use (12).

The SBH/y and SBN/y sub-strains are currently produced solely at the Israeli Rat Genome Center in Ashkelon, Israel. They are available for collaborative studies with laboratories interested in salt sensitivity, hypertension, target organ damage, the genetic basis of hypertension or any other related studies.

The second model that was introduced to the Israeli Rat Genome Center was the Cohen model of diabetes. This model was developed by Prof. A.M. Cohen, also from the Hebrew University. The model consists of two substrains, the Cohen Diabetic sensitive rat (CDs) and the Cohen diabetic resistant (CDr) rat.

The Cohen Diabetic rat is a genetically derived experimental model of diet-induced type 2 diabetes mellitus that reproduces many features of the disease in humans (13; 14). This model stands out among other experimental rodent models of type 2 diabetes mellitus in several important ways. Its most outstanding and distinctive feature is the absolute dependence



Prof. A.M. Cohen

of the phenotype upon dietary perturbation, expressing genetic susceptibility (sensitivity and resistance) to a "diabetogenic diet" (15). When fed regular rat chow (normal diet), both the CDS sensitive and CDr resistant sub-strains remain normoglycemic. When fed a custom-prepared diabetogenic diet that is rich in carbohydrates and casein and poor in copper, CDs invariably develop a diabetic metabolic phenotype within one month, whereas the resistant CDr substrain maintains a normal non-diabetic phenotype. It is important to stress that diabetes does not develop spontaneously in these animals and is totally dependent upon diet. This unique phenotypic feature is not present in other genetically inbred rat strains that simulate type 2 diabetes in humans, including the Goto-Kakizaki (GK) (16;17), the Otsuka Long-Evens Tokushima Fatty (OLETF)(18-20) and the Zucker diabetic fatty rat (ZDF) (18;21;22) that develop diabetes spontaneously, without any important relationship to the composition of diet. Another central feature of the Cohen model is that it consists of two genetically-derived contrasting strains, originating from the same parent strain, which is useful for genetic and physiological studies. A third feature that makes the Cohen rat stand out is that it is a non-obese model of diabetes, which allows dissociation of the confounding obesity factor from other factors that induce the development of diabetes.

The original colony of the Cohen Diabetic rat model was held for many years solely at the Hebrew University animal facility of the Hadassah Medical Center in Jerusalem. In the late 90's, nearly 30 years after the colony had been originally established; a nucleus from this original breeding colony was transferred to the Israeli Rat Genome Center. A program of secondary selective re-inbreeding was undertaken in order to maximize phenotypic and genotypic homogeneity of the respective strains. Animals from the two sub-strains were selectively inbred by stringent criteria for over 10 additional generations, currently bringing overall inbreeding to >55 generations. The IRGC team subsequently studied the phenotype of the newly inbred strains and established an updated reference database for Cohen Diabetic rat model.

The metabolic phenotype the Cohen Diabetic sensitive CDs substrain that is fed regular chow consisted of fasting normoglycemia, normal glucose tolerance to glucose loading, normal fasting insulin levels and a normal insulin response to glucose loading. However, when fed a custom-prepared high-sucrose low-copper diabetogenic diet, CDs become overtly diabetic, with normal or elevated fasting glucose levels and markedly elevated plasma glucose and a reduced insulin response to glucose loading. In sharp contrast, the Cohen Diabetic Resistant CDr substrain that is fed regular or diabetogenic diet does not develop diabetes and maintains normal glucose tolerance and insulin secretion. A striking gender difference is observed in CDs that are fed diabetogenic diet: Males have a lower growth rate and a more severe glucose intolerance pattern than females (15). Gonadectomy shortly after weaning does not prevent the development of the diabetic phenotype in its early phase in either sex but markedly attenuated its expression in males at a later phase, abolishing the gender differences. Importantly, the development of the diabetic phenotype in CDs that are fed diabetogenic diet is not accompanied by obesity or hyperlipidemia.

The genetic profile of the substrains was established using 1590 microsatellite markers evenly distributed throughout the rat genome (15). The genetic homozygosity of CDs and CDr has been verified. The rate of polymorphism between the contrasting strains is 33.8%. The two substrains have been crossbred thrice, generating F₁ and F₂ generations which phenotype has been determined (23-25). Congenic and consomic strains,

introgressing part or entire rat chromosomes from CDr onto the genetic background of CDr, have been constructed and are available at the Israeli Rat Genome Center (25).

The metabolic phenotypes of the re-bred colony of CDs and CDr and their genetic makeup render the Cohen Diabetic rat a useful experimental model that is highly suitable for studying the interaction between nutritional-metabolic environmental factors and genetic susceptibility (sensitivity and resistance) for the development of type 2 diabetes mellitus. The model is also distinctively useful for investigating the effect of gender on the expression of the diabetic phenotype. The presence of a large number of polymorphic markers renders these sub-strains highly suitable for genetic studies.

The CDs and CDr substrains are currently produced at the Israeli Rat Genome Center where they are continuously monitored for phenotypic and genetic homogeneity. They are available for collaborative studies with laboratories interested in diet induced-type 2 diabetes, the genetic basis of diabetes or any other related studies. Animals from the original colony continue to be produced at the Hebrew University.

The third model that was entrusted to the Israeli Rat Genome Center repository is the Cohen Rosenthal Diabetic Hypertensive (CRDH) rat. This model was developed in the early 90's jointly by Professor Talma Rosenthal from the Tel-Aviv University Sackler Faculty of Medicine and Professor Cohen from the Hebrew University. The model combines type-2 diabetes mellitus and essential hypertension in one strain. The development of impaired glucose tolerance after feeding with diabetogenic diet involves both genetic and environmental factors. The combining of hypertension and type-2 diabetes in one experimental model provides an outstanding opportunity to study these concomitant pathologies in one animal strain.



Prof. T. Rosenthal

The CRDH rat is a unique animal model in which genetic spontaneous hypertension and type 2 diet-induced diabetes developed after cross-breeding between the Cohen Diabetic sensitive (CDs) substrain and the Spontaneously Hypertensive Rat – (CDs x SHR) (13). In the selection process, Rosenthal and Cohen selected and mated sibling pairs with the highest spontaneous blood glucose and blood pressure. In the selected generations thereafter, diet-induced type 2 diabetes and spontaneous hypertension became evident.

The phenotype of CRDH incorporates, amongst other important features, diffuse diabetic glomerulosclerosis and hypertensive changes in arteries and arterioles that are not observed in the parental CDs or in the SHR strains. This model is thus useful in probing the mechanisms potentiating cardiovascular and renal morbid events in the setting of spontaneous hypertension and diabetes, reproducing thereby the common occurrence of type- 2 diabetes and hypertension in humans.

The CRDH strain is currently produced at the Barzilai Medical Center in Ashkelon, as well as at the Tel-Aviv University. It is available for collaborative studies with interested laboratories, pending written consent of Prof. Talma Rosenthal.

Beyond the three major genetically derived inbred strains that were entrusted to the care of the Israeli Rat Genome Center, several additional animal models were derived

within the Zootechnic facility and are currently bred within the compound. Notable among these are consomic and congenic strains originating from genetic manipulations between SBN/y and SBH/y (8-10) and between CDs and CDr (24). In these genetically derived strains, part or entire chromosomes of interest were introgressed from one strain (for example from SBN/y or CDr) onto the genetic background of contrasting strain within the same experimental model (for example SBH/y or CDs). Such strains allow investigating the contribution of introgressed chromosomal segment or entire chromosomes to phenotypes of interest. These strains are available to all interested parties on the basis of collaboration.

In addition to hosting and developing genetically derived rat models simulating diseases in humans, the investigators at the Israeli Rat Genome Center have concentrated part of their efforts on performing independent genomic research using their rat models, aiming to elucidate the genetic basis of complex diseases. Their focus has been on the investigation of the genetic basis of salt-sensitive hypertension using the Sabra rat model of salt-sensitive hypertension (6-9;26) and of type 2 diet-induced diabetes using the Cohen rat model of type 2 diet-induced diabetes (15;24;25). The renal phenotype of the Sabra model has also allowed the researchers at the Israeli Rat Genome Center to engage in the genetic dissection of proteinuria and glomerulosclerosis (10;11;27;28). The renal phenotype of the Cohen model of diabetes (29) has allowed them to initiate the genetic dissection of diabetic nephropathy [ongoing studies]. In all these genetic studies, much emphasis was laid on extensive and thorough determination and documentation of the phenotype of the respective models (5;10;15;23;27;29-38), laying thereby a necessary database for future research using these animal models. The genomic research at the Israeli Rat Genome Center has incorporated positional cloning, including multiple F₂ crosses between contrasting strains. These extensive and often ambitious endeavors have successfully led to the detection of novel quantitative trait loci for salt-sensitive hypertension, diet induced type 2 diabetes and proteinuria (6-9;11;24;25;28;30; 37;39;40). The genomic component of these studies has been complemented by transcriptomics, with the global study of gene expression using DNA microarrays and other means (12;25;28;30;41) that led to the identification of novel candidate genes in hypertension, diabetes and proteinuria.

One of the notable findings was the discovery of ACE₂ as a candidate gene for hypertension and cardiovascular homeostasis (42;43), which would not have been possible without the work carried out by the Israeli Rat Genome Center team and its respective animal models of disease. The discovery of ACE₂ has revolutionized our understanding of the renin-angiotensin system and has added a new previously unappreciated dimension to this important system that appears to be involved in multiple pathophysiological pathways incorporated within the cardiovascular, cerebrovascular, and renal systems. The interest generated in ACE₂ has stimulated extensive academic research as well as a major interest of the pharmaceutical industry, which is now developing drugs based on our discoveries. The Israeli Rat Genome Center currently hosts an ACE₂ transgenic animal in which the human ACE₂ gene was introduced into the genome of the SBH/y rat. This model was produced by Prof. Michael Bader at the Max-Delbrück Institute for Molecular Medicine in Berlin, Germany and is currently available at our Center.

The Israeli Rat Genome Center fosters, as its binding policy, national and international collaborations. These collaborations have aimed primarily at promoting and spreading

the use of the rat as an experimental animal model simulating disease in humans. The second major aim of these collaborations has been to enhance our understanding of the genetic basis of complex diseases in humans by expanding the use of our rodent models for genetic research. At the national level, the Israeli Rat Genome Center team has been actively collaborating with researchers from the Hebrew University in Jerusalem (Prof. Itamar Raz, Dr. Sarah Zangen, Prof. Michael Burzstein), the Tel-Aviv University (Prof. Talma Rosenthal, Prof. Yoni Lior, Dr. David Kaine, Dr. Adiel Barak), the Technion in Haifa (Prof. Batya Kristal, Dr. Shifra Sella), the Ben-Gurion University in Beer-Sheba (Prof. Arie Moran, Prof. Israel Sekler, Prof. Yael Segev, Prof. Dani Landau) and the Haifa University in Haifa (Prof. Avraham Korol). At the international level, the Israeli Rat Genome Center team has been collaborating, among others, with investigators from the Max-Delbruck Center for Molecular Medicine (Prof. Detlev Ganten, Prof. Friedrich Luft, Prof. Reinhold Kreutz, Prof. Norbert Huebner, Prof. Michael Bader, Dr. Claudia Goesele, Dr. Ursula Ganten), the University of Wisconsin (Prof. Howard Jacob, Prof. Martin Hessner), and Inserm in Paris, France (Prof. Liz Bankir).

In conclusion, the Israeli Rat Genome Center is a unique Israeli rat resource that holds in its possession inbred genetic rat models of common diseases that afflict a large part of humanity. The models were developed by Israeli researchers over many years of hard and intensive work and consist a valuable asset and a unique national and international resource for investigators interested in promoting our understanding of the physiology, pathophysiology and genetic basis of complex diseases, including cardiovascular, renal and metabolic diseases. The Israeli Rat Genome Center offers its resources to all interested parties on the basis of collaboration and encourages continuing as well as new collaborations nationally and worldwide.

Reference List

- (1) Ben-Ishay D, Saliternik R, Welner A. Separation of two strains of rats with inbred dissimilar sensitivity to doca-salt hypertension. *Experientia* 1972; 28:1321-1322.
- (2) Ben-Ishay D. The Sabra hypertension-prone and -resistant strains. In: de Jong W, editor. Holland: Elsevier Science Publishers B.V, 1984: 296-313.
- (3) Ben-Ishay D, Mekler J, Saliternick-Vardi R. Sabra hypertension-prone and hypertension-resistant rats. *Hypertension* 1987; 9 (suppl. I):I-24-I-26.
- (4) Ben-Ishay D, Yagil Y. The Sabra hypertension-prone and -resistant strains. In: Ganten D, de Jong W, editors. *Experimental and genetic models of hypertension*. Amsterdam: Elsevier Science B.V, 1994: 272-299.
- (5) Yagil Y, Yagil C. The lack of a modulating effect of non-genetic factors (age, gonads and maternal environment) on the phenotypic expression of the salt-susceptibility genes in the Sabra rat model of hypertension. *J Hypertens* 2000; 18(10):1393-9.
- (6) Yagil Y, Yagil C. The genetic basis of salt-susceptibility in the Sabra rat model of hypertension. *Kidney Int* 1998.
- (7) Yagil C, Sapojnikov M, Kreutz R, Katni G, Lindpaintner K, Ganten D, Yagil Y. Salt susceptibility maps to chromosomes 1 and 17 with sex specificity in the Sabra rat model of hypertension. *Hypertension* 1998; 31(1):119-24.
- (8) Yagil C, Sapojnikov M, Kreutz R, Zurcher H, Ganten D, Yagil Y. Role of chromosome X in the Sabra rat model of salt-sensitive hypertension. *Hypertension* 1999; 33(1 Pt 2):261-5.
- (9) Yagil C, Hubner N, Kreutz R, Ganten D, Yagil Y. Congenic strains confirm the presence of salt-sensitivity QTLs on chromosome 1 in the Sabra rat model of hypertension. *Physiol Genomics* 2003; 12(2):85-95.
- (10) Yagil C, Sapojnikov M, Katni G, Ilan Z, Zangen SW, Rosenmann E, Yagil Y. Proteinuria and glomerulosclerosis in the Sabra genetic rat model of salt susceptibility. *Physiol Genomics* 2002; 9(3):167-178.
- (11) Yagil C, Sapojnikov M, Wechsler A, Korol A, Yagil Y. Genetic dissection of proteinuria in the Sabra rat. *Physiol Genomics* 2006.
- (12) Yagil C, Hubner N, Monti J, Schulz H, Sapojnikov M, Luft FC, Ganten D, Yagil Y. Identification of hypertension-related genes through an integrated genomic-transcriptomic approach. *Circ Res* 2005; 96(6):617-625.
- (13) Cohen AM, Rosenmann E, Rosenthal T. The Cohen diabetic (non-insulin dependent) hypertensive rat model. Description of the model and pathologic findings. *Am J Hypertens* 1993; 6:989-995.
- (14) Cohen AM. Genetically determined response to different ingested carbohydrates in the production of diabetes. *Horm Metab Res* 1978; 10(2):86-92.
- (15) Weksler-Zangen S, Yagil C, Zangen DH, Ornoy A, Jacob HJ, Yagil Y. The newly inbred cohen diabetic rat: a nonobese normolipidemic genetic model of diet-induced type 2 diabetes expressing sex differences. *Diabetes* 2001; 50(11):2521-9.
- (16) Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). *Adv Exp Med Biol* 1988; 246:29-31.
- (17) Hughes SJ, Suzuki K, Goto Y. The role of islet secretory function in the development of diabetes in the GK Wistar rat. *Diabetologia* 1994; 37(9):863-870.

- (18) Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. *Diabetes Obes Metab* 2005; 7(4):307-317.
- (19) Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. *Diabetes Res Clin Pract* 1994; 24 Suppl:S317-S320.
- (20) Kim JH, Nishina PM, Naggert JK. Genetic models for non insulin dependent diabetes mellitus in rodents. *J Basic Clin Physiol Pharmacol* 1998; 9(2-4):325-345.
- (21) Kurtz TW, Curtis MR, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. *Hypertension* 1989; 13:896-901.
- (22) Plotkin BJ, Paulson D. Zucker rat (fa/fa), a model for the study of immune function in type-II diabetes mellitus: effect of exercise and caloric restriction on the phagocytic activity of macrophages. *Lab Anim Sci* 1996; 46(6):682-684.
- (23) Yagil Y, Ben-Ishay D, Wald H, Popovtzer MM. Water handling by the Sabra hypertension prone (SBH) and resistant (SBN) rats. *Pflugers Arch* 1985; 404:61-66.
- (24) Yagil C, Barkalifa R, Sapojnikov M, Wechsler A, Ben Dor D, Weksler-Zangen S, Kaiser N, Raz I, Yagil Y. Metabolic and genomic dissection of diabetes in the Cohen rat. *Physiol Genomics* 2007; 29(2):181-192.
- (25) Barkalifa R, Yagil Y, Yagil C. Sex-specific genetic dissection of diabetes in a rodent model identifies Ica1 and Ndufa4 as major candidate genes. *Physiol Genomics* 2010; 42(3):445-455.
- (26) Yagil C, Katni G, Rubattu S, Stolpe C, Kreutz R, Lindpaintner K, Ganten D, Ben-Ishay D, Yagil Y. Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of salt sensitivity and resistance. *J Hypertens* 1996; 14(10):1175-82.
- (27) Hertzan-Levy S, Iaina A, Wollman Y, Chernihovsky T, Yagil C, Yagil Y, Peer G, Skutelsky E. Glomerular basement membrane polyanionic sites and nitric oxide in genetically salt-sensitive and resistant hypertensive rats. *Kidney Blood Press Res* 1997; 20(4):218-24.
- (28) Yagil Y, Hessner M, Schulz H, Gosele C, Lebedev L, Barkalifa R, Sapojnikov M, Hubner N, Yagil C. Geno-transcriptomic dissection of proteinuria in the uninephrectomized rat uncovers a molecular complexity with sexual dimorphism. *Physiol Genomics* 2010; 42A(4):301-316.
- (29) Yagil C, Barak A, Ben Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. *Diabetes* 2005; 54(5):1487-1496.
- (30) Mekler J, Yagil Y, Ben-Ishay D. Renal response to acute saline loading in Sabra hypertension-prone and -resistant rats. *Experientia* 1985; 41:923-924.
- (31) Yagil Y, Mekler J, Wald H, Popovtzer MM, Ben-Ishay D. Sodium handling by the Sabra hypertension prone (SBH) and resistant (SBN) rats. *Pflugers Arch* 1986; 407:547-551.
- (32) Yagil C, Ben-Ishay D, Yagil Y. Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats. *Am J Physiol* 1996; 271(4 Pt 2) :806-13.
- (33) Lippoldt A, Gross W, Schneider K, Hansson A, Nadaud S, Schneider W, Bader M, Yagil C, Yagil Y, Luft FC. Nitric oxide synthase and renin-angiotensin system gene expression in salt-sensitive and salt-resistant Sabra rats. *Hypertension* 1997; 30:409-415.
- (34) Gross V, Lippoldt A, Yagil C, Yagil Y, Luft FC. Pressure natriuresis in salt-sensitive and salt-resistant Sabra rats. *Hypertension* 1997; 29(6):1252-9.

- (35) Yagil Y, Yagil C. Does the Sabra hypertension-prone rat represent a model of salt or mineralocorticoid sensitivity? *J Hypertens* 1998; 16(10):1481-4.
- (36) Kohler R, Kreutz R, Grundig A, Rothermund L, Yagil C, Yagil Y, Pries AR, Hoyer J. Impaired function of endothelial pressure-activated cation channel in salt-sensitive genetic hypertension. *J Am Soc Nephrol* 2001; 12(8):1624-9.
- (37) Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. *Exp Nephrol* 2001; 9(1):1-9.
- (38) Sela S, Mazor R, Amsalam M, Yagil C, Yagil Y, Kristal B. Primed polymorphonuclear leukocytes, oxidative stress, and inflammation antecede hypertension in the Sabra rat. *Hypertension* 2004; 44(5):764-769.
- (39) Yagil Y, Yagil C. Candidate genes, association studies and haplotype analysis in the search for the genetic basis of hypertension. *J Hypertens* 2004; 22(7):1255-1258.
- (40) Yagil Y, Yagil C. The search for the genetic basis of hypertension. *Curr Opin Nephrol Hypertens* 2005; 14(2):141-147.
- (41) Hubner N, Yagil C, Yagil Y. Novel integrative approaches to the identification of candidate genes in hypertension. *Hypertension* 2006; 47(1):1-5.
- (42) Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. *Hypertension* 2003; 41(4):871-3.
- (43) Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 2002; 417(6891):822-8.

THE PROFESSOR JOSEPH MICHAELI

DIVISION OF HEMATOLOGY



Head of Department

Prof Gilles Lugassy, MD

Professor of Medicine Ben-Gurion University

brzgil@barzi.health.gov.il

Medical Team:

- Arnaldo Ducach, MD Specialist in Hematology, Pediatric Hemato-Oncology, and Pediatrics.
- Anatoly Nemets, MD Head of Coagulation and Haemostasis Unit
Specialist in Internal Medicine and Hematology
Lecturer of Medicine Ben-Gurion University
- Joseph Barshai, MD Specialist in Internal Medicine and Hematology

Research:

- Tatyana Buligin Clinical Trials Research
- Dora Ben-Alon Head of Hematology Laboratory

Nursing Team:

- Ms Yona Taktuk Head Nurse
- Ms Nili Ohana Deputy Head Nurse

Main Fields of Research Activities

Experimental

1. Modulation of EPO receptors by Vitamin D and Calcium

Current clinical studies

1. New anticoagulant agents in venous thromboembolism
2. Therapy of Multiple Myeloma, Chronic Lymphocytic Leukemia

Gilles Lugassy, MD

Division of Hematology

ନିରନ୍ତର



ନିରନ୍ତର

List of Publications

1. **Lugassy, G.** Safety and convenience of a 15-minute infusion of zoledronic acid. Not so safe. *The Oncologist*.2005; 10:309-310.
2. Wolak T ,Rogachev B ,Tovbin D, Hertzanu Y, Zlotnik M, **Lugassy G** ,Renal vein thrombosis as a presenting symptom of multiple genetic pro-coagulant defects, *Nephrol Dial Transplant* 2005;20:827-9.
3. Machlenkin A, Paz A, BarHaim E, Goldberger O, Finkel E ,Tirosh B ,Volovitz I, Vadai E, **Lugassy G** ,Cytron S, Lemonnier F, Tzehoval E, Eisenbach L, Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate -3 as candidates for prostates cancer immunotherapy. *Cancer Res* 2005; 65:6435-42.
4. Ohali M, Maizlish Y, Abramov H, Schlesinger M, Branski D, **Lugassy G** Complement profile in childhood immune thrombocytopenic purpura: a prospective pilot study. *Ann Hematol*, 2005; 84; 812-5.
5. Maslovsky I, Gefel D, Uriev L, Ben Dor D, **Lugassy G**, Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura. *Eur J Int Medicine*, 2005;16:523-4

6. Dreiner J, Novack V, Barachana M, Yerushalmi R, **Lugassy G**, Shpilberg O, Non Hodgkin 's lymphoma and residential proximity to toxic industrial waste in southern Israel. *Haematologica*, 2005; 90:1709-10.
7. Nemets A, Ronen M, **Lugassy G**. Chronic paraneoplastic cutaneous syndrome preceding an indolent variant of mantle cell lymphoma: favorable response to rituximab. *Acta Haematol*, 2006; 115:113-6.
8. Maslovsky I ,Gemer O, Gefel D, Zimra Y, **Lugassy G**, Polycythemia as a result of ectopic erythropoietin production in benign cystic leiomyoma of uterus. *Acta Obstet Gynecol Scand* ,2006;85:887-8
9. Nemets A, Isakov I, Huerta M, Barshai Y ,Oren S , **Lugassy G** ,Evaluation of arterial compliance in polycythemia vera patients : short and long –tern influence of phlebotomy, *IMAJ*,2006;8:845-7
10. **Lugassy G**, Autoimmunity in chronic lymphocytic leukemia: which B lymphocyte is the culprit? *IMAJ*,2006;8:864
11. Tirosh B, Daniel-Carmi V, Carmon L, Paz A ,**Lugassy G**, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, Eisenbach L, 1-8 interferon inducible gene family : putative colon carcinoma gene associated antigens, *British J Cancer*, 2007;97:1655-63
12. Barshay Y ,**Lugassy G**, Risk factors for lymphoma and leukemia ,*Medicine Hematology* ,2007;1:6-8 (in Hebrew)
13. Mittelman M, **Lugassy G**, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C. MDS Israel Group,*IMAJ*,2008;10:374-6
14. Barshay Y, **Lugassy G**, Erythropoietin: advantages and risks. *Medical*, 2008;19:20-24
15. Nemets A, **Lugassy G**. New Aspects of Myeloproliferative disorders. *Medicine*, 2008;3:42-45 (in Hebrew)

16. Klepfish A, **Lugassy G**, Kostsianidis I, Rachmilewitz E, Schattner A. Enhancing the action of rituximab in CLL by adding fresh frozen plasma components / rituximab interactions and clinical results in refractory CLL, Annals New York Academy of Sciences, 2009;1173:865-873
17. Barshay Y, **Lugassy G**. The use of Erythropoietin in oncological patients, Israeli Journal of Medicine ,2009,15:10-13 (in Hebrew)
18. Grisariu S, Avni B, Batchelor TT, Van den Bent MJ, Bokstein F, Sciff D, Kuitinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T. International Primary CNS Lymphoma Collaborative Group. Blood, 2010;115:5005-11
19. Rachimi-Levene N, Barshay Y. Thromboelastography (TEG) in clinical practice, Hematology Update 2010; 1:26-29 (in Hebrew). **Lugassy G** ,Editor
20. Lubetski A, Nemets A, Is there a role for anticoagulation in recurrent miscarriage? Hematology Update 2010;1:28-29 (in Hebrew), **Lugassy G**, Editor
21. Nemets A, Lishner M, **Lugassy G**. The New Anticoagulants. Harefuah, in print,2011
22. Ben-Alon D, Eden A, **Lugassy G**, Nathan I, Modulation of 1 ALPHA ,25 (OH)₂ D₃ – induced proliferation of erythroblast, Submitted for publication
23. Cohen O, Scharf S, Levi A, **Lugassy G**, Clinical trials in Hematology. Regulatory and ethical aspects, Medicine (in Hebrew), in print

Co-Investigator in multinational clinical studies

1. Eclap Study .Acute leukemia in Polycythemia Vera : an analysis of 1638 patients enrolled in a prospective observational study, Blood;2005;105:2664-2670
2. Thrive Study. Ximelagatran for the treatment of deep vein thrombosis, A randomized trial, JAMA 2005;293:681-689

3. On behalf of the Israeli multidisciplinary FVIIa task force. Journal of Thrombosis and Hemostasis, 2005;3:1-9
4. Prevail Study .The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after ischaemic stroke ,Lancet 2007;369:1347-1355
5. Bay 59 Study ,Treatment of Rivaroxaban in patients with acute symptomatic deep vein thrombosis,Journal of the American Heart Association , 2007;116
6. Einstein DVT dose ranging Study, Blood ;2008;112;2242-2247
7. Botticelli DVT dose ranging Study ,Journal Thrombosis Haemostasis ,2008;6:1313-1318
8. Exclaim Study , Ann Intern Medicine, 2010;153:8-18
9. Calisto Study ,New England Journal Medicine, 2010;363:1222-1232
10. Einstein Study, New England Journal Medicine, 2010;363:2499-2510

ONCOLOGY DEPARTMENT



Head of Department

Dr Frida Barak, MD

Lecturer of Medicine Ben-Gurion University

fridab@barzi.health.gov.il

Medical Team

- Charkovsky Tatiana, MD
- Irena Hinchin, MD
- Ms. Mazal Amoyal- Head Nurse

Description

The team of three experienced physicians has a special expertise in breast, ovary, gastro-intestinal, gynecological cancers and cancer genetics. We conduct regularly meetings with colleges specialists in breast surgery, gastroenterology gynecology etc.

The treatments provided at the Oncology Institute are mostly delivery of chemotherapy and molecular targeted biological drugs.

The principal aim of the staff is to make the therapeutic environment more comfortable and to give to our patients a feeling of home. In addition a number of volunteers are involved in supportive care offering different beauty treatment, reflexology and shiatsu, all helps to improve patient's mood. We believe that improving mood affects directly the ways of coping with cancer.


Main Fields of Research Activities

1. Comparative genetic and epidemiological studies in cancer patients from different ethnic populations.
2. Palliative and supportive care in patients with malignancy.
3. Epidemiology of breast cancer and early detection.
4. Study of new chemotherapy and molecular targeted biological drugs.

Frida Barak, MD

Oncology Department

פורסם



פורסם

List of Publications

A-Original Articles

1. Lavie O, Ben-Arie A, Segev Y, Faro J, **Barak F**, Haya N, Auslender R, Gemer O. BRCA germline mutations in women with uterine serous carcinoma--still a debate. *Int J Gynecol Cancer*. 2010 Dec; 20(9):1531-4.
2. **Barak F**, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B, Anteby E, Baruch GB, Korach J, Friedman E. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. *Gynecol Oncol*. 2010 Sep 15. [Epub ahead of print]
3. Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, **Barak F**, Cohen OS, Friedman E. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. *J Neurol*. 2009 Mar;256(3):483-7. Epub 2009 Mar 24
4. **Barak F**, Siegelmann-Danieli N, Scharf S. Israel-Gaza conflict. *Lancet*. 2009 Mar 14;373(9667):891.

5. Galore-Haskel G, Azizi E, Mohamdi H, Scope A, Chaudru V, Laitman Y, **Barak F**, Pavlotsky F, Demenais F, Friedman E MC1R variant alleles and malignant melanoma risk in Israel. *Eur J Cancer*. 2009 Jul; 45(11):2015- 22. Epub 2009 Mar 5.
6. Gemer O, Uriev L, Voldarsky M, Gdalevich M, Ben-Dor D, **Barak F**, Anteby EY, Lavie O. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. *Eur J Surg Oncol* 2009; 35:247-51.
7. Gemer O, Gdalevich M, Voldarsky M, **Barak F**, Ben Arie A, Schneider D, Levy T, Anteby EY, Lavie O. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometrioid endometrial cancer: results of a multicenter study. *Eur J Surg Oncol*. 2009 Aug; 35(8):865-9. Epub 2008 Nov 14.
8. **Barak F**, Lugacy G, Kreitler S. Complementary medicine regulations. *Patient Educ Couns*. 2008 Oct; 73(1):166-7; author reply 170-1.
9. Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, **Barak F**, Tavtigian S, Friedman E. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. *Fam Cancer*. 2009; 8(2):127-33. Epub 2008 Sep 17.
10. Kreitler S, Kreitler MM, Len A, Alkalay Y, **Barak F**. Psychological risk factors for colorectal cancer? *Revue Francophone de Psycho-Oncologie*. (2008) 2: 131-145 Springer 2008
11. Lavie O, Uriev L, Gdalevich M, **Barak F**, Peer G, Auslender R, Anteby E, Gemer O. The outcome of patients with stage I endometrial cancer involving the lower uterine segment. *Int J Gynecol Cancer*. 2008 Sep-Oct; 18(5):1079-83. Epub 2007 Dec
12. Gemer O, Ben Arie A, Levy T, Gdalevich M, Lorian M, **Barak F**, Anteby E, Lavie O. Lymphovascular space involvement compromises the survival of patients with stage I endometrial cancer: Results of a multicenter study. *Eur J Surg Oncol* 2007; 33: 644-7.
13. **Barak F**, Khinchin I, Harkovsky T, Kaofer H: Supportive care for breast cancer patients. *BAMAH- Journal for Health Professionals in the Field of Cancer*. Israeli Cancer Association. 2006

B- Accepted for publication

1. Barak F, Ostrowsky A, Kreitler S. Adjuvant chemotherapy for breast cancer patients: Patients expectations and physicians' attitudes. Palliative and Supportive Care

C- Sent for publication

1. **Barak F**, Gdalevich M, Piura B, Anteby EY, Lavie O, Gemer O. The influence of early detection of endometroid endometrium cancer on disease stage and survival
2. **Barak F**, Amoyal M, Kalichman L. Using a simple questionnaire for management of nausea and vomiting during chemotherapy

D- Chapters in Books

1. **Barak F**, Ostrowsky I.: Nutrition of terminally ill cancer patients. Israel Medical Encyclopedia. Vol. 9. Tel Aviv, 2006. Yediot Ahronot Publishers. 2006.
2. **Barak F**, Ostrowsky L, Scharf S.: Herbal therapy for pain control. Handbook of Chronic Pain. Beltrutti, Kreitler, Lamberto, Niv (Ed), VII: 23, 12pp, 2006. Nova Science Publishers, Inc
3. Ostrowsky A, Scharf S and **Barak F**. The Medical Needs of the Dying. Kreitler S (Ed), Nova Science Publishers, Inc. In print

Active Participation in Scientific Meetings

A- Abstracts

1. Kreitler S, **Barak F**, Siegelmann-Danieli N. The survivors' guilt: The case of cancer. IPOS 11th World Congress June 21-25, 2009 Vienna, Austria
2. **Barak F**, Scharf S. Kreitler M, Kreitler S. Psychosocial support of patients and their families during the terminal period of life. IPOS 11th World Congress June 21-25, 2009 Vienna, Austria
3. **Barak F**, Ostrowsky L, Krietler S, Scharf S. **Fist World Congress On Cancer 2009 (WCC-2009)** January 12-14, 2009. Institute for Holistic Medical Sciences, Kottayam, Kerala, India. Invited speaker **Barak F**, Livshitz S, Krietler S, Scharf S: Do our Patients Wish and are they Able to Die at Home? 13th year meeting of "Tmiha" society. Tel Aviv, Israel. Jan. 2008

4. Gemer O, Voldarsky M, Uriev L, Gdalevich M, Ben-Dor D, **Barak F**, Anteby E, Lavie O: The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer, The 15th Biennial meeting of European Society of Gynecological Oncology. Berlin, Germany. Aug, 2007
5. Gemer O, Ben Arie A, Levy T, Gdalevich M, **Barak F**, Lorian M, Anteby E, Lavie O. Lymphovascular involvement is a poor prognostic factor in patients with stage I endometrial cancer. The 6th Meeting of the Israel Society for Gynecological Oncology, Hertzelia, Israel. Apr, 2007
6. Gemer O, Ben Arie A, Levy T, Gdalevich M, **Barak F**, Lorian M, Anteby E, Lavie O. Lymphovascular involvement is a poor prognostic factor in patients with stage I endometrial cancer. 11th biennial meeting of the International gynecologic oncology society. Santa Monica, CA, USA 2006
7. Evaluation of coagulation parameters in oncology patients, after cessation of chemotherapy. Meeting: 2005 ASCO Annual Meeting, Abstract No: 8244. First Author: **F. Barak**

Current clinical studies

Ongoing

1. Genetic screening in elderly Ashkenazi women to identify factors which contribute to breast cancer morbidity in BRCA1/ BRCA2 mutation carriers. 2011
2. The rate and penetrance of the predominant Jewish Ashkenazi mutations (3984Dup4*MSH6 and A636P*MSH2 genes) in unselected patients with HNPCC-associated malignancies. 2011
3. A Randomized, Double-blind, Placebo-controlled, multi-center phase III study of Denosumab as adjuvant treatment for women with Early-stage breast cancer at high risk of recurrence (D-CARE).2011
4. An open label, randomized phase III trial of BIBW 2992 and Vinorelbine versus Trastuzumab and Vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior Trastuzumab treatment. 2011
5. Effect of Shiatsu on chemotherapy-induced nausea and vomiting in breast cancer patients. 2010
6. A multi-center study investigating the correlation between Erlotinib induced rash and efficacy among EGFR-mutated NSCLC patients receiving first-line therapy. 2010
7. Relationships between the personality characteristics and cancer. 2008
8. A phase III Open Label, randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with locally Advanced or Metastatic Breast Cancer

Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy .2007

9. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer.2006
10. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer. 2006
11. A randomised three-arm multi-centre comparison of 1 year and 2 years of Herceptin versus no Herceptin in women with HER2- positive primary breast cancer who have completed adjuvant chemotherapy. 2002
12. Multicenter phase III randomized trial comparing Doxorubicin and Cyclophosphamide followed by Docetaxel (AC-T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (Herceptin) (AC—TH) and with Docetaxel, Carboplatin and Trastuzumab(TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER2 alteration. 2001
13. A multicentre phase III randomised trial comparing Docetaxel in combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin a Cyclophosphamide. Followed by Docetaxel (AC—T) as adjuvant treatment of operable breast cancer HER2NEU negative patients with positive axillary lymph nodes. 2001

Completed Projects

1. A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC). 2006-2010
2. An expanded access program of Tarceva (Erlotinib) in patients with advanced stage IIIB/IV non small cell lung cancer (NSCLC).2006-2010
3. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. 2006-2010
4. Genetic and epidemiologic analyses of Uterine (Endometrial) Malignancy. 2005-2010
5. A randomized controlled study of Docetaxel Monotherapy or Doxil(caelyx) and Docetaxel For the Treatment of Advanced Breast Cancer.2005- 2007
6. A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda) tablets twice daily for 2 weeks in 3-week cycles in patients

with metastatic breast cancer progressing after taxanes and anthracycline therapy. 2005-2007

7. Phase II, randomized, open-label, two-arm, multicenter study of MEDI-522, A humanized monoclonal antibody directed against the human Alpha V Beta 3 Integrin, in combination with Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patient with metastatic Androgen-Independent Prostate cancer. 2004-2007
8. Multi-centre phase III open label randomized trial comparing CPT-11 in combination with 5-FU/FA infusional regimen to the same 5-FU/FA infusional regimen alone as adjuvant treatment after resection of liver metastases for colorectal cancer. 2004-2007
9. Randomized phase III trial comparing Targretin capsules/Cisplatin /Vinorelbine versus Cisplatin/Vinorelbine in chemotherapy- naive patients with advanced or metastatic non-small cell lung cancer. 2001-2006
10. Multi center phase III open label randomized trial comparing CPT- 11 in Combination with a 5-FU/FA infusional regimen to the same 5-FU/FA infusional regimen alone as adjuvant treatment of stage II and III colon cancer. 1999-2010
11. A multicenter, randomized, double-blind study of Idoxifene 40 mg/day versus Tamoxifen 20 mg/day as first-line hormonal therapy in postmenopausal women with metastatic breast cancer. 1997-2007

RHEUMATOLOGY UNIT



Head of Unit

Dr Tatiana Reitblat, MD

Lecture of Medicine Ben-Gurion University

tatyanar@barzi.health.gov.il

Medical Staff

- | | |
|--------------------------|--|
| ▪ Galina Reifman, MD | Clinical researches responsible |
| ▪ Alexander Reitblat PhD | Clinical researches manager, statistics. |
| ▪ Ms. Tatiana Shemetov | Secretary |

Description

Rheumatology Unit serves as an outpatient clinic for patients with rheumatic and systemic autoimmune disorders.

The unit involved in many clinical trials concerning treatments of several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, and others.

Rheumatoid Unit serves as consulting centre for family doctors – lectures, seminars, individual teaching

Main Fields of Research Activities

- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Systemic lupus erythematosus
- Osteoarthritis

List of Publications

1. Zamir D, Zamir M, **Reitblat T**, Zeev W, Polishchuk I. Readmissions to hospital within 30 days of discharge from the internal medicine wards in southern Israel. *Eur J Intern Med.* 2006 Jan; 17(1):20-3.
2. **Reitblat T**, Ben-Horin CL, Reitblat A. Increased 67 Gallium uptake among Polymyalgia Rheumatica patients. Is it additional evidence of its vasculitic nature? *Rheumatology Int.* 2006 Apr 5; [Epub ahead of print]
3. **Reitblat T**, Polyshchuck I, Isakov I, Zamir D, Oren S. Arterial compliance: is it reduced in antiphospholipid syndrome? *J. of Human Hypertention.* 2006 Apr 20; [Epub ahead of print]
4. Zamir D, Weiler Z, Kogan E, Ben-Valid E, Hay E, **Reitblat T**, Polishchuk I. Single-dose quinolone treatment in acute gastroenteritis. *J Clin Gastroenterol.* 2006 Mar; 40(3):186-190.
5. Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, **Reitblat T**, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman P. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A₃ adenosine receptor expression. *Arthritis Res Ther.* 2006; 8(6):R169.
6. Aloush V, Ablin JN, **Reitblat T**, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis *Rheumatol Int.* 2007 May 3; [Epub ahead of print]
7. Silverman MH, Strand V, Markovits D, Nahir M, **Reitblat T**, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P. Clinical evidence for utilization of the A₃ adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. *J Rheumatol.* 2008 Jan; 35(1):41-8. Epub 2007 Nov 15
8. Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R, Amital H, **Reitblat T**, Reitblat A, Ophir J, Konfino I, Chowars Y, Ben-Horin S, Fishman P. The anti-

inflammatory target A (3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. *Cell Immunol.* 2009 May 6. [Epub ahead of print]

9. **Reitblat T**, Zamir D, Polishchuck I, Novochatko G, Malnick S, Kalichman L. Patients treated by tagaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study. *Clinical Rheumatology* 2009; 28(9):1079-1082.
10. Milo R, Kalichman L, Volchek L, **Reitblat T**. Local corticosteroid treatment for carpal tunnel syndrome: A 6-months clinical and electrophysiological follow-up study. *Journal of Back and Musculoskeletal Rehabilitation* 2009; 22(2):59-64

DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY



Head of Department

Dr Jorge-Shmuel Delgado, MD

Lecturer of Medicine Ben-Gurion University

delgado@bgu.ac.il

Medical Team:

- | | |
|-------------------------|--|
| ▪ Genady Katz, MD | Senior Gastroenterologist |
| ▪ Arkady Berezovsky, MD | Senior Gastroenterologist |
| ▪ Nourit Amir, MD | Pediatrician and Senior Gastroenterologist |
| ▪ Jakob Kogan, MD | Senior Hepatologist and Internist. |
| ▪ Ms. Mali Kadosh | Head Nurse |

Description

The Department of Gastroenterology and Hepatology at the Barzilai Medical Center, Ben-Gurion University of the Negev, has been at the forefront of digestive disease care in the Southern Israel for the last years. Today, we provide care for all types of gastrointestinal conditions, from inflammatory bowel disease and liver disorders, to esophageal, pancreatic, and bile duct diseases and all forms of gastrointestinal cancers.

Our department of Gastroenterology features some of the Southern Israel leading experts in fatty liver, hepatitis C, hepatitis B, alcoholic hepatitis, autoimmune hepatitis, liver cirrhosis and liver tumors as well as in inflammatory bowel disease (IBD) treatment and research. In addition, our team includes specialists from adult and pediatric gastroenterology, surgery, pathology, radiology and other disciplines who provide focused expertise in inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Comprehensive Care:

A-Gastrointestinal Diseases

We provide an integrated, comprehensive approach to care that draws upon the expertise of many specialists in the field of IBD and other inflammatory gastrointestinal diseases. We work closely with each patient to develop ongoing, effective treatment plans that improve and maintain overall health and nutrition.

Our endoscopy center specializes in the diagnosis and treatment of complex gastrointestinal diseases, including among others, esophagitis, peptic ulcer, gastrointestinal tumors, and gastrointestinal bleeding. We perform routinely interventional endoscopy to retrieve many of the pre-malignant lesions in the gastrointestinal system, especially gastric and colon polyps.

Our range of advanced interventional endoscopy procedures, include: gastroscopy, colonoscopy, sigmoidoscopy, endoscopic hemostasis, endoscopic mucosal resection (EMR), percutaneous endoscopy gastrostomy and therapeutic endoscopic retrograde cholangiopancreatography (ERCP)

B-Liver Diseases

Our department offers leading-edge approaches for diagnosing and treating the broad spectrum of liver-related diseases, including viral hepatitis, fatty liver disease, alcoholic liver disease, cholestatic liver disease, autoimmune liver diseases, drug-induced liver injury, liver cirrhosis and liver tumors. Furthermore, we perform the following procedures:

- Upper endoscopy and colonoscopy to provide an insider's view of digestive system structures.
- Esophageal variceal banding to treat varicose veins that can cause gastrointestinal bleeding
- Liver biopsy in collaboration with the Radiology and Pathology department for the diagnosing and staging of liver diseases and liver cancer.

Jorge-Shmuel Delgado, MD

Department of Gastroenterology & Hepatology

නලඞනලඞනලඞ



නලඞනලඞනලඞ

Main Fields of Research Activities

Our research focuses on many areas, including new treatments of chronic hepatitis C and primary biliary cirrhosis, diverticulitis, ulcerative colitis and Crohn's disease. Furthermore our center is currently involved in the study of the epidemiology and natural history of autoimmune hepatitis, primary biliary cirrhosis and hepatitis E in the southern Israel.

List of Publications

Refereed articles in scientific journals

A- Original Article

- 1- Fichera A, Little N, Dougherty U, Mustafi R, Cerda S, Li YC, **Delgado J**, et al. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. *J Surg Res.* 2007; 142(2):75-82.
- 2- **Delgado J-S**. Evolving trends in nonalcoholic fatty liver disease. *Eur J Intern Med.* 2008;19(2):75-82.
- 3- Keswani RN, Chumsangsri A, Mustafi R, **Delgado J**, et al. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. *Dis Esophagus.* 2008;21(6):514-21.
- 4- Elbaz G, Etzion O, **Delgado J**, et al. Hypothermia in a desert climate: severity score and mortality prediction. *Am J Emerg Med.* 2008; 26(6):683-8.
- 5- Sikuler E, Tur-Kaspa R, Shemer-Avni Y, **Delgado J**, et al. Sustained virological response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2. *J Clin Gastroenterol.* 2008; 42(6):730-3.
- 6- Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, **Delgado J**, et al. EFGR controls flat dysplastic ACF development and colon cancer progression in the Rat Azoxymethane Model. *Clin Cancer Res.* 2008; 14(8):2253-62.
- 7- Dougherty U, Cerasi D, Taylor I, Kocherginsky M, Tekin U, Badal S, Aluri L, Sehdev A, Cerda S, Mustafi R, **Delgado J**, et al. Epidermal Growth Factor Receptor Is Required for Colonic Tumor Promotion by Dietary Fat in the zoxy methane/Dextran Sulfate Sodium Model: Roles of Transforming Growth Factor- α and PTGS2. *Clin Cancer Res.* 2009;15(22):6780-9.
- 8- **Delgado J-S**, Mustafi R, Lee J, et al. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. *Dig Dis Sci.* 2008; 53(12):3055-64.

- 9- **Delgado J-S**, Yael Baumfeld, Victor Novack, et al. Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. *Hepatology International* 2011 May 8.

Active Participation in Scientific Meetings

1. Cerda S, Mustafi R, Chumsangsri A, Fichera A, **Delgado J**, Bissonnette M. PKC-Delta mediates pro-inflammatory response in Raw 264.7 macrophage cells and is down-regulated in human colon cancer stromal cells. *Gastroenterology* 2007;A-631.
2. Mustafi R, Cerda S, Chumsangsri A, **Delgado J**, Bissonnette M. Differential effects of fluorinated vitamin D₃ analogues on iNOS and COX-2 induction by lipopolysaccharide in Raw 264.7 macrophage cells. *Gastroenterology* 2007;A-440.
3. Dougherty U, Amikar S, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, **Delgado J**, Tretiakova M, Joseph L, Hart J, Cohen E, Lata A, Fichera A, Bissonnette M. EGFR controls flat dysplastic ACF development and colon cancer progression in the rat azoxymethane model. *Gastroenterology* 2008;134:A-240.
4. Dougherty U, Aluri L, Sehdev A, Cerda S, Mustafi R, Kocherginsky M, Tekin U, Badal S, Jagadeeswaran S, Chumsangsri A, **Delgado J**, Joseph L, Hart J, Threadgill D, Fichera A, Bissonnette M. EGFR is required for tumor promotion by dietary fat in a murine model of inflammation-associated colon cancer. *Gastroenterology* 2008;134:A-32.
5. Mustafi R, Chumsangsri A, Cerda S, Dougherty U, **Delgado J**, Fichera A, and Bissonnette M. Cross talk between colonic fibroblasts and colon cancer cells up-regulates Cox-2 and cyclin D1: Role of EGFR. *Gastroenterology* 2008; 134: A-749.
6. **Delgado J-S**, Yael Baumfeld, Victor Novack, Shulamit Monitin, Ohad Etzion, MD and Alexander Fich. Efficacy of Combined Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Jewish Patients in Israel. *Hepatology* 2010; A-1025.

PULMONARY PULMONARY INSTITUTE & PULMONARY PHYSIOLOGY LABORATORY



Head of Department

Dr Zeev Weiler. MD, FCCP

Lecturer of Medicine Ben-Gurion University

weilerz@barzi.health.gov.il

Medical Team

- Polyakov Nelly, MD *Instructor of Medicine Ben-Gurion University*
- Rozov Alexander, MD

Nursing Team

- Ben- Hamo Osnat, Head Nurse
- Shachanowitz Yelena
- Waisburd Regina

Research

- Arush Einat
- Drobitzki Marina
- Yitzchak Rivka
- Yossefian Ronit
- Kalmikov Marta

Field of Research Activity

- COPD: Asthma: Interstitial Lung Disease

Weiler Zeev, MD

Pulmonary Institute & Pulmonary Physiology Laboratory

תורגומן



תורגומן

List of Publications

1. Zamir D, Zamir M, Reitblat T, **Zeev W**, Polychuck I, Readmissions to hospital within 30 days of discharge from the internal medicine wards in southern Israel. Eur J Intern Med. 2006; 17(1): 20-3.
2. Zamir D, **Weiler Z**, Kogan Y, Ben-Valid E, Hai E, Reitblat T, Polychuck I. Single dose quinolone treatment in acute gastroenteritis. J Clin Gastroenteol. 2006: 40(3): 186-90.
3. Zeldin Y, **Weiler Z**, Cohen A, Kalinin M, Schlesinger M, Kidom M, Magen E. Efficacy of nasal Staphylococcus aureus eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. Annals of Allergy, Asthma & Immunology. 2008:100(6): 608-611
4. Yuri Zeldin, **Zeev Weiler**, Eli Magen, Liran Tiosano, Mona Kidon. Safety and efficacy of Allergen Immunotherapy in the Treatment of Allergic Rhinitis and Asthma in Real life. IMAJ 2008;869-872.
5. **Zeev Weiler**, Yuri Zeldin, Eli Magen, Doron Zamir, Mona I. Kidon. Pulmonary function correlates with arterial stiffness in asthmatic patients. Respiratory Medicine 2010 :104,197 - 203.

6. Karakis I, Blumenfels M, Yegev Y, Goldfarb D, Bolotin A, **Weiler W**, Carel R. A computerized surveillance system for Asthma. *International Journal of Health Care Quality Assurance*, 2011: 24(4).

Active Participation in Scientific Meetings

1. Six minute walk test – physiological aspects for health care professionals- Israel Society of Pulmonology annual scientific meeting, March 2006.
2. Bronchiolitis obliterans organizing pneumonia. Israeli Pulmonary Association meeting, Tel Aviv, December 2006.
3. The underdiagnosed disease- actinomyces. Israel Pulmonary Association meeting, Tel- Aviv, October 2007
4. Forced expiratory volume in first second correlate with measurements of arterial stiffness in asthmatic patients but not in non- asthmatic controls. Israeli Pulmonary Association Annual Scientific meeting, June 2008.
5. Biphase Exercise challenge testing in the diagnosis of asthma, Israeli Pulmonary Association Annual Scientific meeting, Jerusalem, June 2009
6. Reitblat T, **Weiler Z**, Jin L, Reifman G, Reitblat A. Tuberculin Skin reaction among healthy people and patients with arthritis in the southern Israeli region, 2011. *Oral & Poster*

New Technologies Used For Pulmonary Evaluation

1. Combined Cardio-Pulmonary Exercise testing.
2. Video bronchoscopic imaging of pulmonary pathologies.
3. Ultrasound guided pleural effusion aspiration.
4. Right heart catheterization assessments for pulmonary hypertension.
5. Fine needle & Core biopsy aspiration of pulmonary nodules.

Current clinical studies

1. **Teva- Fps-AS-202:** Efficacy and safety of Fp Spiromax. Administrated twice daily compared with placebo in adolescent and adult subject with severe persistent asthma uncontrolled on high dose inhaled corticosteroid therapy, (Phase 3, randomized, double-blind, placebo and open label active-controlled, parallel- group, multicenter), 2011
2. **Actelion- ACT- 129968:** Efficacy of different doses in adult patients with partly controlled asthma, (Phase 2b, double blind, placebo- controlled, parallel group study) , 2011
3. **Cephalon- C38072/3082:** The Efficacy and Safety of Reslisumab in the reduction of clinical asthma exacerbations and change in lung function in patients with Eosinophilic asthma. (Phase 3, randomized, double-blind, placebo controlled parallel group, one year study), 2011
4. **Nycomed- PPD RO 2455-404-RD:** Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. (Phase III/IV, randomized, double-blind trial), 2011
5. **PPD – Gilead GS-US-231-0101 ARTEMIS:** Efficacy and safety of Ambrisentan in subjects with early idiopathic pulmonary fibrosis. (Phase 3, randomized, double blind, placebo-controlled, multi-center, parallel group, event driven study), 2009
6. **Novartis, CQAB149B2348:** Comparison of effect of inhaled Indacaterol versus inhaled tiotropium on lung function, rate of exacerbations and related outcomes in patients with COPD (phase 3b multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study, 2009
7. **Boehringer Ingelheim BI 205.389 PAREXEL-** Effect of inhalation of titropium once daily 18 mcg versus salmeterol twice daily 50mcg on time to first exacerbation in COPD patients (a randomized, double-blind, double- dummy, parallel group, one year study), 2008
8. **PPD- Novartis CQMF149A2201-** 14 day dose ranging trial of 4 doses of indacatarol delivered via Twist haler in adult and adolescent patients with persistent asthma (a randomized, multi-center, parallel group, double blind, placebo and formoterol controlled), 2008
9. **Quintiles- Roche- NB19751-** The efficacy and safety study of 5mg R03300074 once daily for 2 years in subject with smoking- related, moderate- to- severe COPD with emphysema receiving concurrent optimal COPD drug therapy (a double- blind, placebo- controlled), 2007
10. **GSK FFA106783-** The efficacy and safety of GW685698X 200 mcg twice daily, GW685698X 200mcg and 400 mcg once daily in the evening compared with placebo for 8 weeks in adolescent and adult subject with persistent asthma (a randomized, double- blind, placebo controlled, parallel group, multi center study), 2006

11. **PPD- XRP1526B/ 3031**- The safety and efficacy of Formoterol HFA MDI (10mg) and Formoterol DPI (Foradil 12 mg) or placebo in adult patient with Asthma (a randomized, Double- Blind, Placebo- and active controlled parallel group, stratified multi center 12 week study), 2006

THE ISRAELI FORUM FOR PREVENTION OF CARDIOVASCULAR DISEASES

פורום

Head of Department

Prof J. Reuven Viskoper, MD

Description

Prof Viskoper is the President of "The Israeli Forum for - Prevention of Cardiovascular Diseases" located at Barzilai Medical Center. This committee was established in 2002 as a result of the joint decision of the Ministry of Health, the four Sick Funds and the scientific societies of the Israel Medical Association that deals with cardiovascular (heart and blood vessel) disease prevention.

The following projects were developed within the forum activity:

1. CVD prevention in "healthy workers" of industry. This project was performed in nine industries - % of high risk for CVD is 50%. After three months of intervention encompassing: physical exercise, healthy nutrition, smoking cessation and MD advise for risk factors control, the risk was reduced by 50%, HBP by 30% and smokers by 20%. The industrial society, Bituach Leumi and Kern Manof cooperate in this mission.
2. Risk factors control in community: some project in several Kibbutzim in north and in south Israel.
3. "The heart prefers green": intervention in food preparation and subsequently, labeling healthy food in green and unhealthy food in red. Performed in several large scale industries and in several Kibbutzim.
4. Training catering firms, especially those working with industries, how to prepare healthy food and monitoring the performance.

5. Healthy lifestyle instruction for elderly, especially in Kiryat-Gat.
6. Training students of Medicine to become health instructors in the community, in cooperation with Deans of faculties of Medicine.
7. Instruction of parents and teachers of 70 schools on healthy lifestyle, in cooperation with ministry of education program "Tafur Alai" and "Kern Karev".
8. Health promotion – prevention of CVD with special approach to CVD offspring by public health nurses in: Ashkelon and Ashdod region, in cooperation with: Ministry of health – public health department and department of health education.
The Kupat Holim Leumit nurses also participate in this program as well as Family physicians treating Arab and Druze populations in northern Israel.

Main Fields of Research Activities:

Its activities are directed to the so called "healthy population" and are two fold:

1. Diagnose those at high risk to develop cardiovascular diseases.
2. Teach those subjects with high risk, healthy life style during a 3 months period and Reduce % of the high risk subjects

J. Reuven Viskoper, MD

*The Israeli Forum for
Prevention of Cardiovascular Diseases*

📖📖📖



📖📖📖

List of Publications

1. Magen E, **Viskoper J.R**, Mishal J, Priluk R, London D, Josefy C. Effects of low- dose Aspirin on blood pressure and endothelial function of treated hypertensive – hypercholesterolemic subjects. *Human hypertension*. 2005; 19, 667-673
2. Magen E, Yosefy C, **Viskoper RJ**, Mishal J. Treatment of allergic rhinitis can improve blood pressure control in adolescent population. *J Hum Hypertens*. 2006 Nov; 20(11):888-93. Epub 2006 Sep 7
3. Kjeldsen S.E, Julius S, Mancia G, **Viskoper J.R**, Zanchetti A. Effects of Valsartan compared to Amlodipine in preventing type 2 diabetes in high- risk hypertensive patients: the VALUE trial. *Journal of Hypertension*. 2006; 24, 7, 1405-1412
4. Chaim Yosefy, Garry Ginsberg, **Reuven Viskoper**, Dror Dicker, Dov Gavish. Cost-Utility analysis of a National project to reduce Hypertension in Israel, *Cost Eff Resour Alloc*. 2007 Nov 28;5:16
5. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Laroche P, Macdonald T, Schmieder RE, Anthony Schork M, **Viskoper R**, Widimsky J, Zanchetti A. *Blood Pressure*. 2008; 17: 170-177.

Active Participation in Scientific Meetings

- Israeli Society of Hypertension meeting Caesarea: April 2011
- Attendances at International Meetings: Sept. 2010, 23 Scientific ISH (International Soc. of Hypertension) meeting – Vancouver Canada.

Departments

DEPARTMENT OF PSYCHIATRY



Head of Department

Prof Gabriel Schreiber MD, PhD

Professor of Medicine Ben-Gurion University

Elected Dean of Faculty of Health Sciences, Ben Gurion University of the Negev.

schreibg@bgu.ac.il

Medical Team:

- | | |
|--------------------------|--|
| ▪ Andrey Belgorodsky, MD | Deputy Director Department
<i>Instructor in Medicine BG University</i> |
| ▪ Katty Major, MD | Director Outpatients Clinic
<i>Instructor in Medicine BG University</i> |
| ▪ Leonid Knyazhansky, MD | Senior Phychiatrist
<i>Instructor in Medicine BG University</i> |
| ▪ Oxana Narsia, MD | Senior Phychiatrist
<i>Instructor in Medicine BG University</i> |
| ▪ Natalia Miroshnik, MD | Deputy Senior Phychiatrist
<i>Instructor in Medicine BG University</i> |
| ▪ Anna Podberegsky, MD | Senior Phychiatrist
<i>Instructor in Medicine BG University</i> |

Additional Medical Team:

- | | |
|----------------------------|----------|
| ▪ Natalia Vasilets , MD | Resident |
| ▪ Alexander Goldshtein, MD | Resident |
| ▪ Anton Lagerev, MD | Resident |
| ▪ Georgy Piven, MD | Resident |
| ▪ Michael Kopilov, MD | Resident |
| ▪ Elena Yahaiov, MD | Resident |
| ▪ Natalia Kabluchic, MD | Resident |

Nursing Team:

- Mr. Moshe Rotshtein Head Nurse
- Ms. Hana Amar Deputy Head Nurse

Research Activity

The research projects at the Department of Psychiatry at Barzilai Medical Center involve:

1. The involvement of G proteins and beta-arrestins, proteins that play a major role cellular signal transduction in the mechanism of action of antidepressants and mood stabilizers and in the pathophysiology, diagnosis and treatment of mood and other mental disorders.
2. The application of mathematical dynamic concepts: non-linear dynamics, chaos, and fractals to understand dynamic principles of psychoanalysis.
3. The epidemiology and prevention and management of ASR, ASD and PTSD syndromes in the Ashkelon area and around the Gaza strip.
4. Treatment of negative symptoms in schizophrenia through the use of NMDA ligands.

Gabriel Schreiber, MD, PhD

Psychiatry Department

නර්මනර්මනර්ම



නර්මනර්මනර්ම

List of Publications

Refereed articles in scientific journals

A-Original Articles

1. Matuzany-Ruban A, Avissar S, **Schreiber G**: Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. *J. Affective Disorders* 88:307-312, 2005.
2. **Schreiber G**, Avissar S: Mood disorders and their treatment: alterations in the regulation of receptor-G protein coupling. *Drug Development Research* 65:147-155, 2005.
3. Matuzany-Ruban A, **Schreiber G**, Farkash P, Avissar S: Phosducin-like protein levels in mononuclear leukocytes of patients with major depression and in rat cortex: the effect of chronic treatment with antidepressants. *Psychiatry Research*. 141:287-294, 2006.

4. Avissar S, **Schreiber G.**: The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. *Clin Chim Acta.* 366:37-47, 2006.
5. **Schreiber G,** Avissar S: Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. *Expert Rev Neurother.* 7:75-84, 2007.
6. Golan M, **Schreiber G,** Avissar S: Antidepressants, Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions. *Curr Pharm Des* 15:1699-1708, 2009
7. **Schreiber G,** Golan M, Avissar S: Arrestin signaling complex as a target for antidepressants and a depression marker. *Drug News Perspect.* 22:467-480, 2009
8. Matuzany-Ruban A, Golan M, Miroshnik N, **Schreiber G,** Avissar S: Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. *Int J Neuropsychopharmacol.* 13:83-91, 2010.
9. Golan M, **Schreiber G,** Avissar S: Antidepressants increase β -arrestin2 ubiquitinylation and degradation by the proteasomal pathway in C6 rat glioma cells. *J Pharmacol Exp Ther.* 332:970-976, 2010
10. Golan M, **Schreiber G,** Avissar S: Antidepressants elevate GDNF expression and release from C6 glioma cells in a β -arrestin1-dependent, CREB interactive pathway. *Int J Neuropsychopharmacol.* *Int J Neuropsychopharmacol.* 2011 Jan 12:1-12. [Epub ahead

B- Chapters in Books

1. **Schreiber G**, Avissar S: Actual etiopathological hypotheses for mental disorders: the role of classical and novel systems of neurotransmission and neurotransduction. In: History of Psychopharmacology. Ed. Munoz, F, L, Editorial Medica Panamericana, Madrid 2006, Chapter 78 p. 1679-1706.
2. Golan M, **Schreiber G**, Avissar S: Regulation of G Protein Receptor Coupling, Mood Disorders and Mechanism of Action of Antidepressants. In: Signal Transduction: Pathways, Mechanisms and Diseases. Edited by Ari Sitaramayya. Springer-Verlag, Berlin 2010, p.63-81.
3. Avissar S and **Schreiber G**: Beta-arrestins in depression: a molecular switch from signal desensitization to alternative intracellular adaptor functions. In: Neurobiology of Depression. Edited by F. Lopez-Munoz. Frontiers in Neuroscience Books, CRC Press, NY. (In press).

C- Book

1. Simply Complex: A Literary-Geometric-Non-Linear Journey from Borges to Lacan. Tel Aviv Resling 2011.

Active Participation in Scientific Meetings

A- Abstracts & Letters

1. Golan M, **Schreiber G**, Avissar S: arrestin plays a major role in the mechanism of action of antidepressant drugs. 21st European College of Neuropsychopharmacology (ECNP) Congress, Barcelona September 2008. European Neuropsychopharmacology, Vol. 18 Supplement 4, 2008, Page S345-S346
2. Golan M, **Schreiber G**, Avissar S: Antidepressants post-receptor mechanism of action involves arrestins and extracellular signal-regulated kinases The 9th World Congress of Biological Psychiatry, Paris June 2009.
3. Golan M, **Schreiber G**, Avissar S: Normalization of GRK2 measures in patients with depression predict response to antidepressants. 2009 Congress of the World Federation for Mental Health, Athens September 2009.

4. Golan M, **Schreiber G**, Avissar S: The Involvement of ERK-dependent processes in antidepressant effects on beta-arrestins. World Congress of Basic and Clinical Pharmacology, WorldPharma2010, Copenhagen 17-23 July 2010.
5. Avissar S, Golan M, **Schreiber G**: The role of beta-arrestins in the mechanism of action of antidepressant drugs. XXVII CINP World Congress – Hong Kong, 2010. The International Journal of Neuropsychopharmacology, Volume 13, Issue S1, June 2010, pp 120-121.

Competitive Research Grants

2005-2007	NARSAD Investigator Award (U.S.A.) 100,000\$/ 2 years Sofia Avissar and Gabriel Schreiber (clinical aspects) "GRK, β -arrestin and PhLP, regulators of receptor-G protein coupling: Involvement in mood disorders and in the mechanism of action of antidepressants and mood stabilizers
1998-2006	50,000\$. Yadgaroff Family Foundation-Gabriel Schreiber Standing Donation for Research in Biological Psychiatry
2007	Lundbeck Grant; 100,000\$ PTSD Prevention Study

DEPARTMENT OF NEUROLOGY



Head of Department

Dr Ron Milo. MD, Director

Lecturer in Medicine, Ben Gurion University

Ronm@barzi.health.gov.il

Medical Team - Consultants

Prof Esther Kahana, MD	Specialist in Pediatric Neurology; Neuroepidemiology
Elena Dorodnicov, MD	Deputy head; Stroke, Vascular Neurology <i>Instructor in Medicine, Ben Gurion University</i>
Zoja Aladjem, MD, Ph.D	Head of memory Clinic
Natalia Tikhmanovich, MD	Specialist in Neurophysiology, Neuromuscular diseases
Lea Pery, MD	Specialist in Headache; Research
Tatiana Katz, MD	Specialist in multiple sclerosis
Alexander Gur, MD	Stroke, vascular neurology
Lior Volchek, MD	Research; Neurophysiology <i>Instructor in Medicine, Ben Gurion University</i>

Additional Medical Team - Residents:

- Jenia Reznik-Zoref, MD Resident
- Larisa Gerasimov, MD Resident
- Alexander Shenker, MD Resident
- Anna Gelfand, MD Resident

Description

The department of neurology is involved in all aspects of neurological clinical services, teaching and research.

The department cares for patients with all neurological problems. Patients are referred for hospitalization from the emergency department, the outpatient clinics, other departments at the hospital and by family physicians and neurologists from community healthcare services in the catchment area.

Three thousand patients are also seen at the outpatient clinics each year, and the department provides consultation services to the emergency and other departments of the hospital and elsewhere.

The Department of Neurology comprises of 12 bed inpatient wards and outpatient clinics which offers care of the following: General neurology, memory and dementia, stroke, neuroimmunology, multiple sclerosis and neuromuscular diseases. Other services provided by the department include acute stroke care, transcranial doppler (TCD) and neurophysiological tests such as EEG, EMG+NCV and evoked potentials (VEP, SEP, BERA).

The Department of Neurology conducts multiple clinical trials in multiple sclerosis, epilepsy, stroke, headache, Alzheimer's disease, Parkinson's disease, neuropathies and other conditions. As a consequence, the Department of Neurology is responsible for the largest number of clinical studies in 2010.

The department is affiliated to the Faculty of Health Sciences at the Ben-Gurion University of the Negev and involved in educational activities such as frontal teaching for medical students and at the School of Nursing at the Barzilai MC, teaching of residents and rotating interns in neurology, and rotating clerkships for medical students from the Ben-Gurion university and all over the world.

Ron Milo, MD

Department of Neurology

🌀🌀🌀🌀🌀



🌀🌀🌀🌀🌀

Main Fields of Research Activity

1. Multiple sclerosis- epidemiology, cognitive dysfunction, quality of life, neuropsychological assessment, breast cancer in MS.
2. Stroke- characteristics of acute stroke patients treated with tPA
3. Creutzfeldt-Jacob disease- protein biomarkers in the CSF, surveillance in Israel, studies on the epidemiology and genetics of the disease in Lybian jews.
4. Epilepsy- epidemiology of the disease in Ashkelon
5. Epidemiology of SSPE.
6. Individual differences in EEG amplitude, frequency and alpha index: relation to differences in psychometric tests of intelligence.
7. Cognitive dysfunction in dementia and other medical conditions.

List of Publications

Refereed articles in scientific journals

A-Original Articles

1. Gigi A, Vakil E, **Kahana E**, Hadar U: Presymptomatic signs in healthy CJD mutation carriers. *Dement. Geriatr Cogn Disord* 2005; 19:246-255.
2. Rosenmann H, Meiner Z, **Kahana E**, **Aladjem Z**, Friedman G, Ben-Yehuda A, Grenader T, Wertman E, Abramsky O: A polymorphism in the complement component C1r is not associated with sporadic Alzheimer's disease. *Neuroscience Letters* 2005; 336:101-104.
3. Alter M, **Kahana E**, Zilber N, Miller A, and the Israeli MS Study Group: Multiple sclerosis frequency in Israel's diverse populations. *Neurology* 2006; 66:1061-1066.
4. Fulbright RK, Kingsley PB, Guod X, Hoffmann C, **Kahana E**, Chapman JC, Prohovnik I. The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation. *Magnetic Resonance Imaging* 2006;24:1121-1129
5. **Milo R**: Clinical Guidelines: Recommendations of the Israel Neurological Association for immunomodulatory therapies in multiple sclerosis. (Hebrew). *Israeli Journal of Neurology* 2007;17:40-42
6. Lewy H, Rotstein A, **Kahana E**, Marrosu MG, Cocco E, Laron Z: Juvenile multiple sclerosis similar to type I diabetes mellitus has a seasonality of month of birth which differs from that in the general population. *J Pediatr Endocrinol Metab* 2008; 21:473-477.
7. **Milo R**, Kalichman L, **Volchek L**, Reitblat T: Local corticosteroid treatment for carpal tunnel syndrome: A 6-months clinical and electrophysiological follow-up study. *J Back Musculoskelet Rehabil* 2009; 22:59-64.
8. Lee H, Rosenmann H, Chapman J, Kingsley PB, Hoffmann C, Cohen OS, **Kahana E**, Korczyn AD, Prohovnik I: Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. *Brain* 2009; 132:2680-2687.

9. **Milo R, Kahana E**: Multiple sclerosis: Geoepidemiology, genetics and the environment. *Autoimmun Rev* 2010; 9:A387-94.
10. Appel SA, Chapman J, **Kahana E**, Rosenmann H, Prohovnik I, Pras E, Reznik-Wolf H, Cohen OS: Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever. *Eur J Neurol* 2010; 17:861-865.
11. Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, **Milo R**, Marder E, Khan O, Eagar TN. Translational Research in Neurology and Neuroscience 2010: Multiple Sclerosis. *Arch Neurol* 2010; 67: 1307-15.
12. **Milo R**: New therapies in multiple sclerosis: Do their potential benefits outweigh the risks? *J Isr Neurol Assoc* 2010; 1:45-47.
13. Meiner Z, **Kahana E**, Baitcher F, Korczyn AD, Chapman J, **Milo R**, Aharon-Perez Y, Abramsky O, Gabizon R, Rosenmann H: Tau and 14-3-3 in CSF and clinical characteristics of genetic and sporadic Creutzfeldt -Jakob disease in Israel- 1991-2006. *J Neurol* 2010 Sep 9. [Epub ahead of print]
14. **Milo R**: Early treatment in multiple sclerosis. *J Isr Neurol Assoc* 2010; 3:36-38.

Co-Investigator in multinational clinical studies

1. Filippi M, Wolinsky JS, Comi G and the CORAL Study Group: Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. *Lancet Neurology* 2006;5: 213-220
2. Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). *Cerebrovasc Dis.* 2007; 23(5-6):368-80.

3. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PROfESS Study Group. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. *N Engl J Med* 2008; 359:1238-51.
4. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PROfESS Study Group. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. *N Engl J Med* 2008; 359:1225-37.
5. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; for the Prevention Regimen for Effectively Avoiding Second Strokes (PROfESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROfESS) trial: a double-blind, active and placebo-controlled study. *Lancet Neurol.* 2008; 7:875-84.
6. GALA Trial Collaborative Group, Lewis SC, Warlow CP, Bodenham AR, Colam B, Rothwell PM, Torgerson D, Dellagrammaticas D, Horrocks M, Liapis C, Banning AP, Gough M, and Gough MJ: General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre randomised controlled trial. *Lancet* 2008; 372:2132-42.
7. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group: 250 microg or 500 microg interferon

beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol* 2009; 8:889-97.

8. Teal P, Davis S, Hacke W, Kaste M, Lyden PD; Modified Randomized Exposure Controlled Trial Study Investigators, Fierus M; Bayer HealthCare AG. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). *Stroke* 2009; 40:3518-25.
9. Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D; NASIS Investigators: Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). *Stroke* 2009; 40:2581-4.
10. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; the FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*. 2010; 362(5):402-15.
11. Karussis D, Teitelbaum D, Sicsic C, Brenner T, the ACOO1 multi-center Israeli study group: Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. *J Neuroimmunol* 2010; 220:125-30.
12. Koton S, Bornstein NM, Tsabari R, Tanne D; NASIS Investigators: Derivation and validation of the prolonged length of stay score in acute stroke patients. *Neurology* 2010; 74:1511-6.
13. Benedek G, Paperna T, Avidan N, Lejbkovicz I, Oksenberg JR, Wang J, Brautbar C, Israel S, Miller A, Israeli MS Genetics group. Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel. *Genes Immun* 2010; 11:423-431.

B- Chapters in Books

1. **Milo R**, Miller A: Multiple Sclerosis. In: Y Shoenfeld, R Cervera, ME Gershwin (Eds), Diagnostic Criteria in Autoimmune Diseases. Humana Press 2008, Chapter 73, pp 401-406.

Active Participation in Scientific Meetings

1. **Milo R**: Addressing immunology and pathology of multiple sclerosis with glatiramer acetate. *Invited lecture* at the Annual Congress of the Taiwan Neurological Society, Taipei, Taiwan, April 23-24.2005.
2. **Milo R**: Real time neuropsychological assessment in early detection of cognitive impairment in multiple sclerosis. 12th Tel-Aviv University Alzheimer's Disease Conference, Tel-Aviv, June 15-16, 2005.
3. **Milo R**, Kertzman S, **Katz T**, **Orljansky A**, Ben-Nahum Z, **Aladjem Z**: Correlations with PASAT and validity of a real time computerized cognitive scanning battery in MS. Mid-Annual Meeting of the Israel Neurological Association, Tel-Aviv, June 28, 2005.
4. **Dorodnicov E**, **Gelfand A**, **Milo R**: Neurosyphilis today. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 20-21, 2005
5. Zamir D, **Aladjem Z**, Vanel M, Polychuck I, Reitblat T, **Milo R**, Kerzman S: Improvement in cognitive functions in patients with chronic hepatitis C under treatment with peg. Interferon +ribavirin. The 5th EFIM - Congress of the European Federation of Internal Medicine, Paris, France, August 31 – September 03, 2005.
6. Zamir D, Kerzman S, **Aladjem Z**, Zamir M, Ben-Nahum Z, **Milo R**: Does acute ingestion of sildenafil impair cognitive functions? The 5th EFIM - Congress of the European Federation of Internal Medicine, Paris, France, August 31 – September 03, 2005.
7. Zamir D, Melnik S, Vanel M, **Aladjem Z**, **Milo R**, Polychuck I, Kerzman S: Severe cognitive impairment in patients with chronic hepatitis C -are they fit to drive? The 5th EFIM - Congress of the European Federation of Internal Medicine, Paris, France, August 31 – September 03, 2005.
8. **Milo R**, **Aladjem Z**, **Orljansky A**, **Bondoriansky L**, Ben-Nahum Z, Kertzman S: Neurocognitive assessment in elderly and geriatric population. 16th Israel Medical Week (MEDAX), Tel-Aviv, February 21-23, 2006.
9. **Milo R**, Panitch H: Additive effects of interferon beta-1b and glatiramer acetate on the immune response to myelin basic protein: Implications for combined immunotherapy of MS. 22th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Madrid. Spain, September 27-30, 2006. *Mult Scler* 2006; 12 (Suppl 1):S12.

10. **Dorodnicov E, Gelfand A, Lebedev V, Milo R:** Dolichoectasia of the vertebral artery presenting as acute vestibular syndromes. Joint World Congress on Stroke, Capetown, South-Africa, October 26-29, 2006. *Int J Stroke* 2006; 1 (Suppl 1):124.
11. **Milo R:** Making therapeutic decisions in MS. 42th National Congress of the Turkish Neurological Society, Antalya, Turkey, November 12-17, 2006.
12. **Shenker A, Rosenmann H, Baitcher F, Meiner Z, Milo R, Kahana E:** CSF 14-3-3 and TAU proteins in Creutzfeldt-Jacob disease and other dementias. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 26-27, 2006
13. **Dorodnicov E, Gelfand A, Lebedev V, Milo R:** Dolichoectasia of the vertebral artery presenting as acute vestibular syndromes. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 26-27, 2006
14. Rotstein A, Lewy H, **Kahana E, Marrosu MG, Cocco E, Laron Z,** and the Israeli MS study group: Abnormal seasonality of month of birth in multiple sclerosis. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 26-27, 2006
15. **Milo R:** Recent advances in the treatment of multiple sclerosis *Invited lecture* at the Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 26, 2006.
16. Brenner T, karussis D, Abramsky O, Arnon R, Cicsic C, Teitelbaum D, The Israeli AC-001 Study Group: Anti-glatiramer acetate antibodies profile in long term treated multiple sclerosis patients. The 6th annual Meeting of the Israel Society of Neuroimmunology, Tel-Aviv, November-28, 2006
17. Benedek G, Israel S, Paperna T, Oksenberg J, Brautbar C, Miller A, for the Israeli MS Genetics Study (IMSGS) Group. HLA immunogenetics of Multiple Sclerosis in Israeli Arabs. The 6th annual Meeting of the Israel Society of Neuroimmunology, Tel-Aviv, November-28, 2006
18. **Milo R:** Mechanisms of action of glatiramer acetate. *Invited lecture* The First International Conference on Advances in Clinical Neuroimmunology, Poznań, Poland, December 7-8, 2007.
19. **Milo R:** Current and up-coming clinical trials in multiple sclerosis *Invited lecture* The Annual Meeting of the Israel Society of Neuroimmunology, Ramat-Gan, November 13 2007
20. Zamir D, Kertzman S, Malnick S, Melzer E, Vanel M, Orljansky A, **Milo R, Aladjem Z:** Neuropsychological improvement in patients with chronic hepatitis C under pegylated interferon and ribaverin treatment. 11th Meeting of the Israel Society for Biological Psychiatry, Kfar Giladi, March 27-29, 2007. *Israel Journal of Psychiatry* 2007; 44:24
21. **Aladjem Z, Kertzman S, Orljansky A, Vanel M, Melnik S, Melzer E, Zamir D, Milo R:** Cognitive impairment in chronic hepatitis c infection. Mid-Annual Meeting of the Israel Neurological Association, Tel-Aviv, June 26, 2007.
22. Inzelberg R, Rabey JM, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Trau H, Aharon-Peretz J, Huberman M, **Milo R, Gilead L, Giladi N:** The relationship of Parkinson's disease (PD) and melanoma: an epidemiological survey in Israel. 11th congress of the European Federation of Neurological societies (EFNS), Brussels, Belgium, August 25-28, 2007.

23. **Kahana E**, Alter M, Zilber N, and The Israeli MS study group: Multiple sclerosis risk in immigrants to Israel. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 18-19, 2007.
24. Inzelberg R, Rabey JM, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Trau H, Aharon-Peretz J, Huberman M, **Milo R**, Gilead L, Giladi N: The relationship of Parkinson's disease and melanoma: an epidemiological survey in Israel. Annual Meeting of the Israel Neurological Association, Tel-Aviv, December 18-19, 2007.
25. **Dorodnicov E**, **Kahana E**, Gelfand A, **Milo R**: Epidemiology of ischemic stroke in young patients. Mid-Annual Meeting of the Israel Neurological Association, Tel-Aviv, June 25, 2008.
26. Appel SA, Chapman J, Kahana E, Prohovnik I, Rosenmann H, Cohen OS. Virulent course of CJD in patients with familial Mediterranean Fever. Mid-Annual Meeting of the Israel Neurological Association, Tel-Aviv, June 25, 2008.
27. Kahana E, Alter M, Zilber N, and The Israeli MS study group: Environmental factors determine multiple sclerosis risk in migrants to Israel. World Congress on Treatment and Research in Multiple Sclerosis, Montreal, Canada, September 17-20 2008.
28. **Dorodnicov E**, **Kahana E**, **Gelfand A**, **Milo R**: Ischemic stroke in young Israeli patients. 6th World Stroke Congress, Vienna, Austria, September 24-27, 2008. Int J Stroke 2006; 3 (Suppl 1):118.
29. **Milo R**: Is there a role for combination therapy in multiple sclerosis? 2nd World Congress on Controversies in Neurology, Athens, Greece, October 23-26, 2008. The 17th European Stroke Conference, Nice, France, May 13-16, 2008.
30. Sacco R, Diener H-C, Yusuf S, for the Steering Committee and PROFESS Study Group: Prevention regimen for effectively avoiding second strokes (PROFESS) trial: comparison of a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel. Cerebrovasc Dis 2008 25(suppl 2):8. The 17th European Stroke Conference, Nice, France, May 13-16, 2008.
31. Yusuf S, Sacco R, Diener H-C, for the Steering Committee and PROFESS Study Group: Prevention regimen for effectively avoiding second strokes (PROFESS) trial: telmisartan versus placebo. Cerebrovasc Dis 2008; 25(suppl 2):9 The 17th European Stroke Conference, Nice, France, May 13-16, 2008.
32. Diener H-C, Yusuf S, Sacco R, for the Steering Committee and PROFESS Study Group: Prevention regimen for effectively avoiding second strokes (PROFESS) trial: cognitive and functional outcomes after stroke. Cerebrovasc Dis 2008; 25(suppl 2):9 The 17th European Stroke Conference, Nice, France, and May 13-16, 2008.
33. G. Comi, M. Filippi on behalf of the PreCISe Study Group: Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome suggestive of MS. J Neurol 2008; 255(Suppl. 2):O59.
34. **Dorodnicov E**, Shkil A, **Milo R**: Thrombolysis in acute ischemic stroke: 3-year experience at the Barzilai Medical Center. Annual Meeting of the Israel Neurological Association, Tel-Aviv, January 6-7, 2009.
35. **Milo R**: Clinical trials in progress and MS therapies on the horizon. Annual conference of the Israel Society of Neuroimmunology, Tel-Aviv, March 31 – April 01, 2009.
36. **Milo R**: New horizons in MS therapy. National congress of the Romanian Neurological Society, Bucharest, Romania, May 13-16, 2009.
37. **Milo R**: New treatments in multiple sclerosis. Invited lecture at the Mid-Annual Meeting of the Israel Neurological Association, Tel-Aviv, June-3, 2009.

38. Hutton G, On Behalf of the CAMMS223 Study Group: The CARE-MS II Trial (Comparison of Alemtuzumab and Rebif[®] Efficacy in Multiple Sclerosis): Updated design of a phase 3, open-label, rater-blinded study of alemtuzumab in patients with MS who have relapsed on therapy. 19th Meeting of the European Neurological Society, Milan, Italy, June 20-24, 2009. *J Neurol* 2009; 256(Suppl 2):S122.
39. **Milo R**: Newly emerging therapies: Do their potential benefits outweigh the risks? 3rd World Congress on Controversies in Neurology, Prague, Czech Republic, October 8-11, 2009.
40. Prohovnik I, Cohen OS, Hoffman C, Lee H, Rosenmann H, **Kahana E**, Chapman J: Correlation between subcortical atrophy and survival of CJD patients. 134th Meeting of the American Neurological Association, Baltimore, MD, October 11-14, 2009.
41. **Dorodnicov E**, Shkil A, Gelfand A, **Milo R**: Sonothrombolysis combined with rt-PA treatment in MCA acute ischemic stroke. Annual Meeting of the Israel Neurological Association, the Dead Sea, November 25-28, 2009.
42. **Milo R**: Risk to benefit for the use of the new monoclonal antibodies and other new treatments in MS. Advances in Neuroimmunological Diseases Plenary Session, Annual Meeting of the Israel Neurological Association, The Dead Sea, November 25-28, 2009.
43. Karussis D, Teitelbaum D, Sicsic C, Brenner T and The ACOO1 Multi-Center Israeli Study Group: Long term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. Annual Meeting of the Israel Neurological Association, the Dead Sea, November 25-28, 2009.
44. **Milo R**: Neuroprotective actions of immunomodulatory drugs in MS. Annual conference of the Israel Society of Neuroimmunology, Caesarea, April 29 – May 1, 2010.
45. **Milo R**: Oral fingolimod for multiple sclerosis. Drug Prediction Meeting, Hamaccabia Village, Ramat-Gan, Israel, May-13, 2010.
46. **Milo R**: Early treatment for multiple sclerosis. The Israel Neurology Conference, Tel-Aviv, Israel, May-26 2010.
47. **Milo R**: Combination therapy for MS. 2nd International Conference on Advances in Neuroimmunology, Gdansk, Poland, May-31 – June 1, 2010. *J Neuroimmunol* 2010; 222:4-5.
48. Kertzman S, **Aladjem-Dimitrov Z**, Shliapnikov N, Grinspan H, Irger M, **Milo R**, Kotler M: Neurocognitive differences between extremely violent and non-violent schizophrenic patients. 14th Congress of the European Federation of Neurological Societies (EFNS), Geneva, Switzerland, September 25-29, 2010. *Eur J Neurol* 2010; 17(Suppl 3):198.
49. **Milo R**: Combination therapy in demyelinating diseases: rationale, experience and prospects. 20th Congress of the Italian Association of neuroimmunology (AINI), Stresa, Italy, September 30 – October 3, 2010.
50. **Milo R**: Should all MS patients be treated with statins? 4th Controversies in Neurology (CONy) Congress, Barcelona, Spain, October 28-31, 2010.
51. **Dorodnicov E**, Gur A, **Milo R**: Intravenous thrombolysis in patients with acute vertebro- basilar stroke: why do we treat so little? Annual Meeting of the Israel Neurological Association, Eilat, December 15-18, 2010. *J Isr Neurol Assoc* 2010; 4:62.
52. **Aladjem Z**, Zamir D, Polishchuk I, Novochatko G, Reitblat T, **Milo R**, Kertzman S: Night duties cause disturbances in memory but not in psychomotor function or

- attention in physicians. Annual Meeting of the Israel Neurological Association, Eilat, December 15-18, 2010. *J Isr Neurol Assoc* 2010; 4:59-60.
53. Kappos L, O'Connor P, Polman C et al, on Behalf of the FREEDOMS Study Group: Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-Month Clinical Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS). A194. The 62rd Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 10-17, 2010. *Neurology* 2010; 74 (suppl 2)
 54. Radue EW, O'Connor P, Polman C et al, on Behalf of the FREEDOMS Study Group: Oral Fingolimod (FTY720) Reduces Inflammatory Activity vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-Month MRI Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS):A194. The 62rd Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 10-17, 2010. *Neurology* 2010; 74 (suppl 2)
 55. O'Connor P, Polman C, R Hohlfeld et al, on Behalf of the FREEDOMS Stud Group: Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-Month Safety and Tolerability Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS). A552. The 62rd Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 10-17, 2010. *Neurology* 2010; 74 (suppl 2)
 56. LaGanke C, on behalf of the CAMMS Study Groups: Exploring alemtuzumab's long term efficacy and safety: design of the CARE-MS extension study. A550. The 62rd Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 10-17, 2010. *Neurology* 2010; 74 (suppl 2)
 57. Hohlfeld R, Calabresi PA, O'Connor P, Polman CH, Agoropoulou C, Haring D, Zhang-Auberson L, Kappos L, on behalf of the FREEDOMS (FTY720 Research evaluating Effects of daily Oral Therapy in multiple Sclerosis Study Group): Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease-modifying therapies for multiple sclerosis and in patients who are treatment naïve: subgroup analysis of data from a 24-month phase III study (FREEDOMS). S21. The 20th Meeting of the European Neurological Society, Berlin, Germany, June 19-23 2010; *J Neurology* 2010;257(Suppl 1):
 58. Kappos L, Calabresi PA, O'Connor P, Hohlfeld R, Polman CH, Agoropoulou C, Haring D, and Zhang-Auberson L, on behalf of the FREEDOMS (FTY720 Research evaluating Effects of daily Oral Therapy in multiple Sclerosis Study Group): Oral fingolimod (FTY720) has consistent, beneficial effect on disability progression outcomes in relapsing multiple sclerosis: 24 month, placebo-controlled results from the phase III FREEDOMS study. S144. The 20th Meeting of the European Neurological Society, Berlin, Germany, June 19-23 2010; *J Neurology* 2010;257 (Suppl 1):
 59. Fernandez O, Baumstarck-Barrau K, Simeoni MC, Auquier P. The MusiQoL Study Group: Factors determining quality of life in an international population of patients with multiple sclerosis: assessment using the MusiQOL and SF-36 questionnaires. 487. The 14th Congress of the European Federation of Neurological Societies (EFNS), Geneva, Switzerland, September 25-29, 2010. *Eur J Neurol* 2010; 17 (Suppl 3)
 60. Meshram C, Bhatt M, Chirileanu D, Stanzione P, Lucini V, Rossetti S, Anand R, for the Study 016 Investigators. Safinamide improves motor function without worsening troublesome dyskinesia as add-on therapy in L-DOPA- treated patients with mid- to late-stage Parkinson's disease (PD) 99. The 14th Congress of the European

- Federation of Neurological Societies (EFNS), Geneva, Switzerland, September 25-29, 2010. *Eur J Neurol* 2010; 17 (Suppl 3)
61. Von Rosenstiel P, Hohlfeld R, Calabresi P, O'Connor P, Polman CH, Radü EW, Zhang-Auberson L, Agoropoulou C, Häring DA, Kappos L, on behalf of the FREEDOMS STUDY GROUP: Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. (*Mult Scler* 2010; 16 Suppl 10):S143. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenburg, Sweden, October 13-16, 2010.
 62. Auquier P, Fernández O, Butzkueven H, Flachenecker P, Idiman E, Pelletier J, Stecchi S, Verdun di Cantogno E, Issard D, Simeoni M-C, on behalf of the MusiQoL Responsiveness Study Group: Responsiveness of the multiple sclerosis international quality of life and short form-36 questionnaires to expanded disability status score changes in patients with multiple sclerosis: 12-month results of an international observational study. *Mult Scler* 2010;16 (Suppl 10):S222-S223. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenburg, Sweden, October 13-16, 2010.
 63. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H-P, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, for the PreCISe study group: Benefit of early treatment with glatiramer acetate (COPAXONE): results from the 5- year prospectively planned follow up in patients with clinically isolated syndrome from the PreCISe study. *Mult Scler* 2010;16 (Suppl 10):S37. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenburg, Sweden, October 13-16, 2010.
 64. Filippi M, Rocca MA, Perego E, Agosta F, Meani A, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H-P, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Comi G, for the PreCISe study group: Benefit of early treatment with glatiramer acetate: MRI results from the 5-year prospectively planned follow up in patients with clinically isolated syndrome enrolled in the PreCISe study. (Suppl 10):S349. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenburg, Sweden, October 13-16, 2010.
 65. Kister I, Bacon T, Chamot E, Cutter G, Butzkueven H, Herbert J, on behalf of the MSBase registry: Multiple Sclerosis Severity Scores decrease with calendar year of first EDSS assignment in MSBase. (Suppl 10):S208. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenburg, Sweden, October 13-16, 2010.
 66. Auquier P, et al, on behalf of the MusiQoL Responsiveness Study Group: Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to Expanded Disability Status State score changes in patients with Multiple Sclerosis: Month 12 results from an international observational study. 13th Annual ISPOR Annual European congress, Prague, Czech Republic, November 6-9, 2010.
 67. Korn-lubetzki I, Molshatzki N, Benderly M, Steiner I, On behalf of the NASIS Investigators: The favorable nature of ischemic stroke within the posterior fossa. Annual Meeting of the Israel Neurological Association, Eilat, December 15-18, 2010. *J Isr Neurol Assoc* 2010; 4:66.

68. **Milo R**: Balancing risks and benefits in newly emerging therapies for MS. Emerging Role of Antibodies in Clinical Neuroimmunology Conference, Pecs, Hungary, March 25-26, 2011.
69. Anand R, Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Lucini V, for the Study 018 Investigators. 63th Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16, 2011, Late Breaking Science Poster Po5.287.
70. **Milo R**: Long term efficacy of glatiramer acetate in multiple sclerosis. Annual Conference of the Israel Society of Neuroimmunology, Jerusalem, April 28-30, 2011.
71. Gur A, Dorodnicov E, Gelfand A, Gerasimov L, Reznic-Zoref J, Senker A, Milo R: Intravenous thrombolysis in patients with acute vertebro-basilar stroke: why do we treat so little? 20th European Stroke conference, Hamburg, Germany, May 24-27, 2011
72. Montalban X, Wolinsky J, Yin M, Leppert D, Glanzman R, Chin P, on behalf of the ORATORIO Study Group. Faze III study of ocrelizumab in patients with primary progressive multiple sclerosis: ORATORIO study design. 63th Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16, 2011. *Neurology* 2011; 76 (Suppl 4):A319-A320.

Current clinical studies

Ongoing

1. Quality of life and neuropsychological assessment in multiple sclerosis patients treated with immunomodulatory agents. 2001
2. MS 27919: A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. 2008
3. BEACON (MP-00102): Betaferon Prospective Study on adherence, Coping and nurse support. 2009
4. AC-058B201: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety and tolerability of three doses of ACT-128800, an oral S1P1 agonist, for six months in patients with relapsing-remitting multiple sclerosis, followed by a study extension up to 24 months. 2009
5. MACSI: A double blind, randomized, placebo-controlled, parallel group, multicenter phase 3 pivotal study to assess the safety and efficacy of 1 mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset. 2009
6. Protocol H9B-MC-BCDJ (a): Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis. 2009

7. Protocol H6L-MC-LFBF: Open-label extension for Alzheimer's disease patients who completed one of two semagacestat phase 3 double blind studies (H6L-LFAN or H6L-MC-LFBC). 2010
8. The IMPACT-24 Trial: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects with Acute Ischemic Stroke. 2010
9. Protocol 28850: Open label trial to determine the long-term safety of safinamide in Parkinson's disease patients. 2010
10. Protocol 205MS301: Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC-HYP) versus avonex (interferon β -1a) in patients with relapsing-remitting multiple sclerosis. 2010
11. Protocol 109MS303: A dose-blind, multicenter, extension study to Determine the long term safety and efficacy of BG00012 monotherapy in subjects with relapsing-remitting multiple sclerosis 2010
12. Protocol E2007-G000-307: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures. 2010.
13. Protocol P09-004: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory partial onset seizures. 2010

Completed clinical Studies

<u>Duration</u>	<u>Name</u>	<u>Type</u>
2003-2007:	BEST	Betaferon in Early relapsing-remitting multiple sclerosis Surveillance Trial
2003-2007		A multicenter, randomized, double-blind, double-dummy, parallel group, study assessing the add-on effect over Glatiramer Acetate (GA) of alfacalcidol or simvastatin in relapsing-remitting multiple sclerosis (RR-MS) subjects treated with GA
2003-2007	Beyond	International, randomized, multicenter, phase IIIb study in patients with relapsing-remitting multiple sclerosis comparing over a treatment of 104 weeks
2004-2006	PREVAIL	An open-label, randomized, parallel group, multicenter study to evaluate the efficacy and safety of enoxaprin versus unfractionated heparin in the prevention of venous thromboembolism in patients following acute ischemic stroke
2004-2008	GALA	A multicenter randomized trial conducted mainly in Europe to compare primarily the risk of stroke, myocardial infarction and death as a result of carotid endarterectomy under either general or local anesthesia
2004-2007	SAINT-II	A double-blind, randomized, placebo-controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 in acute ischemic stroke.
2004-2008		Interferon-beta-1a (Rebif) treatment in multiple sclerosis patients: A preliminary observational study on cognitive parameters.
2004-2005		A multi-center survey to evaluate the antibodies to glatiramer acetate in sera of multiple sclerosis patients treated with copaxone for 2 years or more.
2004-2008	PRoFESS	Prevention regimen for effectively avoiding second strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel, with and without micardis.
2004-2005	EMR 62-225	Feasibility investigation for investigational site selection for the phase III studies with Sarizotan
2005-2006	PADDY-1	A double-blind, placebo-controlled, multicenter multinational phase III study to evaluate the safety

		and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia.
2005-2009	BetaPlus	Observational study to assess drug adherence in patients with multiple sclerosis and after conversion to Betaferon by using elements of the BetaPlus Program
2005-2009	CogniMS	Observational study to assess cognition in patients with early multiple sclerosis
2005-2006	Paddy-O	An open-label, multicenter, multinational phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia
2006-2010	AVNo6	Assessment of CD4+CD25+ regulatory T cells in MS patients and the impact of treatment with Avonex® on them. Analysis of the FoxP3 protein production and its impact on the regulatory cells function
2006-2009	CFTY720D2301	A 24-month, double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis
2006-2008	FORTE (GA9016)	A multinational, multicenter, randomized, parallel group, double-blind, study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to that of glatiramer acetate injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing-remitting (R-) multiple sclerosis (MS).
2006-2007	E2007 E004 301	Multicenter, Randomized, Double-blind, Placebo controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations
2006-2009	ISRO:	The Israeli Stroke Registry and Outcome
2006-2007	VRX-RET-E22-302	(Restore) Study: Randomized double-blind, placebo-controlled, multicenter, parallel-group phase III study to determine the efficacy and safety of two doses of retigabine (900 mg/d and 600 mg/d) used as adjunctive therapy in refractory epilepsy patients with partial-onset seizures
2007-2008	E2007-G000-	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of

	309	the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations
2007-2008	E2007-G000-303	A Multi-centre, open label extension study to evaluate the long term safety, tolerability, and efficacy of E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with Motor Fluctuations
2007-2008		Beyond Follow-up: International, multicenter, phase III-b study of subcutaneous every other-day treatment of patients with relapsing multiple sclerosis with(Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and (Phase B) open-label betaseron/Betaferon 500 µg
2007-2009	ISN 087-CL-084	A phase 4, randomized, parallel group, multi-center study to assess the safety and efficacy of multiple dosing regimens of IV conivaptan in subjects with euvolemic hyponatremia
2007-2009	NTI ASP 0503	A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex TM) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute, Ischemic Stroke
2007-2008	204PD202	A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late-Stage Parkinson's Disease Who Are Also Receiving Treatment with Levodopa
2007-2009	E2007-G000-318	A multi-centre, open label extension study to evaluate the long term safety, tolerability, and efficacy of E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with motor fluctuations
2007-2010	DEFINE, 109MS301	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
2007-2010	MusiQol	A multicenter, multi-regional observational study to test the responsiveness of the validated MusiQol (Multiple Sclerosis International Quality of Life Questionnaire) instrument to EDSS status changes in any form of multiple sclerosis (MS) in patients with and without treatment
2008-2009	204PD203	A Randomized, Double-Blind, Placebo-Controlled,

		Dose-Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects with Early Parkinson's Disease
2008-2010	E2007-G000-305	A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures
2008-2010	H6L-MC-LFAN	Effect of γ -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 versus Placebo
2008-2009	CAMMS32400507	A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon beta 1-a (Rebif®) in patients with relapsing remitting multiple sclerosis who have relapsed on therapy.
2008-2011	CFTY720D2301E1	An extension of the 24-month, double blind, randomized, multicenter, placebo-controlled, parallel group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis
2010-2011	Protocol CENA713DIL01	A 12-week, multi-center, open-label evaluation of caregiver preference, safety and tolerability of Exelon® Patch (Rivastigmine transdermal) in patients with Alzheimer's disease (BETTER Study)
2010-2011	Protocol 101MS305 (SURPASS)	A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β -1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis

DEPARTMENT OF CARDIOLOGY



Head of Department

Prof Amos Katz. MD

Professor of Medicine Ben-Gurion University

amosk@barzi.health.gov.il

Head of Units

- Jamal Jafari, MD Director, Invasive Cardiology Unit.
Lecturer of Medicine Ben-Gurion University
- Vladimir Khalameizer, MD Director, Cardiac Electrophysiology & Pacing Unit.
- Chaim Yosefy, MD Director, Non Invasive Unite.
Associated Professor of Medicine Ben-Gurion University
- Shlyakhover Vladimir, MD Physician in charge, Intensive Coronary Care Unit.
Instructor of Medicine Ben-Gurion University
- Berman, Michael, MD Physician in charge, Cardiology Unit.
- Boris Brodtkin, MD Physician in charge, Nuclear Cardiology Service
and cardiac rehabilitation service
Instructor of Medicine Ben-Gurion University
- Tatiana Droznikov, MD Physician in charge, Clinical Research Unit.

Additional Medical Team:

- Havey Rabbey, MD
- Yan Orlov, MD
- Eugene Fishman, MD
- Tatiana Troshine, MD
- Tatina Koznichovel, MD
- Natalia Golodnizhki, MD
- Tatiana Plaiev, MD
- Zana Yechezkel, MD
- Vitali Sheklovsky, MD
- Gihad Abu Hamed, MD

Description

The Cardiology Department at Barzilai Medical Center provides high quality diagnostic and treatment services for patients referred with actual, or suspected, heart disease. The clinical work of the department encompasses all modern aspects of cardiology. The department employs the leading edge technologies and treatments in all aspects of cardiology.

The department is consisting of several units: Hospitalization, Invasive and Non Invasive Cardiology, Cardiac Electrophysiology and Pacing, Nuclear Cardiology, Cardiac Rehabilitation service, and Clinical Research Unit.

The head of the department, Prof Katz, graduate of the first class of the medical school of the Ben Gurion University of the Negev. He did his cardiology training in Soroka University Medical Center in Beer-Sheva. He is an expert in cardiac electrophysiology and did his fellowship in cardiac electrophysiology in Indianapolis Ind. He is involved in medical education, teaching at Ben Gurion University and was associate Dean for student's affairs for 10 years, and he is going to be the associate dean for academic promotion in the faculty of health sciences.

He is involved in clinical and basic cardiology research and has more than 70 scientific publications in leading national and international medical journals. As one of the leading Israeli Cardiologists he was recently involved in the legislation of the Israeli law to put AEDs [automatic external defibrillators] in the community to prevent sudden cardiac death. He is involved in cardiac arrhythmia basic research at Ben Gurion University collaborating with Dr Yoram Ezion and Prof. Arie Moran. The Arrhythmia Research Laboratory performs original research in arrhythmia prevention and treatment especially atrial fibrillation. The research is funded by competitive national and international research grants.

Amos Katz, MD

Cardiology Department

תורבות



תורבות

Main Fields of Research Activities

Experimental

The Basic cardiac research is conducted in the Arrhythmia Research Laboratory of with Dr Yoram Ezion (Soroka University Medical Center) and Prof. Arie Moran (physiology department). . The Laboratory performs original research in arrhythmia prevention and treatment especially atrial fibrillation mostly on rodent and isolated cardiomyocytes. Research is funded by competitive national and international research grants.

Clinical Epidemiological Studies at Cardiology Department

- Impact of Descent and Stay at the Dead Sea Resort (low altitude) on Patients with Systolic Congestive Heart Failure and an Implantable Cardioverter Defibrillator
- Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events. Results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy study).
- Association Between Mitral and Aortic Valve Calcification and Preferential Left or Right Coronary Artery Disease
- Accuracy of diagnosing atrial flutter and atrial fibrillation from a surface electrocardiogram by hospital physicians: analysis of data from internal medicine departments
- Ultra Short-Term Heart Rate Variability for Early Risk Stratification following Acute ST Elevation Myocardial Infarction

List of Publications

Refereed articles in scientific journals

A- Original Articles

1. Viskin S, Rosso R, Rogowski U, Belhassen B, Levitas A, Wagshal A, **Katz A**, Fourey A, Zeltser D, Rozovski U. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. *European Heart Journal* 2006; 27:469-475.
2. Amit G, **Katz A**, Bar-on S, Gilutz H, Wagshal A, Ilia A, Henkin Association of Statin Therapy and the risk of Atrial Fibrillation in Patients with a Permanent Pacemaker. *Clinical Cardiology* 2006; 29:249-52.
3. Shiyovich A, Z Ben Zion IZ, Plakht Y, Amit G, Grosbard A, **Katz A**. Sexual Dysfunction, Depression and Quality of Life in Male Implantable Cardioverter Defibrillator (ICD) Recipients - with and without Shock Delivery. *Harefua* 2007; 146:594-598.
4. Beharier O, Etzion Y, **Katz A**, Friedman H, Tenbosh N, Zachrish S, Bereza S, Goshen U, Moran A Crosstalk between L-Type Calcium Channels and ZnT-1, A New Player in Rate Dependent Cardiac Remodeling. *Cell Calcium*. 2007; 42; 71-82.
5. Knayzer B, Abramov D, Bilenko N, Tovbin D, Ganiel A, **Katz A**. Atrial fibrillation and Plasma Troponin I Elevation After Cardiac Surgery: Relation to Inflammation-Associated Parameters. *J Card Surgery* 2007; 22; 117-123.
6. Etzion Y, Ganiel A, Beharier O, Shalev A, Novack V, Volvich L, Abrahamov D, Matsa M, Sahar G, Moran A, **Katz A**. Correlation between Atrial ZnT-1 Expression and Atrial Fibrillation in Humans: A Pilot Study. *J Cardiovasc Electrophysiol*. 2008; 19:157-164.
7. Shiyovich A, Munchak I, Zelingher J, Grosbard A, **Katz A**. Admission for Syncope: Evaluation, Cost and Prognosis: The Impact of the Admitting Ward. *IMAJ* 2008; 10:104-108.
8. Knayzer B, Abramov D, Bilenko N, Ganiel A, Ishai Y, **Katz A**. Incidence and predictors of Atrial Fibrillation after Coronary Artery Bypass Grafting in the Negev, if we are different from the rest of the world? *Harefua* 2008; 147:299-304.

9. Etzion Y, Mor N, Shalev A, Dror S, Etzion O, Dagan A, Beharier A, Moran A, **Katz A**. New Insights into the Atrial Electrophysiology of Rodents Using a Novel Modality: the Miniature-Bipolar Hook Electrode. *Am J Physiol Heart Circ Physiol* 2008; 295:1460-1469?
10. Alon H, Zucker N, Levitas A, Sofer S, **Katz A**, Zalztien. A Cardiac manifestation following electrocution in children. *Cardiol Young*. 2008;18:458-460
11. Amit G, Galante O, Wagshal A, Ilia R, **Katz A**. B-type Natriuretic Peptide (BNP) Level Stratify the Risk for Arrhythmia Among Implantable Cardioverter Defibrillator (ICD) Patients. *Clinical Cardiology* 2008;31: 586-589
12. Shuvy M, Arbelle JE, Grosbard A, **Katz A**. A Simple test of one minute heart rate variability during deep breathing for evaluation of sympathovagal imbalance in thyrotoxicosis. *IMAJ* 2008; 10:603-606.
13. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman M, Zeltser D, Halkin A, Steinvil A, Heller K, Glikson M, **Katz A**, Viskin S. J-Point Elevation in Survivors of Primary Ventricular Dibrillation-Arrest and Matched Control Subjects. *J Am Coll Cardiol* 2008; 52:1231-1238.
14. Teerlink JR, Metra M, Felker M, Ponikowski P, Voors AA, Weatherley, BD, Marmor A, **Katz A**, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A Multicenter, Randomized, Placebo-controlled, Parallel-Group, Dose-finding Phase 2b study. *Lancet* 2009;373(9673):1429-1439
15. Karp E, Shiyovich A, Zahger D, Gilutz H, Grosbard A, **Katz A**. Ultra Short-Term Heart Rate Variability for Early Risk Stratification following Acute ST Elevation Myocardial Infarction. *Cardiology* 2009; 114:275-283.
16. Yosefy C, Malushitsky A, Jafary J, Sahar S, **Katz A**. Association Between Mitral and Aortic Valve Calcification and Preferential Left or Right Coronary Artery Disease *J Heart Valve Dis*. 2009; 18(6):627-633.
17. Levy S, Beharier O, Etzion Y, Mor M, Buzaglo L, Shaltiel L, Gheber LA, Kahn J, Muslin AJ, **Katz A**, Gitler G, Moran A. The Molecular Basis for ZnT-1 Action as an Endogenous

Inhibitor of L-Type Calcium Channels. The Journal of Biological Chemistry
2009;20:32434-32443.

18. Murgatroyd FD, Helmling E, Lemke B, Eber B, Mewis C, Hensgens JV, Chang Y, Khalameizer V, **Katz A**. Manual versus Automatic Capture Management in ICDs and CRT-Ds. *Europace*.2010 ;12:811-6.
19. Beharier O, Etzion Y, Levi S, Mor M, Mor M, Dror S, Kahn J, **Katz A**, Moran A. The involvement of ZnT-1, a new modulator of cardiac L-type calcium channels, in [corrected] atrial tachycardia remodeling. *Ann N Y Acad Sci*. 2010; 1188:87-95.
20. Shiyovich A, Wolak A, Yacobovich L, Grosbard A, **Katz A**. Accuracy of diagnosing atrial flutter and atrial fibrillation from a surface electrocardiogram by hospital physicians: analysis of data from internal medicine departments. *Am J Med Sci*. 2010; 340:271-275.

B- Accepted Articles (in press)

1. Mor M, Shalev A, Dror S, Pikovsky O, Beharier O, Moran A, **Katz A**, Etzion Y. INO-8875, a Highly-Selective A₁ Adenosine Receptor Agonist: Evaluation of Chronotropic, Dromotropic and Hemodynamic Effects in Rats. *The J of Pharmacol and experimental therapeutics (JPET)* Published online before print May 21, 2010.
2. Gabizon I, Shiyovich A, Novack V, Khalameizer V, Yosefy H, Moses WS, **Katz A**. Impact of Descent and Stay at the Dead Sea Resort (low altitude) on Patients with Systolic Congestive Heart Failure and an Implantable Cardioverter Defibrillator. Accepted for publication *IMAJ* 2011.
3. Sack S, Wende CM, Nägele H , **Katz A**, Bauer WR, Barr CS , Malinowski K , Schwacke H, Leyva F, Proff J, Berdyshev S, Paul V. Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events. Results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy study). Accepted for publication *Eur J Heart Failure J* 2011

C- Case Reports

1. Shalev A, Gilad J, Riesenber K, Borer A, Kobal A, Schlaeffer F, **Katz A**. Conservative Management of Implantable Cardioverter Defibrillator-Related Endocarditis Due to Bacillus spp. Infection 2007; 35:114-117.
2. Blaer Y, Khalameizer V, Jafari J, **Katz A**, Reisin L, Yosefy C. Transient ventricular fibrillation. A clinical case report. Eur J Cardiovasc Nurs. 2007; 6:337-339.
3. Blaer Y, Shlykhver V, Gabzo R, Hay E, **Katz A**. Unusual hazard of outdoor CPR on a very hot day. Resuscitation. 2008; 77: 293.
4. Tandeter H, Kobal S, **Katz A**. Swallowing-induced atrial tachyarrhythmia triggered by Salbutamol: Case report and review from the literature. Clinical Cardiology 2010; 33:116-120
5. Hay E, Blaer Y, Shlyakhover V, **Katz A**, Jafari J. Acute transient phlebitis during eptifibatide intravenous injection: case report. Heart Lung. 2010; 39:235-236.

D- Editorial & Reviews Article

1. **Katz A**, Grosbard A. Does It All Go Up in Smoke? Cigarette Smoking and Tachyarrhythmias Editorial. J Cardiovasc Electrophysio 2006;17:937-939
2. **Katz A**. Comprehensive Approach to Atrial Fibrillation. Internal Medicine Review 2007; 7: 13-18.
3. Shiyovich A, **Katz A**. "The 'Shock Factor': ICD configuration and programming to optimize shock treatment," Accepted for publication in the Journal of Cardiovascular Electrophysiology

F- Chapters in Books

1. Prystowsky EN and **Katz A**. Atrial fibrillation. In: Topol EJ (ed.) Textbook of Cardiovascular Medicine Philadelphia: Lippincott -Raven, third edition, 2006: 1050 – 1068
2. **Katz A**. Rapid Interpretation of EKG's, Dale Dubin. Editor of the Hebrew edition: Probook Israel 2008.

Active Participation in Scientific Meetings

A- Abstracts

1. O. Beharier, Y. Etzion, **A. Katz**, H. Friedman , N. Tenbosh , S. Zacharish, E. Bental, U. Goshen, A Moran, ZnT-1, a Missing Link in the Regulation of Cardiac L-type Calcium Channels. The 53rd Annual Scientific Session of the American Collage of Cardiology. March 2006, Atlanta, USA. Abstract in J Am Coll Cardiol supp March 2006.
2. O. Beharier, Y. Etzion, H. Friedman, N. Tenbosh , S. Zacharish, E. Bental, U. Goshen, A Moran, **A. Katz**. ZnT-1, a Missing Link in the Regulation of Cardiac L-type Calcium Channels. The 55^d Annual Conference of the Israeli Heart Society, April 2006
3. A Wolak, L Jacobovich , G. Amit , A. Grosbard , R. Ilia , **A. Katz**. Physician Misdiagnosis of Atrial Fibrillation / Flutter. The 53rd Annual Conference of the Israeli Heart Society, April 2006
4. A Shiyovich, I.Z. Ben Zion, Y. Plakht, G. Amit, A. Grosbard , **A. Katz**. Sexual Dysfunction, Depression and Quality of Life in Male Implantable CardioverterDefibrillator Recipients- with and without Shock Delivery. The 53rd Annual Conference of the Israeli Heart Society, April 2006
5. O. Galante, G. Amit, D. Zahger, A. Wagshal, R. Ilia, **A. Katz**. The Association of B-type Natriuretic Peptide and Ventricular Arrhythmia in Patients with Impaired Left Ventricular Function and Implantable Cardioverter Defibrillator. The 53rd Annual Conference of the Israeli Heart Society, April 2006.
6. D. Brosh, **A. Katz**, R. Arbel, Y. Tal, D. Greenberg, R. Kornowski. A Novel Noninvasive Digital Arterial Pulse Wave Analysis during Deep Breathing as an Indicator of Coronary Artery Disease. The 53rd Annual Conference of the Israeli Heart Society, April 2006.
7. D Brosh, **A. Katz**, Ronen Arbel, Yoram Tal, Dan Greenberg, Ran Kornowski. A Novel Noninvasive Digital Arterial Pulse Wave Analysis During a Deep Breathing Exercise as an Indicator of Coronary Artery Disease. American Collage of Cardiology 56 Annual meeting March 2007, e Poster 915-211.
8. A. Beharier, Y Etzion, **A. Katz**, M.Mor, S. Kollt, A Moran. Reduced Surface Expression of L-type Calcium Channels in Rapidly Paced Cardiomyocytes; A New Mechanism of Atrial Electrical Remodeling? The 54th Annual Conference of the Israeli Heart Society, April 2007.
9. C. Yosefy, A. Malushitsky, J. Jafari, S. Gideon, **A. Katz**. Mitral Annulus Calcification, Aortic Valve Calcification and Coronary Artery Disease. Is there Coronary Right or Left Side Preference for Them? The 54th Annual Conference of the Israeli Heart Society, April 2007.
10. C. Yosefy, R. Beeri, D. Gilon, B. Yoffe, S. Oren, **A. Katz**. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in White Coat Hypertension Using Combined Evaluation with 3-D

- Echocardiography and Carotid Intima-Media Thickness. The 54th Annual Conference of the Israeli Heart Society, April 2007.
11. Y. Blaer, J. Jafari, A. Podberezsky, T. David, L. Reisin, A. Katz, J. Benjamin Single-Blind and Double-Blind Randomized Controlled Trials of Palmtherapy®, an Alternative Medical Approach, for Anxiety Before Cardiac Catheterization. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 12. D. Abramov, M. Matsa, A. Katz, A. Ganiel, L. Ruderman, Y. Ishai, J. Asali, G. Saha. Atrial Fibrillation and Plasma Troponin I Elevation after Cardiac Surgery; Relation to Inflammation-associated Parameters. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 13. Y. Etzion, A. Shalev, O. Etzion, M. Mor, O. Beharier, A. Dagan, A. Moran, A. Katz. Bipolar Mini-hook Electrodes; a Novel Technique for Studying Supraventricular Electrophysiology in Rodents. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 14. D. Brosh, A. Assali, A. Katz, R. Arbel, Y. Tal, D. Greenberg, R. Kornowski. A Novel Noninvasive Digital Arterial Pulse Wave Analysis During Deep Breathing as an Indicator of Significant Coronary Artery Disease. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 15. B. Brodtkin, C. Yosefy, S. Avraham, D. Mimon, J. Rozov, A. Katz. Mitral Valve Annulus Diameter: Neglected Contributor of Mitral Regurgitation in Patients with Hypertrophic Obstructive Cardiomyopathy. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 16. C. Yosefy, B. Yoffe, E. Magen, A. Katz, O. Shmuel. Abnormalities in Carotid Intima-Media Thickness, Left Ventricular Stiffness and Arterial Compliance in White Coat Hypertension: Are They Innocent? The 54th Annual Conference of the Israeli Heart Society, April 2007.
 17. Y. Etzion, A. Ganiel, O. Beharier, A. Shalev, L. Volvich, V. Novack, D. Abrahamov, M. Matsa, G. Sahar, A. Moran, A. Katz. ZnT-1 in Human Atrial Fibrillation- a Missing Link? The 54th Annual Conference of the Israeli Heart Society, April 2007.
 18. A. Mashal, Shvartzman, T. Freud, A. Neville, A. Katz. Antithrombotic Prophylaxis, Southern Israel Community Based Study: Need for better Control. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 19. V. Shlyakhover, J. Jafari, I. Manevich, M. Berman, B. Brodtkin, H. Yosefy, V. Khalameizer, A. Katz. Real Life Stent Thrombosis; Incidence, Treatment and Outcomes. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 20. A. Katz, D. Brosh, Y. Blaer, A. Assali, I. Orlov, J. Jamal, R. Kornowski. A Novel Noninvasive Digital Arterial Pulse Wave Analysis during Deep Breathing as an Indicator of Significant Coronary Artery Disease. Inonovations in CV Intervention meeting, Tel Aviv, Israel 3/12/07.
 21. Y. Etzion, Beharier, A. Shalev, Matsa, G. Sahar, A. Moran, A. Katz. ZnT-1 in Expressiom in the Human Atria and new Insights on its Activity as an

Inhibitor of L-type Calcium Channels. American Heart Association Nov 5 2007
Orlando

22. Khalameizer V, Yosefy C, Cohen D, Khazan V, **Katz A**. Implantable Cardiac Rhythm Management Device Infections-A preventable complication. Israel Heart Society Annual Meeting, April 2007, Tel-Aviv, Israel
23. Yosefy C, Beeri R, Gilon D, Yoffe B, Oren S, **Katz A**. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in White Coat Hypertension Using Combined Evaluation with 3-D Echocardiography and Carotid Intima-Media Thickness. Israel Heart Society Annual Meeting, April 2007, Tel-Aviv, Israel
24. More A, Shalev A, Etzion O, Beharier O, Moran A, **Katz A**, Etzion Y. Basic Atrial Electrophysiology and Atrial tachycardia Remodelling in Anesthetized and Conscious Rats. XXIV Annual Meeting of the Israel Group for Heart Research Subsection of the International Society for Heart Research European Section. Feb 28th 2008 Jerusalem.
25. Dror S, Beharier O, Etzion S, **Katz A**, Moran A, Etzion Y. ZnT-1. a New Player in Cardiac Protection from Ischemic Injury. XXIV Annual Meeting of the Israel Group for Heart Research Subsection of the International Society for Heart Research European Section. Feb 28th Jerusalem.
26. **Katz A**, Brosh D, Blaer Y, Assali A, Jafari J, Orlov Y, Kornowski R. Novel Noninvasive Digital Arterial Pulse Wave Analysis During Deep Breathing as an Indicator of Significant Coronary Artery Disease: A Two-Centers Study. The SCAI Annual Scientific Sessions in Partnership with ACC 57th Annual Scientific Sessions in 12 Summit, March 29-April, 2008. Chicago USA.
27. Etzion Y, Shalev A, Mor M, Moran A, **Katz A**. INO-8875, a Highly-Selective A₁ Adenosine Receptor Agonist: Evaluation of Chronotropic, Dromotropic and Hemodynamic Effects in Rats. ACC 57th Annual Scientific Sessions in 12 Summit, March 29-April, 2008. Chicago USA. JACC 2008; sup A 51:A3.
28. **Katz A**, Blaer Y, Tubul O, Orlov Y, Jafari J, Detection of Significant Coronary Artery Diseases Employing a Novel, Non-Invasive Finger Pulse Wave Analysis During Deep Breathing Exercise: a Validation Study. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
29. **Katz A**, Brosh D, Blaer Y, Assali A, Jafari J, Orlov Y, Kornowski R. Novel Noninvasive Digital Arterial Pulse Wave Analysis During Deep Breathing as an Indicator of Significant Coronary Artery Disease: A Two-Centers Study. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
30. Wagshal A, Amit G, **Katz A**, Ilia R, Rosso R, Viskin S, Belhassen B, Costantini O, Rosenbaum D. Is There Really No Role for EPS Testing in Risk-Stratification of the ICD-Eligible Patient Population? 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
31. Kolt S, Beharier O, Buzaglo L, Shaltiel L, Gitler D, Gaber L, Etzion Y, **Katz A**, Moran A. ZnT-1, a Novel Modulator of Cardiac L-type Calcium Channels; Insights into the Molecular Mechanism. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.

32. B. Brodtkin, C. Yosefy, S. Avraham, D. Maimon, J. Rozov, **A. Katz**. Mitral Valve Annulus Diameter and Mitral Valve Leaflets Lengths: Contributors of Mitral Regurgitation in Patients with Hypertrophic Obstructive Cardiomyopathy. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
33. S. Shpilman, G. Amit, C. Cafri, S. Bereza, **A. Katz**, H. Gilutz, R. Ilia, D. Zahger. The Prevalence of Acute Myocardial Infarction Among Patients Presenting with Sustained Monomorphic Ventricular Tachycardia (SMVT). 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
34. C. Yosefy, S. Bornstein, S. Oren, A. Podjarny, **A. Katz**. Correlates of Echocardiographic Left Atrium and Ventricular Parameters and GFR in Hospitalized Patients. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
35. A. Shiyovich, I. Munchak, J. Zelingher, A. Grosbard, **A. Katz**. Admission for Syncope: Evaluation, Cost and Prognosis, According to Etiology. 55th Annual Conference of the Israel Heart Society, April 9-10, 2008, Tel Aviv, Israel.
36. Yosefy C, Gotyain O, Konen E, **Katz A**. Comparison of Fast Instantaneous 3 D Echocardiography Analysis with Cardiac MR Imaging for the Evaluation of Left Ventricular and Left Atrial Volumes: a pilot analysis. Israel Heart Society Annual Meeting, April 2008, Tel-Aviv, Israel.
37. More M, Beharier O, Etzion Y, Levi S, **Katz A**, Moran A. ZnT1 a Novel Regulator of T – type Calcium Channels Mediating a Crosstalk between T-Type and L-Type Calcium Channels. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.
38. Palombo M, Shiyovich A, **Katz A**, Plakht Y, Khazan V, Cohen S, Ben Shuhsan D, Khalameizer V. The Impact of Combined Resynchronization and Implantable Defibrillator Therapy on Mortality in Patients with Narrow QRS vs. Wide QRS Complex. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.
39. Zigel Y, Mor M, **Katz A**, Zviling V, Ofer G, Etzion Y. Automatic Surface ECG-Based Analysis of Atrial Electrical Activity / Refractoriness – The Rodent Model. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.
40. Shiyovich A, **Katz A**, Blair A, Herve R, Orlov Y, Yosefy C, Grosbard A. Jafari J. An Innovative Non-Invasive Respiratory Stress Test Indicates Significant Coronary Artery Disease- From Feasibility to Validation. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.
41. Gabizon T, Khalamizer V, Yosefy C, Cohen D, Gabzu R, Avraham S, Bernstein M, **Katz A**. Safety and Beneficial Effect of Low Altitude (Dead Sea Location) in Patients with Systolic Heart Failure after ICD / ICD CRT Implantation. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.
42. Shiyovich A, Palombo M, **Katz A**, Krits I, Berenshtain C, Cohen D, Khazan V, Levi S, Ben Shushan D, Khalamizer V. The Impact of Combined Resynchronization and Implantable Defibrillator Therapy vs. Stand Alone Implantable Defibrillator on Medical Services Utilization and Quality of Life:

The Patients' View. 56th Annual Conference of the Israel Heart Society, April 23, 2009, Tel Aviv, Israel.

43. Weissman N, **Katz A**, Zigel A. A New Method for Atrial Electrical Activity Analysis from Surface ECG Signals Using an Energy Ratio Measure. Computers in Cardiology Conference. Park City Utah USA, September, 2009.
44. Lieu H, Young J, Elkayam U, **Katz A**, Darius H, Massie B, Costello-Boerrigter L, Burnett J. A Phase II, Dose-ranging Study with CD-NP, a Chimeric Natriuretic Peptide, in Acute Decompensated Heart Failure Patients with Renal Compromise. J Am Coll Cardiol.2011; 57: E2029.
45. Mor M, Dror S, Tsadok Y, Bachner-Hinenzon N, **Katz A**, Etzion Y, Liel-Cohen N. Effect of Pacing Site on Left Ventricular Synchronization - Validation of a Novel Rat Model. 58th Annual Conference of the Israel Heart Society, May 4, 2011, Tel Aviv, Israel.
46. Yosefy C, Shenhav S, Feldman V, **Katz A**, Antebi E. Left Atrial Function during Pregnancy: A 3-Dimensional Echocardiographic Study. 58th Annual Conference of the Israel Heart Society, May 4, 2011, Tel Aviv, Israel.
47. Brodtkin B, **Katz A**, Yosefy C. Evaluation of LVEF in CAD: Comparison Study of GSPECT, 2D and 3D Echo Techniques. 58th Annual Conference of the Israel Heart Society, May 5, 2011, Tel Aviv, Israel.
48. Pertzov B, Zahger D, **Katz A**, Amit G. Insufficient Compliance with ICD Guidelines is Associated with Increased Mortality. 58th Annual Conference of the Israel Heart Society, May 5, 2011, Tel Aviv, Israel.
49. Yosefy C, Shenhav S, Feldman V, Sagi Y, **Katz A**, Antebi E. Left Atrial Function during Pregnancy: A 3-Dimensional Echocardiographic Study. Israel Heart Society Annual Meeting, May 2011, Tel-Aviv, Israel.

B- Invited Lectures & Presentations

1. Prof **Amos Katz**: Invited speaker The Israel Innovation Summit, Haifa Israel, April 2006
2. Prof **Amos Katz**: Invited speaker; Do we need AEDs in the era of liberalizes ICDs use for primary prevention? The 7th International Dead Sea Symposium Tel Aviv Israel
3. Prof **Amos Katz**: Invited speaker; Electrophysiology in the CCU: New AF Guidelines. 5th International Meeting Intensive Cardiac Care. Tel Aviv, Israel.
4. Prof **Amos Katz**: Invited speaker; Drug Therapy of Cardiac Arrhythmias, Session I Antiarrhythmic Action of Non-antiarrhythmic Drugs. Statines. XII World Congress on Cardiac Pacing and Electrophysiology, Rome, Italy.
5. Prof **Amos Katz**: The 1st World Congress on Controversies in Cardiovascular Diseases (C-Care) July 3-6, 2008, InterContinental Hotel, Berlin, Germany. Organizing Committee & Lecturer.
6. Prof **Amos Katz**: First International Cardiovascular Conference: Focus on the Middle East, Faculty. April 1-2 Indianapolis Indiana USA.
7. Prof **Amos Katz**: Plenary Session lecture in the 56th Israeli Heart Society annual meeting "Joint session: Israel Heart Society European Society of Cardiology (ESC),

New Frontiers in Heart Failure. Controversies and New Directions in Device Therapy for CHF.

8. Prof **Amos Katz**: Anglo-Israeli Symposium Future Directions in Cardiology. Atrial Fibrillation: Is there a light at the end of the tunnel? Dan Caesarea, Israel
1. Prof **Amos Katz**: Chairman and presenter in the Symposium: Drug Therapy for Atrial Fibrillation: Current Options and Future Promises. Lecture title: Antithrombotic Therapy Past, Present and Future. 9th Annual Dead Sea Symposium, Tel-Aviv. Israel.
2. Prof **Amos Katz**: Chairman, Session on Diagnosis and Electrophysiology of Ventricular Arrhythmia. American Heart Association 2010 annual scientific meeting, Chicago US

Competitive Research Grants

2006 Israel Ministry of Health, Chief Scientist grant: [20,000 \$ X 3 years].

ZnT-1, an intrinsic modulator of Zinc and Calcium influx; Possible role in Atrial Fibrillation.

Prof. **Amos Katz** With Dr Yoram Ezion, Internal Medicine E Soroka University Medical Center and Prof. Arie Moran from the Department of Physiology, Faculty of Health sciences, Ben-Gurion University.

2007 Israel Science Foundation; [194,000 IS for 4 years]

Involvement of ZnT-1 in rapid pacing and ischemia in electrical changes as a modulator to arrhythmia induction. Induction.

Prof **Amos Katz** With Prof. Arie Moran from the Department of Physiology, Faculty of Health sciences, Ben-Gurion University and Dr Yoram Ezion, Internal Medicine E Soroka University Medical Center.

The Cardiology Department Current clinical studies

Ongoing

A *Acute Coronary Syndrome studies:*

1. **SEPIA 2 TAO:** A multi center randomized, double-blind , triple-dummy trial to compare otamixaban to unfractionated Heparin + eptifibatide, in patients with unstable angina/Non ST segment elevation Myocardial infarction scheduled to undergo an early invasive strategy.
2. **IMPROVE IT:** A multi-centre, randomized, double-blind, placebo-controlled study to examining outcomes in subjects with acute coronary syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin.
3. **TRILOGY ACS:** A multi-centre, randomized study. A comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
4. **TIMI 50 TRA 2P:** A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with a history of atherosclerotic disease: thrombin receptor antagonist for secondary prevention of atherothrombotic ischemic events
5. **SYR-322-402** A multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with Alogliptin in Addition to standard of care in subjects with type 2 diabetes and ACS.
6. **TIMI 52 SOLID:** A multicenter, randomized, double-blind, placebo-controlled study to evaluate long-term treatment with Darapladib enteric coated tablets, 160 mg (oral once daily dose) as compared to placebo when added to standard of care in an ACS patient population on the incidence of first occurrence of the composite of MACE (i.e., CV death, non-fatal myocardial infarction [MI], non-fatal stroke).

B *Atrial Fibrillation studies*

7. **PALLACE:** A multicenter, randomized, double-blind, placebo-controlled study to evaluate Dronedarone treatment in patients with permanent atrial fibrillation.
8. **RELAY able:** A multicenter, open label continues study to evaluate the efficacy of Dabigatran to Warfarin
9. **AVEROES LTOLP:** A multicenter, open label continues study to evaluate the efficacy of Apixaban to Warfarin

C *Congestive Heart Failure Studies*

10. **ASTRONAUT:** A multicenter, randomized, double-blind, placebo-controlled study to evaluate long-term treatment with Aliskerin in patients with congestive heart failure
11. **AMGEN:** A multicenter, randomized, double-blind, placebo-controlled study to evaluate long-term treatment with Drabepetin in patients with congestive heart failure and Anemia.

D Pacemaker / Defibrillator Studies (Conducted in the Electrophysiology and pacing unite)

- 12 ECHO CRT Biotronik
- 13 Pain Free Medtronic
- 14 MADIT RIT. Rochester University USA

E Invasive Cardiology Studies (coronary angiography, stents) (Conducted in the invasive cardiology unite)

- 15 DELIVERY -Medtronic

Completed Clinical Research Projects

- | | |
|---------------------|----------------------------|
| 1. ABLYNX | 15. ACTIVE |
| 2. Astellas 6517-CL | 16. PROTECT I, II, P |
| 3. DOT HF | 17. BAS PRE RELAX |
| 4. MADIT RIT | 18. ESPIRE |
| 5. COGNIS 4 | 19. BIOGEN Trident1 |
| 6. ASSERT | 20. NILE |
| 7. PreFerMVP | 21. TAXUS OLIMPIA |
| 8. IN TIME | 22. PROTECT Endeavor stent |
| 9. HOME CARE | 23. PLATO |
| 10. ALPHEE | 24. SEPIA-ACS1 TIMI 42 |
| 11. MADIT CRT | 25. APPRAISE 2 |
| 12. TRACER study | 26. ROCKET |
| 13. KAI – MEDPACE | 27. ARISTOTLE |
| 14. SEQUEL | 28. AVEROES |

Chaim Yosefy, MD

Director, Non Invasive Unit

Associated Professor of Medicine Ben Gurion University

חלום חלום חלום



חלום חלום חלום

Additional Physicians

- Boris Brodtkin, MD
- Tatiana Droznikov, MD

List of Publications

A- Original Articles

1. Oren S, Isakov I, Golzman B, Kogan J, Turkot S, Peled R, **Yosefy C**. The influence of smoking cessation on hemodynamics and arterial compliance. *Angiology* 2006; 57(5):564-8.
2. Cantor A, **Yosefy C**, Potekhin M, Ilia R, Keren A. The value of changes in QRS width and in ST-T segment during exercise test in hypertrophic cardiomyopathy for identification of associated coronary artery disease. *International Journal of Cardiology* 2006; 112(1):99-104.
3. Ton-Nu TT, Levine RA, Handschumacher MD, Dorer DJ, **Yosefy C**, Fan D, Hua L, Jiang L, Hung J. Geometric determinants of functional tricuspid regurgitation: insights from 3-dimensional echocardiography. *Circulation* 2006; 114(2):143-9.

4. Messas E, **Yosefy C**, Chaput M, Guerrero JL, Sullivan S, Menasche P, Carpentier A, Desnos M, Hagege AA, Vlahakes GJ, Levine RA. Chordal cutting does not adversely affect left ventricle contractile function. *Circulation* 2006; 114:1524-8.
5. Dicker D, Maya I, Vasilevsky V, Gofman M, Markowitz D, Beilin V, Sarid M, **Yosefy C**. Blood pressure variability in acute ischemic stroke depends on hemispheric stroke location. *Blood Pressure* 2006; 15 (3):151-6.
6. Magen E, **Yosefy C**, Viskoper RJ, Mishal J. Treatment of allergic rhinitis can improve blood pressure control. *Journal of Human Hypertension* 2006; 20 (11):888-93.
7. **Yosefy C**, Levine RA, Solis J, Vaturi M, Handschumacher MD, Hung J. Proximal Flow Convergence Region as Assessed by Real-time 3-Dimensional Echocardiography: Challenging the Hemispheric Assumption. *Journal of the American Society of Echocardiography* 2007; 20(4):389-96.
8. Klainman E, **Yosefy C**, Caspi A, Landau A, Vishnitzer R and Fink Recovery kinetics of oxygen uptake in patients with various degrees of coronary artery disease. *Journal of Clinical and Basic Cardiology*. 2007
9. **Yosefy C**, Ginsberg G, Dicker D, J.R. Viskoper, Gavish D. Cost-utility analysis of a national project to reduce hypertension in Israel. *Cost Effectiveness and Resource Allocation* 2007; 28; 5(1):16.
10. **Yosefy C**, Eric M. Isselbacher, Michael H. Picard, Vaturi M, Robert A. Levine. Pseudodyskinesia of the Left Ventricular Inferior Wall: recognizing an Echocardiographic Mimic of Myocardial Infarction. *Journal of the American Society of Echocardiography* 2007; 20(12):1374-9.
11. Beeri R, **Yosefy C**, Guerrero JL, Abeidat S, Handschumacher M, Trounstein E, Sullivan S, Chaput M, Gilon D, Vlahakes GJ, Spinale FG, Hajjar RJ, Levine RA. Early Repair of Moderate Ischemic MR Reverses LV Remodeling: A Functional and Molecular Study. *Circulation*. 2007 11; 116:1288-93.
12. Beeri R, **Yosefy C**, Hung J, Handschumacher MD, Levine RA. Mitral Regurgitation Augments Post-Myocardial Infarction Remodeling: Failure of Hypertrophic Compensation. *Journal of the American College of Cardiology* 2008 29; 51(4):476-86.

13. **Yosefy C**, Hung J, Chua S, Vaturi M, Ton-Nu TT, Handschumacher, Levine RA. Direct measurement of vena contracta area by real-time 3-dimensional echocardiography for assessing severity of mitral regurgitation. *Am J Cardiol.* 2009 Oct 1; 104(7):978-83.
14. Magen E, Mishal J, Paskin J, Glick Z, **Yosefy C**, Kidon M, Schlesinger M. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. *J Clin Hypertens (Greenwich).* 2008 Sep; 10(9):677-83.
15. Chua S, Levine RA, **Yosefy C**, Handschumacher MD, Chu J, Qureshi A, Neary J, Ton-Nu TT, Fu M, Wu CJ, Hung J. Assessment of right ventricular function by real-time three-dimensional echocardiography improves accuracy and decreases interobserver variability compared with conventional two-dimensional views. *Eur J Echocardiogr.* 2009; 10(5):619-24.
16. Beeri R, Chaput M, Guerrero JL, Kawase Y, **Yosefy C**, Abedat S, Karakikes I, Morel C, Tisosky A, Sullivan S, Handschumacher MD, Gilon D, Vlahakes GJ, Hajjar RJ, Levine RA. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. *Circ Heart Fail* 2010 1; 3(5):627-34.
17. **Yosefy C**, Beeri R, Guerrero JL, Vaturi M, Scherrer-Crosbie M, Handschumacher MD, Levine RA. Mitral regurgitation after anteroapical myocardial infarction: new mechanistic insights. *Circulation.* 2011; 123(14):1529-36.

B- Review Article

3. **Yosefy C**, Feingold M. Continuation of hormone replacement therapy during acute myocardial infarction after the women's health initiative study. Is it the time for change? *International Journal of Cardiology* 2006; 107(3):293-8.
4. **Yosefy C**. Diabetic heart and the cardiovascular surgeon. *Cardiovasc Hematol Disord Drug Targets.* 2008; 8(2):147-52.
5. **Yosefy C**. Ben Barak A Floppy mitral valve/mitral valve prolapse and genetics. *J Heart Valve Dis.* 2007; 16(6):590-5.
6. Gabbay U, **Yosefy C**. The underlying causes of chordae tendinae rupture: a systematic review. *Int J Cardiol* 2010; 143(2):113-8.

C- Letters

1. **Yosefy C.** Response to IJC-D-08-03075 entitled "Phentermine Cardiovascular Safety. Int J Cardiol. 2009 Mar 19.
2. **Yosefy C,** Beeri R. Phentermine cardiovascular safety II: response to Rothman Hendricks Int J Cardiol. Int J Cardiol 2010 19; 145(2):407-8 Comment on Int J Cardiol. 2010; 144(2):241-2; author reply 242-3.

Active Participation in Scientific Meetings

A- Abstracts

1. Annual meeting. 2006, Afeka, Israel. Ben-Ishay R., Harman M, Scharf S, **Yosefy C.** Classification of Left Heartnctional Dimensions by Clustering Cardiac Echo-Doppler Measurements.
2. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel. **Yosefy C,** Jafari J, Kleinman E, Brodtkin B, Handsshumacher MD, Vatury M. The prognostic value of post-exercise blood pressure reduction in patients with hypertensive response during exercise stress test.
3. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel **Yosefy C,** Levine RA, Vaturi M, Shahzad K, Handschumacher MD, Hung J. Proximal Flow Convergence Region as Assessed by Real-Time 3D Echocardiography: Challenging the Hemispherical Assumption. New Insight.
4. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel Vatury M, Hung J, Handsshumacher M, **Yosefy C,** Sagie A, Levine AR. A new mechanism of tricuspid regurgitation in patients with pulmonary hypertension and associated left ventricular dysfunction: consequences of ventricular interaction. .
5. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel Beeri R, **Yosefy C,** Hung J, Handschumacher MD, Levine RA. Mitral Regurgitation Augments Post-Myocardial Infarction Remodeling: Failure of Hypertrophic Compensation.
6. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel Beeri R, **Yosefy C,** Hung J, Handschumacher MD, Levine RA. Early Repair of Moderate Ischemic MR Reverse LV Remodeling: A functional and Molecular Study
7. Israel Heart Society Annual Meeting, April 2006, Tel- Aviv, Israel. **Yosefy C,** Eric M. Isselbacher, Michael H. Picard, Robert A. Levine. Pseudodyskinesis of the Left Ventricular Inferior Wall: Recognizing an Echocardiographic Mimic of Myocardial Infarction.
8. Annual International Society of Hypertension Meeting, October 14-19 2006, Fokoca, Japan. **Yosefy C,** Beeri R, Gilon D, Yoffe B, Oren S, Katz A. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in White Coat Hypertension Using Combined Evaluation with 3-D Echocardiography and Carotid Intima-Media Thickness.
9. **C. Yosefy,** A. Malushitsky, J. Jafari, S. Gideon, A. Katz. Mitral Annulus Calcification, Aortic Valve Calcification and Coronary Artery Disease. Is there Coronary Right or

- Left Side Preference for Them? The 54th Annual Conference of the Israeli Heart Society, April 2007.
10. **C. Yosefy**, R. Beeri, D. Gilon, B. Yoffe, S. Oren, A. Katz. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in White Coat Hypertension Using Combined Evaluation with 3-D Echocardiography and Carotid Intima-Media Thickness. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 11. **C. Yosefy**, B. Yoffe, E. Magen, A. Katz, O. Shmuel. Abnormalities in Carotid Intima-Media Thickness Left Ventricular Stiffness and Arterial Compliance in White Coat Hypertension: Are They Innocent? The 54th Annual Conference of the Israeli Heart Society, April 2007.
 12. V. Shlyakhover, J. Jafari, I. Manevich, M. Berman, B. Brodtkin, **C. Yosefy**, V. Khalameizer, A. Katz. Real Life Stent Thrombosis; Incidence, Treatment and Outcomes. The 54th Annual Conference of the Israeli Heart Society, April 2007.
 13. Beeri R, **Yosefy C**, Hung J, Handschumacher MD, Levine RA. Mitral Regurgitation Augments Post-Myocardial Infarction Remodeling: Failure of Hypertrophic Compensation. Israel Heart Society Annual Meeting, April 2007, Tel- Aviv, Israel
 14. **Yosefy C**, Beeri R, Gilon D, Yoffe B, Oren S, Katz A. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in White Coat Hypertension Using Combined Evaluation with 3-D Echocardiography and Carotid Intima-Media Thickness. Israel Heart Society Annual Meeting, April 2007, Tel- Aviv, Israel
 15. **Yosefy C**, Ben Ishay R, Herman M. Classification of Left Heart Functional Dimensions by Clustering Cardiac Echo-Doppler Measurements. A Mathematical Data Mining Technique Can be Used to Find Pathological Patterns. Israel Heart Society Annual Meeting, April 2008, Tel-Aviv, Israel.
 16. **Yosefy C**, Gotyain O, Konen E, Katz A. Comparison of Fast Instantaneous 3-D Echocardiography Analysis with Cardiac MR Imaging for the Evaluation of Left Ventricular and Left Atrial Volumes: a pilot analysis. Israel Heart Society Annual Meeting, April 2008, Tel-Aviv, Israel.
 17. **Yosefy C**, Ginsberg G, Viskoper R, Dicker D and Gavish D. Cost-utility analysis of a national project to reduce hypertension in Israel. Israel Heart Society Annual Meeting, April 2008, Tel-Aviv, Israel.
 18. Beeri R, **Yosefy C**, Guerrero JL, Nesta F, Abedat S, Chaput M, del Monte F, Handschumacher MD, Stroud R, Sullivan S, Pugatsch T, Gilon D, Vlahakes GJ, Spinale FG, Hajjar RJ, Levine RA. SERCA2A Gene Delivery Prevents Deterioration of Global Function and Retards Remodeling in a Sheep Model of Mitral Regurgitation. Israel Heart Society Annual Meeting, April 2008, Tel-Aviv, Israel.
 19. **Yosefy C**, Shenhav S, Feldman V, **Katz A**, Antebi E. Left Atrial Function during Pregnancy: A 3-Dimensional Echocardiographic Study. The 58th Annual Conference of the Israeli Heart Society May 2011 Tel-Aviv, Israel.
 20. **Yosefy C**, Shenhav S, Feldman V, Sagi Y, **Katz A**, Anteby E. Left Atrial Function during Pregnancy: A 3-Dimensional Echocardiographic Study. The 58th Annual Conference of the Israeli Heart Society, May 2011 Tel-Aviv, Israel

B- Invited Lectures & Presentations

1. Dr **Yosefy Chaim**. Debate with Prof. Weisgerten Shki: The future of Beta-Blocker in the treatment of hypertension. The Israel Society of Internal Medicine Annual meeting; January 3, Tel-Aviv, Israel.
2. Dr **Yosefy Chaim**. Echocardiography in the Diagnosis of Hypertensive Heart Disease. The Israel Society of Hypertension Annual meeting; December 2006, Tel Aviv, Israel.
3. Dr **Yosefy Chaim**. Debate with Prof. Weisgerten Shki: The future of Beta-Blocker in the treatment of hypertension. The 1st Obesity, Hypertension and Diabetes (DOT) Annual meeting; January 2, Tel-Aviv, Israel.
4. Dr **Yosefy Chaim**: Left Atrium, Left Ventricle and Hypertrophy Regression. The Israel Society of Hypertension Annual meeting; May 2007, Eilat, Israel.
5. Dr **Yosefy Chaim**: LVH and Cardiomyocytes loss in chronic renal failure. The Israel Society of Nephrology Annual meeting; May 2007, Ramot, Israel.
6. Dr **Yosefy Chaim**: Left Ventricular Hypertrophy and the Kidney. The Israel Society of Hypertension Annual meeting; December 2007, Tel Aviv, Israel.
7. Prof **Yosefy Chaim**: Atherosclerosis, Metabolic Syndrome and the Gordian knot. The 2nd Obesity and Metabolic syndrome Society Annual meeting; January 30, Tel-Aviv, Israel.
8. Prof **Yosefy Chaim**: Advisory Board: Smoking prevention and cessation in the Community. The Israel Society for Smoking Prevention and Cessation. February 6-9, the Dead Sea, Israel.
9. Prof **Yosefy Chaim**: New Diagnostic Advances in Cardiology: Cardiac CT and 3D Echocardiography. The 2nd Obesity, Hypertension and Diabetes (DOT) Annual meeting; March 19, Tel-Aviv, Israel.
10. Prof **Yosefy Chaim**: Salt and Hypertension (Lecture and Chairperson). The Israel Society of Nephrology Annual meeting; May 2008, Ramot, Israel.
11. Prof **Yosefy Chaim**: Debate with Prof. Weisgerten Shki: The future of Beta-Blocker in the treatment of hypertension. Obesity, Hypertension and Diabetes (DOT) Annual meeting; March 18, Tel-Aviv, Israel.
12. Prof **Yosefy Chaim**: Hypertension news. The Israel Society of Nephrology Annual meeting; April 2009, Goshrim, Israel.

Jamal Gafari, MD

Director, Invasive Cardiology Unit

✂✂✂✂✂✂



✂✂✂✂✂✂

Director of Invasive Cardiology Unite

Dr Jafari Jamal, MD

Lecturer of Medicine Ben-Gurion University

jafarij@barzi.health.gov.il

✂✂✂✂✂✂

List of Publications

Co-Investigator in clinical studies

1. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. Marc S. Sabatine, Christopher p. Canoon, C. Michael Gibson, Jose L. Lopez-Sendon, Gilles Montalescot, Pierre Theroux, Marcj. Claeys, Frank Cools, Karen A. Hill, Allan M. Skene, Carolyn H. McCabe, and Eugene Braunwald. CLARITY- TIMI 28 investigators **Jafari J**, The New England Journal of Medicine; 2005 vol 352 no.12 p 1179-1189.
2. Design and methodology of the Occluded Artery Trial (OAT). The Occlude Artery (OAT) Research Group. Am Heart J 2005; 150:627-42. Association between mitral and aortic valve calcification and preferential left or right coronary artery disease.

Yosefy C, Malushitsky A, **Jamal J**, Sahar G Katz A. J Heart Valve Dis 2009; 18(6):627-33.

Active Participation in Scientific Meetings

A- Abstracts

1. Y. Blaer, **J. Jafari**, A. Podberezsky, T. David, L. Reizin, J. Benjamin Single-blind and double-blind randomized controlled trials of PALMTHERAPY^R, an alternative medical approach, for anxiety before cardiac catheterization. Poster presentation. Acute Cardiac Care Congress. 21-24 October 2006, Prague, Czech Republic.
2. V. Jorapur, Z. Sadowski, H. Reynolds, A.C. Carvalho, C.E. Buller, J. Rankin, P.G. Steg, HD White, C. Vozzi, E. Balcells, M. Ragosta, CE. Martin, J.E. Tamis-Holland, V. Srinivas, W. Wharton, S. Abramsky, AC. Mon, B. Barton, GA. Lamas, J.S. Hochman. Chronic kidney disease, Ejection Fraction and Heart Failure in Patients with Occluded Infarct Related Arteries Post Myocardial Infarction. Data from the Occluded Artery Trial Oral Sessions at the American Association, Nov 2006.
3. V. Jorapur, T. Steigen, C.E. Buller, V. Dzavik, J. Webb, B.H. Strauss, E. Yeoh, P. Kurray, L. Sokalski, M. Machado, S. Forman, G.A. Lanas, J.S. Hochman, G.J. Mancini. Clinical and Coronary Angiographic Correlates of Myocardial Perfusion Grade Following Late Mechanical Reperfusion of Occluded Infarct-Related Arteries Post Myocardial Infarction. A sub study of the Total Occlusion Study of Canada-2 sub study. Poster Sessions at the American Heart Association, Nov 2006.
4. T. Steigen, V. Jorapur, C.E. Buller, V. Dzavik, M. Cardona, D. Almond, N. Brass, J. Burton, A. Zurakowski, S. Forman, G.A. Lanas, J.S. Hochman, G.J. Mancini, Terje K. Steigen. Association of Myocardial Perfusion Grade After Late Infarct Reperfusion with Baseline Indices of Global LV Function; Analysis from the Total Occlusion Study of Canada-2 (an ancillary study of OAT). Poster Sessions at American Association, Nov 2006.
5. Vladimir Dzavik on behalf of the TOSCA – 2 Investigators. Effect of Percutaneous Revascularization of Occluded Infarct-related on Left Ventricular Function and Late Vessel Patency: Results of the Total Occlusion Study of Canada (TOSCA -2), an Ancillary study of the Occluded Artery Trial. Plenary at American Association, Nov 2006.
6. Judith S. Hochman on behalf of the OAT Investigators. The Occluded Artery Trial (OAT). Plenary at American Association, Nov 2006
7. Y. Blaer, **J. Jafari**, A. Podberezsky, T. David, L. Reizin, J. Benjamin. A Single-blind and double-blind randomized controlled trials of PALMTHERAPY^R, an alternative medical approach, for anxiety before cardiac catheterization. Acute Cardiac Care. (Suppl. II): 8, 2006.
8. Y. Blaer, **J. Jafari**, A. Podberezsky, T. David, A. Katz, L. Reizin, J. Benjamin Single-blind and double-blind randomized controlled trials of PALMTHERAPY^R, an alternative medical approach, for anxiety before cardiac catheterization. Poster presentation. At the 27th European Winter Conference on Brain Research. March 10 - 17, 2007 in Villars Sur Ollon, Switzerland.

9. V. Shlyakhver, **J. Jafari**, I. Manevich, M. Berman, B. Brodtkin, H. Yosefy, V Khalameizer, A Katz. Real Life Stent Thrombosis; Incidence, Treatment and Outcomes. Apr. 2007.
10. C. Yosefy, A. Malushitsky, **J. Jafari**, S. Gideon², A Katz¹; Mitral Annulus Calcification, Aortic Valve Calcification and Coronary Artery Disease. Is there Coronary Right or Left Side Preference for Them? Paper Presentation at the Annual Meeting of the 54th Israel Heart Society .Tel Aviv, April 18-19 2007
11. B. Blaer, **J. Jafari**, A. Podberezsky, T. David, LReisin, A. Katz, J. Benjamin; Single-Blind Randomized Controlled Trials of Palmtherapy[®] , an Alternative Medical Approach, for Anxiety Before Cardiac Catheterization . Paper Presentation at the Annual Meeting of the 54th Israel Heart Society. Tel Aviv, April 18-19 2007.
12. Y. Blaer, **J. Jafari**, A. Podberezsky, T. David, L. Reizin, J. Benjamin. Single-blind and double-blind randomized controlled trials of PALMTHERAPY^R, an alternative medical approach, for anxiety before cardiac catheterization. Evidence-based Complementary and Alternative Medicine 2007; doi: 10.1093/ecam/nel111.
13. Yosef Blaer, Vladimir Khalameizer, **Jamal Jafari**, Amos Katz, Leonardo Reisin, Chaim Yosefy. Transient Ventricular Fibrillation. A Clinical Case Report. Euro J Cardiovas Nurs. Vol 6, Issue 4, Pages 337-339, 2007.
14. Chim Yosefy, Ariel Malushitsky, **Jafary Jamal**, Gideon Sahar, Amos Katz. Association between Mitral and Aortic Valve Calcification and Preferential Left or Right Coronary Artery Disease The 54th Annual Conference of the Israeli Heart Society, April 2007
15. A. Katz, D. Brosh, Y. Blaer, A. Assali, **J. Jafari**, Y. Orlov, R. Karnovwski. A Novel Non-invasive Digital Arterial Pulse Wave Analysis during Deep Breathing as an Indicator of Significant Coronary Artery Diseases –A Two Center Study. Poster presentation. The 55th Annual Conference of the Israel Heart Society. April 9-10, 2008. Tel-Aviv, Israel.
16. Ran Karnovwski, David Brosh, Yosi Blaer, Abid Assali, **Jamal Jafari**, Amos Katz. A Novel Non-invasive Stress Test during Deep Breathing as an Indicator of Significant Coronary Artery Diseases –A Two Center Study. Poster presentation. CRT 2008 (Cardiovascular Revascularization Therapies 2008). "Interventional Cardiology". Feb 11-13, 2008. Omni Shoreham Hotel 2500 Calvert Street, NW Washington, Distr. Columbia Unated States 2008.

Vladimir Kalhamiezer, MD

Director, Cardiac Pacing & Electrophysiology Unit

ክላሕክላሕክላሕ



ክላሕክላሕክላሕ

Director of Cardiac Pacing & Electrophysiology Unit

Dr Vladimir Khalameizer, MD

vladimirh@barzi.health.gov.il

ክላሕክላሕክላሕ

Description

The Electrophysiology and Pacing Unit evaluates and treats patients with all types of arrhythmia disorders. Using advanced cardiac mapping technology, the cardiac electrophysiologists perform diagnostic electrophysiology studies and cardiac ablations. In addition, pacemaker, ICD, and cardiac resynchronization device implantation are performed by our highly trained staff. The unit became the leading unit in Israel for Cardiac Resynchronization Device Implantation and a referral center for complex cases from all over the country. The unit is a teaching center for all the device company for physicians from Israel and international staff.

List of Publications

Refereed articles in scientific journals

1. **Khalameizer V**, Pancheva N, Reizin L, Ovsyshcher IE. "Benign" course and malignant clinical presentations of congenital long QT syndrome. *Europace* 2005; 7(1):50-53.
2. Blaer Y, **Khalameizer V**, Jafari J, Katz A, Reisin L, Yosefy C. Transient ventricular fibrillation. A clinical case report. *European Journal of Cardiovascular Nursing* 2007; 6(4):337-339.
3. Onalan O, Crystal A, Lashevsky I, **Khalameizer V**, Lau C, Goldman B, Femes S, Newman D, Lukomsky M, Crystal E. Determinants of Pacemaker Dependency after Coronary and/or Mitral or Aortic Valve Surgery with Long-Term Follow-Up. *The American Journal of Cardiology* 2008; 101(2):203-208.
4. Murgatroyd FD, Helmiling E, Lemke B, Eber B, Mewis C, van der Meer-Hensgens J, Chang Y, **Khalameizer V**, Katz A. Manual vs. Automatic capture management in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. *Europace* 2010; 12:811-816
doi:10.1093/europace/euq053.

Active Participation in Scientific Meetings

A- Abstract

1. **Khalameizer V**, Yosef C, Cohen D, Khazan V, Katz A. Implantable Cardiac rhythm management device infections – A preventable complication. International Meeting. Intensive Cardiac Care. Tel-Aviv, Israel. April 28-3 July, 2007.

B- Invited Lectures

1. Dr **Vladimir Kalahmaiezer**: Presentation of First CRT-D implantation using femoral approach -7th Annual Dead Sea Symposium, Tel Aviv 2006
2. Dr **Vladimir Kalahmaiezer**: Presentation of first in History LV leads implantation through Diaphragmatic Veins-8th Annual Dead Sea Symposium, Tel-Aviv 2008-

Brodkin Boris, MD

Nuclear Cardiology Service & Rehabilitation Service

නර්මාලය



නර්මාලය

Head of Unit

Dr Brodkin Boris, MD

Instructor of Medicine Ben-Gurion University

borisb20@barzi.health.gov.il

නර්මාලය

List of Publications

1. Yosefy C, Jafari J, Klainman E, **Brodkin B**, Handschumacher M, Vaturi M. The prognostic value of post-exercise blood pressure reduction inpatients with hypertensive response during exercise stress test. Int J Cardiology 2006; 111: 352-3576.

Lecture & Presentations at National and International Meetings

1. **Brodkin B**, Yosefy C, Avraham S, Mimon D, Rozov J, Katz A. Mitral Valve Annulus Diameter: Neglected Contributor of Mitral Regurgitation in Patients with Hypertrophic Obstructive Cardiomyopathy Ashkelon. The 55th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery. April 18-19, 2008, Tel-Aviv
2. **Brodkin B**, Yosefy C, Avraham S, Maimon D, Rozov J, Katz A. Mitral Valve Annulus Diameter and Mitral Valve Leaflets Lengths: Contributors of Mitral Regurgitation in Patients with Hypertrophic Obstructive Cardiomyopathy. The 55th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery. April 18-19, 2008, Tel-Aviv
3. **Brodkin B**, Katz A, Yosefy C. Evaluation of LVEF in CAD: Comparison Study of GSPECT, 2-D and 3-D Echo Techniques. The 58th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery. March 2011, Tel-Aviv.

DEPARTMENT OF INTERNAL MEDICINE C

Dov Gefel, MD

Medicine C

☎☎☎☎☎☎



☎☎☎☎☎☎

Head of Internal Medicine C

Dr Dov Gefel, MD

gefeld@barzi.health.gov.il

☎☎☎☎☎☎

Medical Team:

- Irena Barash, MD Deputy head of the Department
- Ms. Ester Gueta Head Nurse

Research Activity

Experimental

A single genetic factor controls the transition from prediabetes to diabetes in *Psammomys obesus* (fat sand rat).

List of Publications

1. Hillel J, **Gefel D**, Kalman R, Ben-Ari G, David L, Feldman M.W, Bar-On H, Blum S, Raz I, Schaap T, Shpirer I, Lavi U, Shafrir E, Ziv, E. Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in *Psammomys obesus*. *Heredity* 95(2):158-165, 2005
2. Maslovsky I, **Gefel D**. What causes clubbing? *Am J Med*; 118(12):1350-1, 2005
3. Maslovsky I, **Gefel D**, Uriev I, Ben-Dor D, Lugassy G. Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura. *Eur J Internal Med* 16 (7):523-524, 2005
4. Maslovsky I, **Gefel D**. Hodgkin's disease. *Haematologica* 90:17 (12 Suppl); 2005
5. Maslovsky I, **Gefel D**. Virchow's node and Horner's syndrome. *Am J Med* 119 (2):180-181, 2006
6. Maslovsky I, **Gefel D**, Paget-von Schrotter syndrome. *Am J Med.* 119 (4):368, 2006
7. Maslovsky I, Gemer O, **Gefel D**, Zimra Y, Lugassy G. Polycythemia as a result of ectopic erythropoietin production in benign cystic leiomyoma of uterus. *Acta Obstet Gynecol Scand*; 85(7):887-8, 2006
8. **Gefel D**, Maslovsky I, Hillel J. Application of single nucleotide polymorphisms (SNPs) for the detection of genes involved the control of complex diseases. *Harefuah* 147(5):449-454, 2008 (Hebrew).
9. Kopelman NM, Stone L, Wang C, **Gefel D**, Feldman MW, Hillel J, Rosenberg NA. Genomic microsatellites identify shared Jewish ancestry intermediate between Middle Eastern and European populations. *BMC Genet*; 8; 10:80, 2009

Active Participation in Scientific Meetings

Abstract

- D.Gefel, R. Kalman, D. Ben Avraham², L. David, C. Baxter-Jones, E. Ziv, J. Hillel, G. Atzmon. A single genetic factor controls the transition from prediabetes to diabetes in *Psammomys obesus* (fat sand rat). Presented in the 4th Internal Congress on prediabetes and the metabolic syndrome, Madrid, Spain, April 6-9, 2011

DEPARTMENT OF GYNECOLOGY & OBSTETRICS



Head of Department

Prof Eyal Anteby, MD - Chairman

Associate Professor of Medicine, Ben-Gurion University.

anteby@barzi.health.gov.il

Head of Units:

Gemer Ofer, MD

Head of Gynecologic Endoscopy

And in charge of Gynecology

Associate Professor Ben-Gurion University

Zohav Efraim, MD

Head of Obstetric and Gynecologic Ultrasound

Senior Lecturer Ben-Gurion University

Orvieto Raoul, MD

Head of IVF Unit

Professor of Medicine Ben-Gurion University

Shenhav Simon, MD

Head of High Risk Pregnancy unit and vice chairman

Lecturer in Medicine, Ben-Gurion University

Zalis Yosef, MD

Head Labor and Delivery

Additional Medical Team:

- Michael Volodarsky, MD
- Victoria Kapostian, MD
- Octav Segal, MD
- Mordehia Yaniv, MD
- Prof. Roi Homburg, MD
- Anatoli Shaperberg, MD
- Gringeild Livio, MD
- Meltcer Shimon, MD
- Felix Erelevitch, MD
- Dov Krol, MD
- Svetlana Rosinsky, MD
- Marina Bergman, MD
- Faina Lectick, MD
- Lorian Miki, MD
- Gadi Liberty, MD
- Weissman Dora, MD
- Arkadi Varshavsky, MD
- Genia Kruchkovich, MD
- Shohat Victoria, MD
- Riss Bozana, MD
- Ravit Nahum, MD
- Bord Elia, MD
- Yair Sagi, MD
- Marchak Eva, MD
- Sianov Arena, MD
- Saaid Azbarga, MD
- Elisha Avi, MD
- Putish Maria, MD
- Harmati Yael, MD
- Elbo Jaak, MD
- Ela Eivshin, MD
- Silverhish Andress, MD

Eyal Anteby, MD

Chairman, Department of Obstetrics & Gynecology

නරඹනුයෙහි



නරඹනුයෙහි

Main Fields of Research Activity

- Ultrasound in Obstetrics and Gynecology
- High risk pregnancy
- Cardiac function in pregnancy
- The effect of stress on obstetric parameters
- The effect of stress on neonatal parameters

List of Publications

A- Original Articles

1. Anteby EY, Ayesh S, Shocina M, Hamani Y, Schneider T, Hochberg A , Ariel I. Growth factor receptor-protein bound 2 (GRB2) is upregulated in the placenta in preeclampsia. Eur J Obstet Gynecol Reprod Biol, (In Press).
2. Anteby EY, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Haimov-Kochman R, Holzer H, Yagel S. Human Placental Hofbauer Cells Express Sprouty Proteins: A Possible Modulating Mechanism of Villous Branching. Placenta, (In Press).
3. E. Zohav, EY. Anteby, J. Rabinson, O. Segal, S. Meltzer, R. Orvieto. Low

Endometrial Volume May Predict Early IVF-Pregnancy Loss. Fertil Steril (Accepted for publication).

4. J. Rabinson, I. bar-Hava, S. Meltzer, **E. Anteby**, R. Orvieto. Does gravidity influence the success of IVF-ET cycle? Gynecol Endocrinol 2006;22(4):175-8
5. R. Orvieto, J. Rabinson, S. Meltzer, E. Zohav, **E. Anteby**, R. Homburg. Substituting hCG by GnRH-agonist to trigger final follicular maturation- a retrospective comparison to two different controlled ovarian hyperstimulation protocols. RBMonline 2006; 2:198-201.
6. Messing B, Porat S, Imbar T, Valsky DV, **Anteby EY**, Yagel S. Mild tricuspid regurgitation: a benign fetal finding at various stages of pregnancy. Ultrasound Obstet Gynecol. 2005 Nov; 26(6):606-9.
7. E. Zohav, O. Segal, J. Rabinson, S. Meltzer, **E. Anteby**, R. Orvieto. Quality of nuchal translucency measurements in multifetal pregnancies. JFMNM_2006; 19:663-6.
8. R. Orvieto, J. Rabinson, S. Meltzer, R. Homburg, **E. Anteby**, E. Zohav. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked? Clin Exp Obstet Gynecol 2006;33:197-9.
9. R. Orvieto, S. Meltzer, M. Volodarski, S. S. Scharf, J. Rabinson, E. Zohav, **E. Anteby**, R. Homburg. Luteal phase support for patients undergoing frozen-thawed embryo transfer cycles- The required progesterone dose. Clin Exp Obstet Gynecol (Accepted for publication).
10. R. Orvieto, E. Zohav, J. Rabinson, S. Meltzer, **E. Anteby**, R. Homburg. GnRH agonist versus GnRH antagonist in controlled ovarian stimulation for *in-vitro* fertilization: The role of estradiol to follicle/oocytes ratios. Gyn Endocrinol.
11. Vasky DV, **Anteby EY**, Hiller N, Amsalem H, Yagel S, Hochner-Celnikier D. Postpartum pubic separation associated with prolonged urinary retention following spontaneous delivery. Acta Obstet Gynecol Scand. 2006; 85: 1267-9.
12. Gemer O, Kruchkovich J, Huerta M, Kapustian V, Kroll D, **Anteby EY**. Perioperative predictors of successful hysteroscopic endometrial ablation. Gynecol Obstet Invest. 2006; 63: 205-208.

13. Gemer O, Simonovsky A, Huerta M, Kapustian V, [Anteby EY](#), Linov L. A radiological study on the anatomical proximity of the ureters and the cervix. *Int Urogynecol J Pelvic Floor Dysfunct* 2007; 13.
14. Zohav E, Orvieto R, [Anteby EY](#), Segal O, Meltcer S, Tur-Kaspa I. Low endometrial volume may predict early pregnancy loss in women undergoing in vitro fertilization. *J Assist Reprod Genet* 2007 Mar 14.
15. Zohav E, [Anteby EY](#), Orvieto R. Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system. *Reprod Biomed Online* 2007 Apr; 14(4):495-7.
16. Orvieto R, Zohav E, Scharf S, Rabinson J, Meltcer S, [Anteby EY](#), Homburg R. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization. *Gynecol Endocrinol* 2007 Feb; 23(2):72-75.
17. Orvieto R, Kruchkovich J, Zohav E, Rabinson J, [Anteby EY](#), Meltcer S. Does methotrexate treatment for ectopic pregnancy influence the patient's performance during a subsequent in vitro fertilization/embryo transfer cycle? *Fertil Steril* 2007 May 9.
18. Natanson-Yaron S, [Anteby EY](#), Greenfield C, Goldman-Wohl D, Hamani Y, Hochner-Celnikier D, Yagel S. FGF 10 and Sprouty 2 modulate trophoblast invasion and branching morphogenesis. *Mol Hum Reprod* 2007 May 12.
19. Orvieto R, Rabinson J, Meltcer S, Gemer O, [Anteby EY](#), Zohav E. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists? *Fertil Steril* 2007 May 9.
20. Rabinson J, Meltcer S, Zohav E, Gemer O, [Anteby EY](#), Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome. *Fertil Steril* 2007 Jun 18.
21. Orvieto R, Kruchkovich J, Rabinson J, Zohav E, [Anteby EY](#), Meltcer S. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in-vitro fertilization/embryo transfer programs. *Fertil Steril* 2007 Aug 4.
22. Orvieto R, Volodarsky M, Hod E, Homburg R, Rabinson J, Zohav E, [Anteby EY](#), Meltcer S. Controlled ovarian hyperstimulation using multi-dose gonadotropin-

- releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. *Gynecol Endocrinol* 2007 Jun 22;1-3.
23. Gemer O, Anteby E, Lavie O. Uterine inversion associated with uterine sarcoma. *Int J Gynaecol Obstet* 2007 Dec 26.
 24. Orvieto R, Meltzer S, Rabinson J, Zohav E, Anteby EY, Nahum R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. *Fertil Steril* 2008 Oct; 90(4):1294.
 25. Orvieto R, Meltzer S, Rabinson J, Gemer O, Anteby EY, Nahum R. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues? *Fertil Steril* 2008 Oct; 90(4):1297-300.
 26. Shenhav S, Volodarsky M, Anteby EY, Gemer O. Fetal acid-base balance after betamethasone administration: relation to fetal heart rate variability. *Arch Gynecol Obstet* 2008 Feb 14.
 27. Gemer O, Gdalevich M, Voldarsky M, Barak F, Ben Arie A, Schneider D, Levy T, Anteby EY, Lavie O. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometrioid endometrial cancer: Results of a multicenter study. *Eur J Surg Oncol* 2008 Nov 13.
 28. Homburg R, Meltzer S, Rabinson J, Zohav E, Anteby EY, Orvieto R. Do stimulation characteristics of the first in vitro fertilization cycle predict pregnancy in women of 40 years old and over? *Fertil Steril* 2009 Apr; 91(4 Suppl):1311-3.
 29. Homburg R, Meltzer S, Rabinson J, Scharf S, Anteby EY, Orvieto R. Is there a limit for the number of in vitro fertilization cycles for an individual patient? *Fertil Steril* 2009 Apr; 91(4 Suppl):1329-31.
 30. Orvieto R, Homburg R, Meltzer S, Rabinson J, Anteby EY, Scharf S. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori. *Fertil Steril* 2009 Apr; 91(4 Suppl):1378-80.
 31. Orvieto R, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltzer S. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. *Fertil Steril* 2009 Apr; 91(4 Suppl):1398-400.
 32. Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltzer S. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian

- hyperstimulation for in vitro fertilization: is there any difference? *Fertil Steril* 2009 Apr; 91(4 Suppl):1522-5.
33. Rabinson J, Ashkenazi J, Homburg R, Meltcer S, **Anteby EY**, Orvieto R. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists. *Fertil Steril* 2009 Apr; 91(4 Suppl):1473-5.
 34. Orvieto R, Meltcer S, Nahum R, Rabinson J, **Anteby EY**, Ashkenazi J. The influence of body mass index on in vitro fertilization outcome. *Int J Gynaecol Obstet* 2009 Jan; 104(1):53-5.
 35. Orvieto R, Nahum R, Meltcer S, Homburg R, Rabinson J, **Anteby EY**, Ashkenazi J. Ovarian stimulation in polycystic ovary syndrome patients: the role of body mass index. *Reprod Biomed Online* 2009 Mar; 18(3):333-6.
 36. Gemer O, Gdalevich M, Ravid M, Piura B, Rabinovich A, Gasper T, Khashper A, Voldarsky M, Linov L, Ben Shachar I, **Anteby EY**, Lavie O. A multicenter validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. *Eur J Surg Oncol* 2009 Mar 27.
 37. Gemer O, Huerta M, Simonovsky A, Linov L, **Anteby E**, Lavie O. Diameter-by-Age Reference Curves for the Uterine Cervix by Computerized Tomography. *J Comput Assist Tomogr* 2009 May-Jun; 33(3):405-7.

B- Chapters in Books

1. **Anteby EY**, Yagel S. 2003 from fetal to neonatal circulation. In: *Fetal echocardiography*. Eds: Yagel S, Silverman NH, Gembruch U. Martin Dunitz, London, pp: 435-438.
2. **Anteby EY**. Invasive procedures in pregnancy: amniocentesis and chorionic villous sampling. *The Israeli Encyclopedia for Medicine (Hebrew)*.

Gemer Ofer, MD

Head of Gynecologic Endoscopy and In charge of Gynecology

Associate Professor of Medicine BGU

תלמוד תלמוד



תלמוד תלמוד

Medical Team

- Viktoria Kapostian, MD *Instructor of Medicine, BG University*
- Mark Treger, MD *Instructor of Medicine, BG University*
- Michael Volodarsky, MD
- Marina Bergman, MD
- Dov Krol, MD

Current clinical studies

- A multicenter study of PET CT in triage of patients with cervical cancer
- Prospective randomized trial of versus Non-closure of the Visceral and Parietal Peritoneum at Cesarean section and adhesions formations at subsequent cesarean delivery.

List of Publications

A- Original Articles

1. **Gemer O**, Lurian M, Gdalevich M, Kapustian V, Piura E, Schneider D, Lavie O, Levy T, Fishman A, Dgani R, Levavi H, Beller U. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. *Eur J Surg Oncol*; 2005; 31:1006-10
2. **Gemer O**, Kruchkovich J, Huerta M, Kapustian V, Kroll D, Anteby E. Perioperative predictors of successful hysteroscopic endometrial ablation. *Gynecol Obstet Invest* 2007; 63:205-8.
3. **Gemer O**, Simonovsky A, Huerta M, Kapustian V, Anteby E, Linov L. A radiological study on the anatomical proximity of the ureters and the cervix. *Int Urogynecol J Pelvic Floor Dysfunct.* 2007; 18:991-5.
4. **Gemer O**, Ben Arie A, Levy T, Gdalevich M, Lorian M, Barak F, Anteby E, Lavie O. Lymphovascular space involvement compromises the survival of patients with stage I endometrial cancer: Results of a multicenter study. *Eur J Surg Oncol* 2007; 33:644-7.
5. **Gemer O**, Huerta M, Simonovsky A, Linov L, Anteby E, Lavie O. Diameter-by-age reference curves for the uterine cervix by computerized tomography. *JCAT* 2009; 33:405-7.
6. **Gemer O**, Uriev L, Voldarsky M, Gdalevich M, Ben-Dor D, Barak F, Anteby EY, Lavie O. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. *Eur J Surg Oncol* 2009; 35:247-51.
7. **Gemer O**, Gdalevich M, Voldarsky M, Barak F, Ben Arie A, Schneider D, Levy T, Anteby EY, Lavie O. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometrioid endometrial cancer: Results of a multicenter study. *Eur J Surg Oncol* 2009; 35:865-9.
8. **Gemer O**, Gdalevich M, Ravid M, Piura B, Rabinovich A, Gasper T, Khashper A, Voldarsky M, Linov L, Ben Shachar I, Anteby EY, Lavie O. A multicenter validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. *Eur J Surg Oncol.* 2009; 35:1109-12.

9. Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N, Auslender R, **Gemer O**. BRCA Germline Mutations in Women With Uterine Serous Carcinoma-Still a Debate. *Int J Gynecol Cancer*. 2010; 20: 1531-4.

Active Participation in Scientific Meetings

Presentation at National and International Conferences (Oral and Poster)

1. **Gemer O**, Lavie O, Gdalevich M, Uriev L, Peer G, Barak F, Anteby E. The outcome of patients with stage I endometrial cancer involving the lower uterine segment. The 14th Biennial meeting of European Society of Gynecological Oncology, Istanbul Turkey, 2005.
2. **Gemer O**, Kruchkovich J, Huerta M, Kapustian V, Kroll D, Anteby E. Perioperative predictors of successful hysteroscopic endometrial ablation. The 34th annual meeting of the American Society of Gynecological Laparoscopy. Chicago, USA 2005.
3. **Gemer O**, Simonovsky A, Huerta M, Kapustian V, Anteby E, Linov L. The distance between the ureters and the cervix by computed tomography in women cervical pathology. 11th biennial meeting of the International gynecologic oncology society. Santa Monica, CA, USA 2006.
1. **Gemer O**, Ben Arie A, Levy T, Gdalevich M, Barak F, Lorian M, Anteby E, Lavie O. Lymphovascular involvement is a poor prognostic factor in patients with stage I endometrial cancer. 11th biennial meeting of the International gynecologic oncology society. Santa Monica, CA, USA 2006.
2. **Gemer O**, Voldarsky M, Uriev L, Gdalevich M, Ben-Dor D, Barak F, Anteby F, Lavie O. The reproducibility and prognostic significance of histological parameters employed in the novel binary grading systems of endometrial cancer. The 15th Biennial meeting of European Society of Gynecological Oncology, Berlin Germany, 2007
3. **Gemer O**, Gdalevich M, Voldarsky M, Barak F, Ben Arie A, Schneider D, Levy T, Anteby EY, Lavie O. Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometroid endometrial cancer: Results of a multicenter study. 12th biennial meeting of the International gynecologic oncology society. Bangkok, Thailand, 2008.
4. **Gemer O**, Huerta M, Simonovsky A, Linov L, Anteby EY, Lavie O. Diameter-by-age reference curves for the uterine cervix by computerized tomography. 12th biennial meeting of the International gynecologic oncology society. Bangkok, Thailand, 2008.
5. **Gemer O**, Gdalevich M, Ravid M, Rabinovich M, Piura B, Voldarsky M, Linov L, Ben-Schahar I, Anteby EY, Lavie O. A multicenter validation of computerized tomography models as predictors of non- optimal primary cytoreduction of advanced epithelial ovarian cancer. 12th biennial meeting of the International gynecologic oncology society. Bangkok, Thailand, 2008.

6. **Gemer O**, Gdalevich M, Voldarsky M, Barak F, Ben Arie A, Schneider D, Levy T, Anteby E, Lavie O. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. 16th Biennial meeting of European Society of Gynecological Oncology, Belgrade, Serbia, 2009
7. **Gemer O**, Piura B, Mamanov A, Rabinovich A, Ryss B, Halperin R, Eitan R, Levavi H, Finci S, Beller U, Ben Arie A, Ben Shachar I, Meirovitz A, Gdalevich M, Lavie O. Does pre-operative pet-ct reduce the rate of post -operative radiotherapy in patients with early cervical cancer treated by primary surgery? 13th biennial meeting of the International gynecologic oncology society. Prague, 2010.
8. **Gemer O**. The value of preoperative imaging in gynecological cancer. China –FIGO congress of gynecological oncology. Shanghai 2010.
9. **Gemer O**. Management decision and survival of patients with cervical cancer. China –FIGO congress of gynecological oncology. Shanghai 2010.

THE INFERTILITY & IVF UNIT AND MALE INFERTILITY CLINIC



Director of Infertility & IVF Unit and Male Infertility Clinic

Prof Raoul Orvieto, MD

Professor of Medicine Ben-Gurion University

raoulo@barzi.health.gov.il

Medical Team

- Simion Meltcer, MD
- Ravit Nahum, MD
- Gadi Liberty, MD
- Yaacov Rabinson, MD
- Jenya Kruchkovich, MD
- Prof. Roy Homburg, MD

Description

The Fertility and In-vitro Fertilization (IVF) Unit is part of the department of Obstetrics and Gynaecology. The unit treats infertile couples referred from the region and performs between 400-500 cycles of IVF and a further 200-300 cycles of other infertility treatments a year, with an overall live-births rate (take-home babies) of 25%.

The Unit includes an outpatient clinic with an adjacent laboratory and operating theater.

In the outpatient clinic, we operate a Women's Fertility Clinic and a Male infertility Clinic. Treatments include IVF and ICSI, freezing of embryos and blastocysts, intra-uterine insemination, testicular surgery to extract sperm, etc.

The Unit is affiliated to the Ben-Gurion University of the Negev and is active academically in basic and clinical studies.

Raoul Orvieto, MD

*Head of Infertility & In Vitro Fertilization Unit
and Male Infertility Clinic*

ଡକ୍ଟର



ଡକ୍ଟର

List of Publications

A- Original Articles

1. Y. Yogev, A. Ben Haroush, P. Vardi, M. Hod, **R. Orvieto**. Insulin autoantibodies in cord blood from neonates with and without a sibling with IDDM- Prevalence and characterization Eur J Obstet Gynecol Reprod Biol 2005;118:166-169
2. I. Bar-Hava, R. Kerner, R. Yoeli, J. Ashkenazi, Y. Shalev, **R. Orvieto**. Immediate ambulation after embryo transfer- a prospective study Fertil Steril 2005; 83:594 -7.
3. Z. Zukerman, Y. Roslik, **R. Orvieto**. Treatment of vaginismus with the Paula Garburg sphincter muscle exercises. Harefuah 2005; 144 (4):246-248.
4. A. La Marca, S. Giulini, **R. Orvieto**, V. De Leo, A. Volpe. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005; 20: 1569-1572.
5. **R. Orvieto**, A. La Marca, W. Badir, O. Golan, J. Bar, B. Fisch Influence of urinary versus recombinant gonadotropin on serum P-selectin levels in vivo. Gynecol Endocrinol 2005;20:185-187

6. Y. Gilboa, I. Bar-Hava, B. Fisch, J. Ashkenazi, I. Voliovitch, T. Borkowski, **R. Orvieto**. Does intravaginal probiotics supplementation increase pregnancy rate in IVF-ET cycles? *RBMonline* 2005; 11:71-75.
7. B. Kaplan, R. Nahum, Y. Yairi, M. Hirsch, J. Pardo, Y. Yogev, **R. Orvieto**. Use of various contraceptive methods and time of conception in a community-based population. *Eur J Obstet Gynecol Reprod Biol* 2005; 123(1): 72-76
8. A. La Marca, V. De Leo, S. Giulini, **R. Orvieto**, S. Malmusi, L. Giannella, A. Volpe, Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. *J Soc Gynecol Investig* 2005; 12(7):545-8.
9. **R. Orvieto**, N. Fisch, V. Yulzari-Roll, A. La-Marca. Ovarian androgen but not estrogen correlates with the degree of systemic inflammation observed during controlled ovarian hyperstimulation. *Gynecol Endocrinol* 2005;21(3):170-173.
10. **R. Orvieto**, V. Yulzari-Roll, A. La-Marca, J. Ashkenazi, B. Fisch. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in-vitro fertilization cycle. *Gynecol Endocrinol* 2005; 21(4): 218-222
11. I. Bar-Hava, R. Yoeli, V. Yulzari-Roll, J. Ashkenazi, J. Shalev, **R. Orvieto**. Controlled ovarian hyperstimulation: Does prolonged stimulation justify cancellation of in vitro fertilization cycles? *Gynecol Endocrinol* 2005; 21(4):232-4.
12. G. Oron, A. Ben-Haroush, M. Hod, **R. Orvieto**, J. Bar. Serum soluble CD40-ligand in normal pregnancy and in preeclampsia. *Obstet Gynecol* 2006;107(4):896-900.
13. A. La Marca, M. Pati, **R. Orvieto**, G. Stabile, AC Artenisio, A. Volpe. Serum anti-mullerian hormone levels in women with secondary amenorrhea. *Fertil Steril* 2006; 85:1547-9.
14. J. Rabinson, I. Bar-Hava, S. Meltzer, E. Zohav, E. Anteby, **R. Orvieto**. Does gravidity influence the success of *in vitro* fertilization-embryo transfer cycles? *Gynecol Endocrinol* 2006; 22(4):175-8.
15. E. Horowitz, **R. Orvieto**, D. Rabinerson, R. Yoeli, I. Bar-Hava. Hysteroscopy combined with hysterosalpingo contrast sonography (HyCoSy): A new modality for comprehensive evaluation of the female pelvic organs. *Gynecol Endocrinol* 2006; 22(4):225-9.

16. J. Rabinson, I. Bar-Hava, S. Meltzer, E. Zohav, E. Anteby, **R. Orvieto**. Does gravidity influence the success of in vitro fertilization-embryo transfer cycles? *Gynecol Endocrinol* 2006; 22(4):175-8.
17. J. Rabinson, **R. Orvieto**, A. Shapira, Z. Brownstein, K.B. Avraham, S. Meltzer, I. Turkaspa. Mullerian Anomalies, Hearing Loss and Connexin 26 Mutations. *Fertil Steril* 2006; 85:1824-5.
18. **R. Orvieto**, J. Rabinson, S. Meltzer, E. Zohav, E. Anteby, R. Homburg. Substituting hCG by GnRH-agonist to trigger final follicular maturation- a retrospective comparison to three different controlled ovarian hyperstimulation protocols. *RBMonline* 2006; 2:198-201.
19. S. Orbach-Zinger, L. Friedman, A. Avramovich, N. Ilgiaeva, **R. Orvieto**, J. Sulkes, LA Eidelman. Risk factors for failure to extend labor epidural analgesia to epidural anesthesia for Cesarean section. *Acta Anaesthesiol Scand* 2006; 50:793-7.
20. **R. Orvieto**, B. Schachter, V. Yulzari-Roll, A. La-Marca, J. Bar, B. Fisch. Soluble CD40 ligand levels during controlled ovarian hyperstimulation- a possible culprit of systemic inflammation. *Am J Reprod Immunol* 2006;56:243-8
21. **R. Orvieto**, I. Zagatski, V. Yulzari-Roll, A. La-Marca, B. Fisch. Substituting hCG by GnRH-agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation *Gynecol Endocrinol* 2006;22(8):437-440.
22. E. Zohav, O. Segal, J. Rabinson, S. Meltzer, E. Anteby, **R. Orvieto**. Quality of nuchal translucency measurements in multifetal pregnancies. *JFMNM* 2006; 19(10):663-666.
23. Y. Yairi-Oron, J. Rabinson, **R. Orvieto**. A simplified approach to religious infertility. *Fertil Steril* 2006; 85:1771-2.
24. **R. Orvieto**, J. Rabinson, S. Meltzer, R. Homburg, E. Anteby, E. Zohav. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked? *Clin Exp Obstet Gynecol* 2006;33(4):197-
25. **R. Orvieto**, E. Zohav, S. Scharf, J. Rabinson, S. Meltzer, E. Anteby, R. Homburg The influence of E2/follicle and E2/oocyte ratios on the outcome of controlled ovarian stimulation for *in-vitro* fertilization. *Gynecol Endocrinol* 2007; 23:72 - 75.

26. **R. Orvieto**, S. Meltcer, M. Volodarski, S. Scharf, J. Rabinson, E. Zohav, E.Y. Anteby, R. Homburg. Luteal phase support for patients undergoing frozen-thawed embryo transfer cycles- The required progesterone dose. *Clin Exp Obstet Gynecol* 2007; 34(1):25-26.
27. E. Zohav, **R. Orvieto**, E.Y. Anteby, O. Segal, S. Meltcer, I. Tur-Kaspa. Low endometrial volume may predict early pregnancy loss in women undergoing in vitro fertilization. *J Assist Reprod & Genet* 2007; 24(6):259-61.
28. **R. Orvieto**, J. Kruchkovich, E. Zohav, J. Rabinson, E.Y. Anteby, S. Meltcer. Does Methotrexate treatment for Ectopic Pregnancy influence patients' performance during IVF-ET cycle? *Fertil Steril* 2007; 88(6):1685-6.
29. **R. Orvieto**, M. Volodarsky, E. Hod, R. Homburg, J. Rabinson, E. Zohav, E.Y. Anteby. S. Meltcer. Controlled ovarian hyperstimulation using the multi-dose GnRH-antagonist results in less systemic inflammation when compared to the GnRH-agonist long protocol *Gynecol Endocrinol* 2007;23:494 – 496.
30. Yoeli, **R. Orvieto**, J. Ashkenazi, M. Shelef, Z. Ben-Rafael, I. Bar-Hava. Comparison of embryo quality between intracytoplasmic sperm injection and in vitro fertilization in sibling oocytes. *J Assist Reprod Genet* 2008; 25(1):23-8.
31. J. Rabinson, S. Meltcer, E. Zohav, O. Gemer, E.Y. Anteby, **R. Orvieto**. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in-vitro fertilization outcome. *Fertil Steril* 2008; 89:472-4.
32. **R. Orvieto**, J. Rabinson, S. Meltcer, O. Gemer, E.Y. Anteby, E. Zohav. Does physicians' experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists? *Fertil Steril* 2008; 89(3):736-7.
33. R. Abir, A. Ben-Haroush, C. Felz, E. Okon, H. Raanani, **R. Orvieto**, S. Nitke. B. Fisch. Selection of patients before and after anticancer treatment for ovarian cryopreservation. *Hum Reprod* 2008; 23(4):869-77.
34. **R. Orvieto**, E. Hod, M. Volodarsky, R. Homburg, J. Rabinson, E.Y. Anteby. S. Meltcer. Controlled ovarian hyperstimulation- Are we monitoring the appropriate sex-steroid hormones? *Fertil Steril* 2008; 89:1269-72.

35. **R. Orvieto**, J. Kruchkovich, J. Rabinson, E. Zohav, E.Y. Anteby, S. Meltcer. Ultrashort GnRH-agonist combined with flexible multidose GnRH-antagonist for poor-responders in IVF-ET programs. *Fertil Steril* 2008; 90:228–30.
36. R. Oren-Benaroya, **R. Orvieto**, A. Gakamsky, M. Pinchasov, M. Eisenbach. The sperm chemoattractant secreted from human cumulus cells is progesterone. *Hum Reprod* 2008; 23(10):2339-45.
37. **R. Orvieto**, S. Meltcer, J. Rabinson, E. Zohav, E.Y. Anteby, R. Nahum. GnRH agonist versus GnRH antagonist in ovarian stimulation: The role of endometrial receptivity? *Fertil Steril* 2008; 90:1294–6.
38. **R. Orvieto**, S. Meltcer, J. Rabinson, O. Gerner, E.Y. Anteby, R. Nahum. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH-analogues? *Fertil Steril* 2008; 90:1297–300.
39. E. Zohav, I Bar-Hava, S Meltcer, J Rabinson, EY Anteby, **R Orvieto**. Early endometrial changes in following successful implantation: 2 and 3-dimensional ultrasound study. *Clin Exp Obstet Gynecol* 2008;35(4):255-6
40. **R. Orvieto**, R. Homburg, S. Meltcer, J. Rabinson, E.Y. Anteby, R. Nahum. HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study. *RBM Online* 2009;18:205-208
41. J. Ashkenazi, I Bar-Hava, S Meltcer, J Rabinson, EY Anteby, **R Orvieto**. The possible influence of increased body mass index on the clinical efficacy of standard human chorionic gonadotropin dosage. *Clin Exp Obstet Gynecol* 2009; 36(1):20-2.
42. **R. Orvieto**, R. Nahum, S. Meltcer, R. Homburg, J. Rabinson, E.Y. Anteby, J. Ashkenazi. Controlled Ovarian Hyperstimulation in Polycystic Ovary Syndrome Patients: The Role of Body Mass Index. *RBM Online* 2009; 18(3): 333-336
43. Homburg, S. Meltcer, J. Rabinson, S. Scharf, E.Y. Anteby, **R. Orvieto**. Is there a limit for the number of in-vitro fertilization cycles for an individual patient? *Fertil Steril* 2009; 91:1329-31.

44. R. Homburg, S. Meltcer, J. Rabinson, E. Zohav, E.Y. Anteby, **R. Orvieto**. Do stimulation characteristics of the first in-vitro fertilization cycle predict pregnancy in women of 40 years old and over? *Fertil Steril* 2009; 91:1311-3
45. J. Rabinson, J. Ashkenazi, R. Homburg, S. Meltcer, E.Y. Anteby, **R. Orvieto**. Repeated in-vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation using GnRH-antagonists *Fertil Steril* 2009; 91:1473-5.
46. **R. Orvieto**, R. Nahum, J. Rabinson, J. Ashkenazi, E.Y. Anteby, S. Meltcer. Follitropin (Gonal-F®) versus Follitropin (Puregon®) in Controlled Ovarian Hyperstimulation for in-Vitro Fertilization: Is there any difference? *Fertil Steril* 2009; 91:1522-5.
47. **R. Orvieto**, R. Homburg, S. Meltcer, J. Rabinson, E.Y. Anteby, S. Scharf. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: Their role in patients with an unfavorable prognosis- *a priori*. *Fertil Steril* 2009; 91:1378-80.
48. **R. Orvieto**, R. Nahum, J. Rabinson, O. Gemer, E.Y. Anteby, S. Meltcer. Ultrashort flare GnRH-agonist combined with flexible multidose GnRH-antagonist for patients with repeated IVF failures and poor embryos quality. *Fertil Steril* 2009; 91:1398-400.
49. **R. Orvieto**, R. Homburg. Chronic Ultra-Low Dose FSH regimen for PCOS patients- One click, one follicle, one pregnancy. *Fertil Steril* 2009; 91:1533-5.
50. **R. Orvieto**, S. Meltcer, R. Homburg, R. Nahum, J. Rabinson, J. Ashkenazi. What is the preferred GnRH-analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for *in-vitro* fertilization? *Fertil Steril* 2009; 91:1466-8.
51. **R. Orvieto**, S. Meltcer, R. Nahum, J. Rabinson, E.Y. Anteby, J. Ashkenazi. The influence of body mass index on in-vitro fertilization outcome. *Int J Gynecol Obstet* 2009; 104(1):53-5.
52. R. Abir, R. Biron-Shental, **R. Orvieto**, R. Garor, H. Krissi, B. Fisch. Transplantation of frozen-thawed late gestational age human fetal ovaries into immunodeficient mice. *Fertil Steril* 2009;92(2):770-7.

53. J. Farhi, **R. Orvieto**. Influence of smoking on outcome of COH and IUI in subfertile couples. *J Assist Reprod Genet* 2009; 26(7):421-4.
54. R. Haimov-Kochman, D. Rosenak, **R. Orvieto**, A. Hurwitz. Infertility counseling for orthodox Jewish couples. *Fertil Steril* 2010;93(6):1816-1819.
55. J. Farhi, **R. Orvieto**, R. Homburg. The administration of clomiphene citrate in PCOS patients, without inducing withdrawal bleeding, achieves comparable treatment characteristics and outcome. *Fertil Steril* 2010; 93:2077-9.
56. **R. Orvieto**, V. Shuhat, G. Liberty, R. Homburg, R. Nahum, J. Rabinson, S. Meltcer. Serum retinol-binding protein-4 levels in polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for *in-vitro* fertilization cycle. *Clin Exp Obstet Gynecol* 2010; 37:100-104.
57. J. Farhi, **R. Orvieto**. Cumulative clinical pregnancy rates after COH and IUI in subfertile couples *Gyn Endocrinol* 2010; 26(7):500-4.
58. J. Farhi, **R. Orvieto**, O. Gavish, R. Homburg. The association between follicular size on hCG day and pregnancy rate in clomiphene citrate treated PCOS patients. *Gynecol Endocrinol* 2010; 26(7):546-8.
59. **R. Orvieto**, S. Meltcer, G. Liberty, J. Rabinson, EY Anteby, R. Nahum. A combined approach to patients with repeated IVF failures. *Fertil Steril* 2010; 94:2462-4.
60. **R. Orvieto**, S. Meltcer, G. Liberty, J. Rabinson, EY Anteby, R. Nahum. Human menopausal gonadotropin (hMG) versus highly purified-hMG in controlled ovarian hyperstimulation for in vitro fertilization: Does purity improve outcome? *Gyn Endocrinol* 2010; 26:733-5.
61. **R. Orvieto**, E. Zohav, G. Liberty, G. Morgante, R. Nahum, J. Rabinson, S. Meltcer. Does centre's experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists? *The Open Women's Health Journal* 2010; 4: 69-71.

62. R. Abir, B. Fisch, S. Jessel, C. Felz, A. Ben Haroush, **R. Orvieto**. Improving post-transplantation survival of human ovarian tissue by treating the host and graft. *Fertil Steril* 2011; 95(4):1205-10.
63. **R. Orvieto**, B. Saar-Ryss, G. Morgante, O. Gemer, E.Y. Anteby, S. Meltcer. Does salpingectomy affect the ipsi-lateral ovarian response to gonadotropin during IVF-ET cycle? *Fertil Steril* 2011; 95 (5):1842-4.
64. Morgante G, Tosti c, **Orvieto R**, Musacchio mc, Piomboni p, De Leo v. Metformin improves semen characteristics of oligo-terat-asthenozoospermic men with metabolic syndrome. *Fertil Steril* 2011; 95: 2150–2.

B- Accepted Articles (in press)

1. G. Morgante, **R. Orvieto**, A. Di Sabatino, MC. Musacchio, F. Petraglia, V. De Leo. The role of inositol supplementation in polycystic ovary syndrome patients, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. *Fertil Steril* (Accepted for publication).
2. L. Governini, **R. Orvieto**, C. Guerranti, L. Gambera, V. De Leo, P. Piomboni. The impact of environmental exposure to perfluorinated compounds on oocyte quality and fertilization capacity. *J Assist Reprod Genet* (Accepted for publication).

C- Case Reports

1. E. Zohav, E. Anteby, **R. Orvieto**. Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system. *RBMonline* 2007; 14(4):495-7.

D- Review Article

1. **R. Orvieto**. Can We Eliminate Severe Ovarian Hyperstimulation Syndrome? *Hum Reprod* 2005; 20: 320-322.

E- Letters to the Editor

1. **R. Orvieto**. Reply: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005; 20: 2367-2368.
2. **R. Orvieto** Replies: Can we eliminate severe ovarian hyperstimulation syndrome. Comments 1 and 2. Hum Reprod 2005; 20: 2369-2370.
3. Z. Zukerman, **R. Orvieto**. Copious pre-ejaculation: small glands major headaches. J Androl 2007; 28(5):635
4. **R. Orvieto**. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 2007;22: 3042
5. **R. Orvieto**. Appropriate methods to monitor controlled ovarian hyperstimulation? Fertil Steril 2008; 89(4):1025-6.

F- Other Publications

1. **R. Orvieto**, Male contraception in mice using N-Butyldeoxynojirimycin. Obstet Gynecol Update 2006; 55:22.

Chapters in Books

1. **R. Orvieto**, O. Avrech. Male infertility: diagnosis and treatment. In: Human Reproduction: Fertility, Contraception and Sexual Health. DS. Seidman, Ed. Aurora-Medical Publications. Tel Aviv, Israel, 2005, pp. 12-15.
2. **R. Orvieto**. Bleeding and PID following ART. In: Contemporary Perspectives on Assisted Reproductive Technology. G. Allahbadia, R. Merchant, Eds. Elsevier, New Delhi, India, 2006, pp. 217-221396-9.
3. **R. Orvieto**, B. Fisch. Ovarian Hyperstimulation Syndrome. In: The Israeli Medical Encyclopedia. Y. Scohenfeld, J. Shemer, G. Keren. Eds. Miskal-Yedioth Ahronoth Bookd and Chemed Books. Tel-Aviv, Israel, 2007, pp. 1086-8.
4. E. Feigin, E. Freud, B. Fisch, **R. Orvieto**, D. Kravarusic, G. Avrahami, A. Ben Haroush, R. Abir. Fertility preservation in female adolescents with malignancies. In:

Cancer in Female Adolescents, M.T. Moorland Ed, Nova Science Publishers Inc.
Hauppauge, NY, USA, 2008, Chapter 3, pp 103-138.

5. **R. Orvieto**, A Golan Ovarian hyperstimulation syndrome. In: Obstetrics, Gynecology and Fertility. A. Golan, Ed. Probook, Ltd, Tel Aviv, Israel, 2009, pp. 539-544.

Active Participation in Scientific Meetings

A- Abstracts

1. **R. Orvieto**, I. Zagatski, V. Yulzari-Roll, B. Fisch. Substituting hCG by GnRH-agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May, 2005
2. Y. Gilboa, I. Bar-Hava, B. Fisch, J. Ashkenazi, I. Voliovitch, T. Bourkowski, **R. Orvieto**. Does intravaginal probiotics supplementation increase pregnancy rate in IVF-ET cycles? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May, 2005
3. R. Nahum, B. Kaplan, Y. Yairi, M. Hirsch, J. Pardo, Y. Yogev, **R. Orvieto**. Use of various contraceptive methods and time of conception in a community-based population. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May, 2005
4. **R. Orvieto**, V. Yulzari-Roll, J. Ashkenazi, B. Fisch. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in-vitro fertilization cycle Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May, 2005
5. **R. Orvieto**, A. La Marca, W. Badir, J. Bar, B. Fisch. Influence of urinary versus recombinant gonadotropin on serum P-selectin levels in vivo. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May, 2005
6. R. Abir, A. Ben Haroush, H. Raanani, **R. Orvieto**, D. Feldberg, B. Fisch A pilot study investigating if and when cryopreservation of ovarian tissue should be considered after initiation of chemotherapy. 21st Annual Meeting of the European Society of Human Reproduction and Embryology, Copenhagen, Denmark. June 2005
7. E. Zohav, E. Anteby, J. Rabinson, O. Segal, S. Meltzer, **R. Orvieto**. Low endometrial volume may predict early IVF-pregnancy loss Biannual Meeting of the Israel Society of Ultrasound in Obstetrics and Gynecology, Tel Aviv, Israel. February 2006
8. E. Anteby, J. Rabinson, **R. Orvieto**, O. Segal, S. Meltzer, E. Zohav. The role of uterine and endometrial 3D ultrasound parameters in uteri with congenital mullerian anomalies. Biannual Meeting of the Israel Society of Ultrasound in Obstetrics and Gynecology, Tel Aviv, Israel. February 2006
9. J. Rabinson, I. Bar-Hava, S. Meltzer, E. Anteby, **R. Orvieto**. Does gravidity influence the success of IVF-ET cycle? 12th World Congress of Gynecological Endocrinology, Florence, Italy. March 2006
10. **R. Orvieto**, J. Rabinson, S. Meltzer, R. Homburg, E. Anteby, E. Zohav. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked? 12th World Congress of Gynecological Endocrinology, Florence, Italy. March 2006

11. **R. Orvieto**, J. Rabinson, S. Meltzer, R. Homburg, E. Anteby, E. Zohav. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2006
12. R. Homburg, **R. Orvieto**, J. Rabinson, S. Meltzer, E. Zohav, E. Anteby. Substituting hCG by GnRH-agonist to trigger final follicular maturation- a retrospective comparison to three different controlled ovarian hyperstimulation protocols. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2006
13. **R. Orvieto**, B. Schachter, V. Yulzari-Roll, A. La-Marca, J. Bar, B. Fisch. Soluble CD40 ligand levels during controlled ovarian hyperstimulation- a possible culprit of systemic inflammation. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2006
14. Y. Yairi-Oron, J. Rabinson, **R. Orvieto**. Religious Infertility- A simplified approach. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2006
15. E. Zohav, M. Lorian, **R. Orvieto**, O. Segal, J. Rabinson, S. Meltzer, E.Y. Anteby 3D study of uterine and endometrial parameters in uteri with Mullerian anomalies versus normal uteri. 16th World Congress on Ultrasound in Obstetrics and Gynecology, London, UK, September 2006
16. S. Shenhav, I. Bord, **R. Orvieto**, E. Anteby. The role of repeat oral-GTT in women at risk for gestational diabetes. 4th International Symposium on Diabetes and Pregnancy, Istanbul, Turkey, March 2007
17. **R. Orvieto**, E. Zohav, S. Scharf, J. Rabinson, S. Meltzer, E. Anteby, R. Homburg The influence of E2/follicle and E2/oocyte ratios on the outcome of controlled ovarian stimulation for *in-vitro* fertilization. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2007
18. **R. Orvieto**, J. Rabinson, S. Meltzer, E.Y. Anteby, E. Zohav. Does physicians' experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2007
19. **R. Orvieto**, J. Kruchkovich, E. Zohav, J. Rabinson, E.Y. Anteby, S. Meltzer. Does Methotrexate treatment for Ectopic Pregnancy influence patients' performance during IVF-ET cycle? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2007
20. J. Rabinson, S. Meltzer, E. Zohav, O. Gerner, E.Y. Anteby, **R. Orvieto**. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on *in-vitro* fertilization outcome. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2007
21. E. Zohav, J. Rabinson, S. Meltzer, O. Segal, O. Gerner, E.Y. Anteby, **R. Orvieto**. The use of 3D ultrasound for diagnosis of unicornuate and didelphys uteri with twins gestation during first trimester of pregnancy. 17th World Congress on Ultrasound in Obstetrics and Gynecology, Florence, Italy, October 2007.
22. **R. Orvieto**, J. Kruchkovich, J. Rabinson, E. Zohav, E.Y. Anteby, S. Meltzer. Ultrashort GnRH-agonist combined with flexible multidose GnRH-antagonist for poor-responders in IVF-ET programs. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2008
23. **R. Orvieto**, E. Hod, M. **Volodarsky**, R. Homburg, J. Rabinson, S. Meltzer. 17-hydroxy progesterone levels during controlled ovarian hyperstimulation. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2008

24. **R. Orvieto**, S. Meltcer, J. Rabinson, E. Zohav, E.Y. Anteby, R. Nahum. GnRH agonist versus GnRH antagonist in ovarian stimulation: The role of endometrial receptivity? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2008
25. **R. Orvieto**, R. Homburg, S. Meltcer, J. Rabinson, E.Y. Anteby, R. Nahum. Human menopausal gonadotropin improves IVF outcome in patients with high basal FSH/LH ratio. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2008
26. R. Homburg, S. Meltcer, J. Rabinson, E. Zohav, E.Y. Anteby, **R. Orvieto**. Do stimulation characteristics of the first in-vitro fertilization cycle predict pregnancy in women of 40 years old and over? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2008
27. Lerner-Geva L, Farhi A, Mashiach S, Dor J, Margalioth EJ, Levran D, Calderon I, **Orvieto R**, Ellenbogen A, Meyerovitch J, Ron-El R. Risk for congenital malformations in infants conceived following in vitro fertilization (IVF) treatment. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
28. Rabinson J, Ashkenazi J, Homburg R, Meltcer S, Anteby EY, **Orvieto R**. Repeated in-vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation using gnrh-antagonists. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
29. **Orvieto R**, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltcer S Ultrashort flare gnrh-agonist combined with flexible multidose gnrh-antagonist for patients with repeated ivf failures and poor embryo quality. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
30. **Orvieto R**, Shuhav V, Homburg R, Nahum R, Rabinson J, Meltcer S Serum retinol-binding protein-4 levels in polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in-vitro fertilization cycle. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
31. **Orvieto R**, Meltcer S, Homburg R, Nahum R, Rabinson J, Ashkenazi J. What is the preferred gnrh-analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in-vitro fertilization? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
32. Homburg R, Meltcer S, Rabinson J, Scharf S, Anteby EY, **Orvieto R**. Is there a limit for the number of in-vitro fertilization cycles for an individual patient? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2009
33. **Orvieto R**. Body mass index and assisted reproductive technique- A clinical perspective 44th Annual Meeting of the European Society of Clinical Investigation, Bari, Italy, February 2010 (Eur J Clin Invest 2010;40:75).
34. **Orvieto R**, Fisch B, Jessel S, Felz C, Ben-Haroush A, Abir R. Methods to improve survival of grafted human. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2010.
35. **Orvieto R**, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R. Human menopausal gonadotropin (hMG) versus highly purified- hMG in controlled ovarian hyperstimulation for in-vitro fertilization: does purity improve outcome? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2010.
36. **Orvieto R**, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R. A combined approach to patients with repeated IVF failures. Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2010.

37. **Orvieto R.** Body mass index and assisted reproductive technique- A clinical perspective XI National Congress of Infertility, Contraception and Hormone Replacement Therapy. Plovdiv, Bulgaria, May 2010.
38. **Orvieto R.** Does Metformin Prevent Spontaneous Abortions in PCOS patients? 12th National Congress of Sterility, Contraception and Hormone Replacement Therapy, Borovetz, Bulgaria, March 2011
39. **Orvieto R.** Does Metformin Prevent Spontaneous Abortions in PCOS patients- pro? 6th International Symposium on Diabetes and Pregnancy (DIP). Salzburg, Austria, March 2011
40. Friedman O, Fisch B, **Orvieto R.**, Ben-Haroush A; Abir R. Melatonin, Hyaluronan, Vascular Endothelial Growth Factor and Vitamin E improve human ovarian grafting Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, and May 2011.
41. **Orvieto R.**, Saar-Ryss B, Morgante G, Gemer O, Anteby EY, Meltcer S. Does salpingectomy affect the ipsi-lateral ovarian response to gonadotropin during IVF-ET cycle? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2011.
42. Zohav E, Melcer Y, Tur-Kaspa I, Rabinson J, Partouche-Avidan Y, Anteby EY, **Orvieto R.** The role of 3-dimensional ultrasound for the diagnosis of congenital uterine anomalies Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2011.
43. **Orvieto R.**, Zohav E, Liberty G, Nahum R, Rabinson J, Meltcer S. Does center's experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists?? Annual Meeting of the Israeli Fertility Association, Tel Aviv, Israel, May 2011.

B- Lecture & Presentations

1. Workshop of the Israeli Fertility Association: Recurrent Abortions: Etiology, Investigation and Treatment. Petah Tikva, Israel 2005. Invited Speaker.
2. Premature Ovarian Failure and Poor Ovarian Response Symposium, Sophia, Bulgaria. 2007. Invited Speaker
3. Workshop of the Israeli Fertility Association: Optimal Infertility Management- Issues and Innovations Yearot Hacarmel, Israel. 2008. Invited Speaker.
4. Infertility Treatment in Advanced Reproductive Age- Outcome and Possible Complications, Sophia, Bulgaria 2008. Invited Speaker.
5. Workshop of the Israeli Fertility Association: Issues in Fertility- Current Trends and Debates. Yearot Hacarmel, Israel. 2009, Invited Speaker
6. PCOS & Infertility Treatment, Sophia, Bulgaria-2009, Invited Speaker
7. The 10th Annual Meeting of the Israeli Society of Gynecological Endoscopy, Dead sea, Israel 2009, Invited Speaker.
8. The 44th Annual Meeting of the European Society of Clinical Investigation, Workshop on Obesity and Reproduction. Bari, Italy 2009, Invited Speaker.
9. XI National Congress of Infertility, Contraception and Hormone Replacement Therapy. Plovdiv, Bulgaria 2009, Invited Speaker.
10. The 6th World Congress on Ovulation Induction, Naples, Italy. 2009, Invited Speaker.
11. La nascita nel 2010: un evento non globalizzato. Siena, Italy 2009, Invited Speaker.

12. The 2nd Annual Congress of the Society of Ambulatory Gynecology, Eilat, Israel 2011, Invited Speaker
13. Meeting of the Israeli Society of Obstetrics and Gynecology. Jerusalem, Israel. 2011, Invited Speaker
14. The 12th National Congress of Sterility, Contraception and Hormone Replacement Therapy, Borovetz, Bulgaria 2011, Invited Speaker
15. The 6th International Symposium on Diabetes and Pregnancy (DIP). Salzburg, Austria 2011, Invited Speaker

DEPARTMENT OF PEDIATRIC



Head of Department from October 2010

Prof Haim Bibi. MD

Associated Professor of Medicine Ben-Gurion University

haimb@barzi.health.gov.il

Head of Units

- Prof Menachem Schlesinger MD *Head of Department up to August 2010.
Professor of medicine of Medicine
Ben-Gurion University*

- Aviner Shraga, MD *Head of Pediatric Day Hospital
Lecturer of Medicine BG University*

- Dorit Ater, MD *Head of Pediatric Pulmonology Unit
Instructor of Medicine BG University*

- Enda Kurtzbart, MD *Lecturer of Medicine BG University*

- Alina Evestein, MD *Pediatric Pulmonology
Instructor of Medicine BG University*

- Jaffar Jaffry, MD *Pediatric Neurology
Instructor of Medicine BG University*

- Yaron Razon, MD *Pediatric Cardiology*

- Nurit Amir, MD *Pediatric Gastroenterology*

- Yuri Zeldin , MD *Allergy and clinical immunology*

Main Fields of Research Activities

Experimental

1. Evaluation of the apoptotic machinery in platelets of patients with acute and chronic ITP, the organisms that trigger ITP and the epitops for the corresponding antibodies, and the relation between these components and the clinical picture.

2. Immunologic chip for stratification of children newly diagnosed with ITP

Haim Bibi. MD

Pediatric Department

ଡକ୍ଟର



ଡକ୍ଟର

List of Publications

A- Original Articles

1. **Aviner S**, Dabby D, London D, Feinmesser M, Ash S, Steinberg R, Jakim I. Renal cell carcinoma in a child presented as bilateral femur neck fractures caused by severe vitamin D deficiency. *J Pediat Hematol Oncol.* 29:848-850, 2007.
2. Katz A, Bibi H, London D, **Aviner S**. Pneumomediastinum as presentation of an uncommon disease in previously healthy child. *Acta Paediatrica.* 96:1848-1852, 2007.
3. **Aviner S**, Ronen M, London D, Tobar A, Zangen S. Natural Course of Langerhans Cell Histiocytosis in A Premature Baby Presenting with Skin-Isolated Disease. *Acta Paediatrica.* 97:1751-1754, 2008.
4. **Aviner S**, Ben-Zion Garty BZ, Rachmel A, Baris HN, Sidransky E, Shuffer E, Attias J, Yaniv Y, Cohen IJ. Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare. *Blood Cells, Molecules & diseases,* 43:294-297, 2009.
5. **Aviner S**, Berkovitch M, Dalkian H, Lomnicki Y, Schlesinger M. Use of a Homeopathic Preparation for "Infantile Colic" in Patients Who Have Experienced an Apparent Life-Threatening Event. *Pediatrics* 125(2):e318-e323, 2010.
6. Tamary H, Nishri D, Yacobovich J, Zilber R, Dgany O, Krasnov Y, **Aviner S**, Stepensky P, S. Vilck-Ravel, Bitan M, Kaplinsky C, Ben Barak A, Elhasid R, Kapelusnik

- J, Koren A, Levin C, Atias D, Laor R, Yaniv I, Rosenberg PS, Alter BP. Frequency and Natural History of Inherited Bone Marrow Failure Syndromes: the Israeli Inherited Bone Marrow Failure Registry. *Hematologica* 95(8):1300-7, 2010.
7. Aviner S, London D, Horowitz S, Schlesinger M. Mycoplasma pneumonia infection – a Possible Trigger for Immune Thrombocytopenia. *Ind J Hem Blood Transf.* 27:46-50, 2011.
 8. Offer S, Yedgar S, Schwob O, Krimli M, **Bibi H**, Eliraz A, Madar Z, Shoseyov D. Negative feed-back between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats. *Am J Physiol Lung Cell Mol Physiol* 2005; 288(3):523-9
 9. Keinan E, Alt A, Amir G, Bentur L, **Bibi H**, Shoseyov D. Natural ozone scavenger prevents asthma in sensitized rats. *Bioorg Med Chem* 2005;17:13(2):557-62
 10. Shoseyov D, **Bibi H**, Offer S, Schwob O, Krinsky M, Kleiman M, Yedgar S. Treatment of ovalbumin – induced experimental allergic in rats by inhaled inhibitor of secretory phospholipase A2. *Thorax* 2005; 60(9):747-53
 11. Efrati O, Modan-Moses D, Ben-Abraham R, **Bibi H**, Paret G. Atropine abort bradycardic effect of endotracheally administered vasopressin. *Med. Sci Monit* 2005; 11(9):CR410-414
 12. Peled R, Friger M, Bolotin A, **Bibi H**, Epstein L, Pilpel D, Scharf S. Fine particles and meteorological conditions are associated with lung function in children with asthma living near two power plants. *Public Health* 2005; 119(5):418-25
 13. Bentur L, Shoseyov D, Feigenbaum D, Gorochofsky Y, **Bibi H**. Dexamethasone inhalations in RSV bronchiolitis: a double blind, placebo controlled study. *Acta Ped* 2005; 94:866-871
 14. **Bibi H**, Feigenbaum D, Hessen M, Shoseyov D. Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? *Respir Med* 2006;100:458-462
 15. Chemtob D, Weiler-Ravell D, Leventhal A, **Bibi H**. Epidemiological characteristics of pediatric active tuberculosis occurring among immigrants from high to low tuberculosis endemic countries: the Israeli experience. *IMAJ* 2006;8:21-26
 16. Huerta M, Gdalevich M, Haviv J, **Bibi H**, Scharf S. Ten year trends in obesity among Israeli schoolchildren: 1990-2000. *Acta Paediatr* 2006; 95(4):444-9.

17. Huerta M, **Bibi H**, Haviv J, Scharf S, Gdalevich M. Parental smoking and education as determinants of overweight and obesity in Israeli schoolchildren. *Prevent Chronic Dis* 2006;3(2):48:1-9
18. Huerta M, Gdalevich M, Tlashadze A, Scharf S, Schlesinger M, Efrati O, **Bibi H**. Appropriateness of US and international BMI for age reference curves in defining adiposity among Israeli school children. *Eur J Ped* 2007; 166 (6):573-8.
19. Handzel ZT, Barak V, Altman Y, **Bibi H**, Lidgi M, Iancovici-Kidon M, Yassky D, Raz M. Increased Th1 and Th2 type cytokine production in patients with active tuberculosis. *IMAJ* 2007;9(6):479-83
20. Efrati O, Harsh O, Rivlin J, **Bibi H**, Meir MZ, Blau H, Mussaffi H, Barak A, Levy I, **Vilozni D**, Kerem E, Modan-Moses D. Hemoptysis in Israeli CF patients Prevalence, treatment, and clinical characteristics. *J Cyst Fibros* 2008 ;7:301-306
21. Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, Yahav Y, Kerem E, **Bibi H**, Picard E, Wilschanski M. Nasal Potential Difference in non classic Cystic Fibrosis – Long term Follow up. *Pediatr Pulmonol* 2008;43(6):545-549
22. Zeldin Y, Kidon MI, Magen E, **Bibi H**, Cohen A, Waisel Y, Kivity S. Impact of specific allergen sensitization on the prevalence of asthma in patients with allergic rhinitis from adjacent distinct geographic areas. *Ann Allergy Asthma Immunol* 2008; 101:30-34
23. Huerta M, Zarka, S, **Bibi H**, Scharf S, Gdalevich M, Validity of childhood adiposity classification in predicting adolescent overweight and obesity. *International Journal of Pediatric Obesity Int J Pediatr Obes.* 2010 May 3; 5(3):250
24. - Yogevev Bagio T, **Bibi H**, Dubnov J, Or hen K, Carel R, Portnov BA. Who is affected more by air pollution – Sick or healthy? Some evidence from a health survey of schoolchildren living in the vicinity of the coal – fired power plant in Northern Israel. *Health Place.* 2010; 16(2): 399-408

B- Publications as investigator in multi-center trials

1. Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen YZ, Lamm CJ, O'Byrne PM; START Investigators Group. **Bibi H** as investigator. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of

early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008;121:1167-1174

2. Amir J, Schonfeld T, Danino D, Prais D. Israeli respiratory syncytial virus monitoring group, **Bibi H** as investigator. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest 2005; 128(4):2765-71
3. Treatment with hypertonic inhalations in viral bronchiolitis: mechanism and rationale Medicine, Pediatric Medicine, 15: 22-25, December 2010 , Dorit Ater, Avigdor Mandelberg

C- Case Reports

1. Elenberg, Y, Shani-Adir A, Hecht Y, Ephros M, **Bibi H**. Pyoderma gangrenosum as an indicator for recurrent leukocyte adhesion deficiency, type 1 (LAD 1). IMAJ 2010; 12: 78-79

D- Editorial & Reviews Article

1. Mahamid J, Armoni M, **Bibi H**. The relationship between RSV bronchiolitis and the development of asthma. Harefuah 2007; 146 (6):480-4. (Hebrew).

Active Participation in Scientific Meetings

A- Abstracts

1. Huerta M, **Bibi H**, Haviv J, Scharf S, Gdalevich M. Socioeconomic determinants of overweight and obesity among Israeli schoolchildren Annual Scientific Conference of the Association of Public Health Physicians in Israel. Haifa, January 2006
2. Huerta M, Tlachadze A, Gdalevich M, Scharf S, Schlesinger M, **Bibi H**. BMI for age reference curves for elementary schoolchildren in the Ashkelon District of Israel. Annual Scientific Conference of the Association of Public Health Physicians in Israel. Haifa, January 2006
3. **Bibi H**. The relationship between air-pollution and asthma. ISEEQS Meeting, Haifa, Israel, June 2006
4. Huerta M, **Bibi H**, Haviv J, Scharf S, Gdalevich M Short term effects of ambient nitrogen oxides on emergency department cardiac patient load. American Public Health Association, 134th Annual Meeting & Exposition, Philadelphia, Pennsylvania, USA, Nov 2006
5. Huerta M, Zarka S, **Bibi H**, Haviv J, Scharf S, Gdalevich M. Validity of childhood BMI in predicting adolescent overweight and obesity American Public Health Association, 134th Annual Meeting & Exposition, Philadelphia, Pennsylvania, USA, Nov 2006.
6. Huerta M, Gdalevich M, Haviv J, **Bibi H**, Scharf S. Ten year trends in obesity among Israeli schoolchildren: 1990-2000 Annual Conference of the Israeli Ambulatory Pediatric Association, Tel Aviv, Israel, 2006
7. Huerta M, **Bibi H**, Haviv J, Scharf S, Gdalevich M Parental smoking, education and socioeconomic status and the risk of childhood overweight Annual Conference of the Israeli Ambulatory Pediatric Association, Tel Aviv, Israel, 2006.
8. Huerta M, Tlachadze A, Gdalevich M, Scharf S, **Schlesinger M**, Efrati O, **Bibi H**. Appropriateness of US and international BMI for age reference curves in defining adiposity among Israeli schoolchildren Annual Conference of the Israeli Ambulatory Pediatric Association, Tel Aviv, Israel, 2006.
9. Netzer-Tomkins H, Gittin Y, Efrat M, Bentur Y, **Bibi H** Seizures in a four month old infant Israel Society of Toxicology, Tel Aviv, Israel, 2007.
10. Netzer-Tomkins H, Gittin Y, Efrat M, Bentur Y, **Bibi H**. Convulsions with out known reason in an infant. Israel Society of Clinical Pediatrics Meeting, Tel Aviv, Israel 2007.
11. Elenberg Y, Shani-Adir A, Hecht Y, Efrat M, **Bibi H**. Recurrent painful skin lesions 13 years after bone marrow transplantation for Leukocyte Adhesion Deficiency Type 1. Israel Society of Clinical Pediatrics Meeting, Tel Aviv, Israel 2007.
12. Kiyal K, Zelnik N, Mahajne M, **Bibi H**. Annual Conference of the Israeli Ambulatory Pediatric Association. Tel Aviv, Israel, 2007. The prevalence of genetic malformation in an Arab village in Israel
13. Zangen S, Polak M, Zeitlin M, **Bibi H**. The effect of passive prophylaxis treatment (Palivizumab vaccination) on morbidity among infants that were born under 28 weeks gestation The 25th International Congress of Pediatrics, Athens, Aug 2007.
14. Gdalevich M, Broday D, Bassal R, **Bibi H**, Scharf S, Huerta M. Acute cardio respiratory effects of SO₂ and NO₂ exposure in southern Israel American Public Health Association. 135th Annual Meeting & Exposition. Washington DC, USA November 2007.

15. Gdalevich M, Broday D, Yuval, **Bibi H**, Scharf S, Huerta M. Acute cardio- respiratory effects of SO₂ and NO₂ exposure in southern Israel – a case-control design for data collection and analysis. International society for environmental epidemiology & International society of exposure analysis, 2008 Joint Annual Conference, Pasadena, California, USA, October, 2008.
16. Aviner S, Kalinin M, Braunstein R, **Schlesinger M**. Evaluation of parental knowledge in updated recommendations on the treatment of gastroenteritis and examining the impact of educational intervention. Annual meeting of the Israel Clinical Pediatric Society. Tel Aviv, February 2008.
17. Tamary H, Nishri D, Yacobovich J, Zilber R, **Aviner S**, Stepensky P, Vilk-Ravel S, Bitan M, Kaplinsky, Ben Barak A, Kapelusnik, Koren A, Levin C, Yaniv I, Rosenberg PS, Alter BP. Frequency and Natural History of Inherited Bone Marrow Failure Syndromes: The Israeli Inherited Bone Marrow Failure Registry. American Society of Hematology conference. San Francisco, December 2008.
18. Reches O, Hecht Y, **Bibi H** Unusual Presentation of childhood ankylosing spondylitis Annual Conference of the Israeli Clinical Pediatric Association. Tel Aviv, Israel, 2009.
19. Yigal Elenberg, Rihani O, Keinan E, **Bibi H**. The value of D-limonene as anti oxidant in the treatment of asthma in mice model. Annual Conference of the Israeli Clinical Pediatric Association. Tel Aviv, Israel, 2009.
20. **Bibi H**, Kenefnicki M, Vivat Y, Gavriely N. Wheeze monitoring of severe asthmatics in the emergency setting – the "silent lung" phenomenon. Am Rev Respir Crit Care Med 2009; 174:6:A452 ATS Meeting, San Diego, USA, May 2009
21. **Bibi H**, Kenefnicki M, Vivat Y, Gavriely G. ATS Meeting, San Diego, USA, May 2009 Continuous Wheeze Monitoring during Bronchodilator Administration in Pediatric Asthma. Am Rev Respir Crit Care Med 2009; 174:6:A452
22. **Bibi H**, Gavriely N. Cough monitoring during bronchodilator administration in pediatric Asthma. ILSA 34th meeting, Haifa, September 10th, 2009.
23. **Bibi H**, Gavriely N. Cough monitoring during bronchodilator administration in pediatric Asthma. s 239. ERS annual Meeting, Vienna, September 2009
24. Elenberg Y, Rihani O, Keinan E, **Bibi H**. The effect of D-limonene as an antioxidant in asthmatic mice model, s1204. ERS annual Meeting, Vienna, September 2009.
25. Aviner S, Kostinetsky B, **Schlesinger M**. Homeopathic Preparation for "Infantile Colic" and the Risk of Apparent Life-Threatening Event. Annual meeting of the Israel Clinical Pediatric Society. Tel Aviv, February 2009.
26. Aviner S, London D, Horowitz S, **Schlesinger M**. Mycoplasma pneumonia Infection Role in Immune Thrombocytopenia. Annual meeting of the Israel Society of Pediatric Hematology and Oncology, Ramot, Israel, April 2009.
27. Aviner S, Berkovitch M, Lomnicki Y, **Schlesinger M**. Use of a Homeopathic Preparation for "Infantile Colic" in Patients Who Have Experienced an Apparent Life-Threatening Event. Annual Meeting of the European Society of Developmental, Paediatric, Perinatal Pharmacology (ESDPPP). Chamonix, France, June 2009.
28. **Bibi H**, Vinokur V, Eliashar R, Waisman D, Chevion M. American Thoracic Meeting New Orleans May 2010. ZGD- A selective iron chelator attenuates inflammatory process in Asthma Mouse Model. A 415
29. **Bibi H**, Schichter V, Vivat Y, Gavriely N. Cough during Bronchodilator administration in Pediatric acute wheezing. A175 American Thoracic Meeting New Orleans May 2010.

30. **Bibi H**, Waisman D, Landsberg A. Quantification of the respiratory effort in an asthmatic mouse model by a novel modality for monitoring the ventilation with miniature motion sensors, A176. American Thoracic Meeting New Orleans May 2010.
31. A. Mandelberg, D. Ater, **T. Zangen**, E. Meiri, s. Frank and A. Levine. Simultaneous objective recording of pH Impedance and respiratory symptoms is crucial to establish the causality of reflux-cough events.
32. **Aviner S**, Ben-Zion Garty BZ, Rachmel A, Baris HN, Sidransky E, Shuffer E, Attias J, Yaniv Y, Cohen IJ. Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare. Annual meeting of the Israel Society of Pediatric Hematology and Oncology. Ginosar, Israel, April 2010.
33. **Aviner S**, Berkovitch M, Lomnicki Y, Schlesinger M. Use of a Homeopathic Preparation for "Infantile Colic" in Patients Who Have Experienced an Apparent Life-Threatening Event. Italian-Israeli Scientific Pediatric Meeting, Yad Hashmona, Israel, June 2010.

Current clinical studies

Ongoing

1. Adverse effect of prolonged Ritalin treatment on cardiac functions.
2. Treatment of Encomprexis in Children. Experience of an out-patient clinic.
3. Evaluation of oral status as guide for pediatric hospitalization.

Completed Projects

Submitted for publication.

1. Evaluation of parental knowledge in updated recommendations on the treatment of gastroenteritis and examining the impact of educational intervention.
2. Septicemia Following Rotavirus Gastroenteritis - Two cases and a Literature Review
3. Posttraumatic fat necrosis presented as cellulitis of the shine.
4. Sinus tachycardia as a sign of tracheal foreign body.

Manuscript

5. Evaluation of the use of anti colic medications in the Ashkelon district.
6. Maternal stress during pregnancy, iron status and infant development.
7. Recurrent septic shock after common infectious diseases in a boy.
8. The effects of the sex of previous children in the family on sex of a subsequent child.

PEDIATRIC DENTAL CLINIC



Head of Department

Dr Uri Zilberman DMD, PhD

Senior Lecturer in Dental Medicine

ori@barzi.health.gov.il

Medical Team:

- Eliyahu Mass, DMD *Senior Lecturer in Dental Medicine*
- Gizela Aizman-Berenstein, DMD

Description

The Pediatric Dental Clinic at Barzilai Medical Center was established in 1998. The clinic provides high level dental treatment to children suffering from genetic and hereditary disorders, health problems, dental phobia and dental trauma. The treatments are given using conscious sedation or under general anesthetics. In 2008 the clinic was accredited to start a three and a half years specialization program in pediatric dentistry, and in November 2008 the first 3 dentists were accepted to the program. Today there are six residents in the program.

Uri Zilberman, MD

Pediatric Dental Clinic

නරපතලනර



නරපතලනර

Research Activities

The clinic is involved in clinical and basic research in pediatric dentistry and bioanthropology and more than 20 papers were published and 15 presentations (Oral or Poster) were given in local and international meetings during the last 5 years.

The staff and the residents are conducting several studies involving the use of local anesthetics in pediatric dentistry, the knowledge of pediatrics in the field of pediatric dentistry, and the use of iodoform paste for pulpotomies in primary molars.

List of Publications

Refereed articles in scientific journals

A-Original Articles

1. **Zilberman U** (2005): Formaldehyde from POM brackets. Am Orthod Dentofacial Orthop. 128: 147-148.
2. Gordon M, Gorfil C, Segal S, **Mass E**. (2005). Treatment policies among Israeli specialists in paediatric dentistry. Eur J Paediatr Dent 6: 73-78.
3. **Mass E**, Lapidot M, Gadoth N. (2005). Case report: multiple endocrine neoplasia type B2 misdiagnosed as familial dysautonomia. Eur J Paediatr Dent 6: 48-50.
4. **Mass E**, Aharoni K, Vardimon AD. (2005). Labial cervical vertical groove in maxillary permanent incisors- prevalence, severity and affected soft tissue Quintessence Int 36: 281-286.
5. Keinan D, Smith P, **Zilberman U**. (2006): Microstructure and chemical composition of primary teeth in children with Down syndrome and cerebral palsy. Arch Oral Biol. 51:836-843.
6. Keinan D, Smith P, **Zilberman U**. (2007): Prenatal growth acceleration in maxilla deciduous canines of children with Down syndrome: Histological and chemical composition study. Arch Oral Biol. 52:961-966.
7. Young L, **Mass E**, Beni L, Weinreb M, Vardimon AD. (2007). Enamel, dentine and pulp in a talon primary maxillary central incisor: a histomorphometric study. Eur Arch Paediatr Dent 8:136-140.
8. **Mass E**, Oelgiesser D, Tal H. (2007). Transitional implants in a patient with Williams- Beuren syndrome: a four year follow-up. Spec Care Dentist 27: 112-116.
9. Shpack N, Dayan T, **Mass E**, Vardimon AD. (2007). Labial cervical vertical groove (LCVG) distribution and morphometric characteristics. Arch Oral Biol 52: 1032-1036.
10. Ziskind D, **Mass E**, Vardimon AD. (2007). Effect of different restorative materials on caries: a retrospective in vivo study. Quintessence Int 38: 429-434.

11. **Zilberman U.** (2007). Tooth components in archaic Homo Sapiens/Neanderthal specimens from Israel and their taxonomic affiliation. In: M. Faerman, L. Kolska-Horwitz, T. Kahana and U. Zilberman (eds). *Faces from the Past: Diachronic Patterns in the Biology of Human Populations from the Eastern Mediterranean. Papers in honour of Patricia Smith. BAR International Series 1603.* Oxford: Archaeopress. pp. 44-57.
12. **Zilberman U.** (2008): New materials in dentistry. *Dental* 1:54-57. (Hebrew)
13. **E. Mass,** K. Aharoni, AD. Vardimon: (2008). Labiozervikale grubchen bleibender oberer schneidezahne – pravalencz, schweregrad und beteiligtes weichteilgewebe. *Kieferorthopädie.* 22(2):133-138.
14. **E. Mass:** (2008) Advantages of dental treatment of children under general anesthesia in cpmparison to other methods. *Dental* 2: 26-29. (Hebrew)
15. Keinan D, Radko A, Smith P, **Zilberman U.** (2009). Acid Resistance of the Enamel in Primary Second Molars from Children with Down Syndrome and Cerebral Palsy. *The Open Dent J.* 3:132-136.
16. **Zilberman U,** Keinan D, Smith P. (2009). The Dental Evidence for Prenatal and Early Postnatal Growth Insults in Down Syndrome. In: D. Jelinek and G. Dvorak (eds). *Handbook of Down Syndrome Research.* Nova Science Publishers Inc. pp. 409-425,
17. Itskovitz R, **Zilberman U.** (2010). The genetic basis of Amelogenesis Imperfecta. *Dental* 11:28-38. (Hebrew)
18. **Zilberman U.** (2010). Caries Risk Assesment in Mixed Dentition. *Israel Dental Hygine Journal.* 37: 28-32. (Hebrew).
19. **Zilberman U,** Zilberman S, Keinan D, **Mass E.** (2010). Enamel development in primary molars from children with Familial Dysautonomia
Arch Oral Biol. 55: 907-912.
20. Keinan D, **Mass E,** **Zilberman U** (2011). Absorption of nickel, chromium, and iron by the root surface of primary molars covered by stainless steel crowns.
Int J Dent. Epub 2011 Jan 17.

21. Gadoth N, **Mass E.** (2011). The lingual taste papillae: A delicate and complicated nature's design for taste modalities perception. In: Gordon R, Stillwaggon Swan L, Seckbach J, (eds), *Origins of Design in Nature*. Dordrecht, Springer. (In Press).

Active Participation in Scientific Meetings

A-Abstract

1. Stroianu A, Evensteen A, Shlezinger M, **Zilberman U**: The relation between carious activity and hospitalization length. (*Poster*). The 20th International Congress of the International Association of Pediatric Dentistry, Sydney, Australia, 2005.
2. Stroianu A, Buksemboim P, **Zilberman U**: Nager syndrome and its implications on dental treatment- case report. (*Poster*). The 21th International Congress of the International Association of Pediatric Dentistry, Hong-Kong, 2007.
3. **Zilberman U, Mass E**: Amelogenesis Imperfecta- the earliest hereditary dental syndrome described and a case report with 20 years follow-up. (*Poster*). The 9th Congress of the European Academy of Pediatric Dentistry, Dubrovnik, Croatia
4. Stroianu A, Segal S, **Zilberman U**: Phenotype and treatment of Amelogenesis Imperfecta with unerupted and resorbed permanent teeth. (*Poster*) The 22nd Congress of the international Association of Pediatric Dentistry, Munich, 2009.
5. **Zilberman U**, Yanku R, Lustig JP. Use of dental implants in young patient with Down syndrome. Case report with 10 years follow-up. (*Poster*) The 20th Congress of the International Association of Disability and Oral Health (iADH), Ghent, Belgium, 2010.
6. **Berenstein-Ajzman G.**, Hazan-Molina H, Drori D, Aizenbud D. Axenfeld Rieger Syndrome (*Poster*). The 20th Congress of the International Association of Disability and Oral Health (iADH), Ghent, Belgium, 2010.
7. Palmon Y, **Berenstein-Ajzman G**. Severe hypodontia in a 4Y old girl with ectodermal dysplasia-case report and treatment option (*Poster*). The 20th Congress of the International Association of Disability and Oral Health (iADH), Ghent, Belgium, 2010.
8. Stroianu A, **Zilberman U**. Facial and dental manifestation of Sialic Acid Storage disease (Salla Disease) (*Poster*). The 20th Congress of the International Association of Disability and Oral Health (iADH), Ghent, Belgium, 2010.

B- Lecture & Presentations

1. Keinan D, **Zilberman U**, Smith P: Chemical composition changes in deciduous teeth from two congenital disorders. (*Oral presentation*). The Annual Meeting of the International Association for Dental Research- Israel Division, Tel-Aviv, Israel 2005

2. Natan Y, Avishai G, **Zilberman U**, **Mass E**, Smith P: Developmental defects in the primary teeth of children with FD. (*Oral presentation*). The Annual Meeting of the International Association for Dental Research- Israel Division, Tel-Aviv, Israel 2005
3. Lev-Tov Chattah N, Smith P, **Zilberman U**: Differences in odontoblastic function between first and second permanent molars. (*Oral presentation*). The Annual Meeting of the International Association for Dental Research- Israel Division, Tel-Aviv, Israel 2005
4. **Zilberman U**, Holan G, Fuks A: Acetal versus Stainless-steel crowns: In-vitro assessment of marginal adaptation. (*Oral presentation*). The 20th International Congress of the International Association of Pediatric Dentistry, Sydney, Australia, 2005.
5. Keinan D, Smith P, **Zilberman U**. Prenatal development in deciduous canines of Down syndrome and CP. (*Oral presentation*). The 21th International Congress of the International Association of Pediatric Dentistry, Hong-Kong, 2007.
6. **Zilberman U**, Zilberman S, **Mass E**: Pre and post natal enamel formation of primary second molars in children with familial Disautonomia. (*Oral presentation*). The 22nd Congress of the international Association of Pediatric Dentistry, Munich, 2009.
7. **Zilberman U**. The Dental Evidence for Prenatal and Early Postnatal Growth Insults in Down syndrome. The 20th Congress of the International Association of Disability and Oral Health (IADH), Ghent, Belgium, 25-28 August 2010. *Invited Speaker (Key note speaker)*

Current clinical studies

Ongoing

Current clinical studies:

Two large Helsinki Committees' approved clinical researches are ongoing these days:

1. The use of new preformed, tooth colored acetal crowns for primary molars, sponsored by Dentsply Int. (USA).
2. The relation between caries activity in children and length of hospitalization due to child diseases, in collaboration with the pediatric department.

Complete Project

In July 2011, the last paper on a new method of pulp treatment in young permanent molars with carious pulp exposure will be published. This was a 10 years clinical project with a long follow-up period.

DEPARTMENT OF GENERAL & VASCULAR SURGERY



Head of Department

Prof Boris Yoffe, MD, FACS

Associated Professor of Medicine Ben-Gurion University

borisy@barzi.health.gov.il

Medical Team

- Efim Harah, MD Head of unit of vascular Surgery
Instructor of Medicine Ben-Gurion University
- Youri Mnouskin, MD Head of Trauma Unit
Instructor of Medicine Ben-Gurion University
- Ben-Dor Dora, MD Head of Department of Pathology

Research

- Ms. Tsarfati Becky CRA and Research coordinator

Main Fields of Research Activities:

Experimental

1. Vascular medicine and surgery
2. Laparoscopic surgery
3. Gastrointestinal surgery

Boris Yoffe, MD, FACS

Department of General & Vascular Surgery

නර්මාලය



නර්මාලය

List of Publications

A- Original Articles

1. **Yoffe B**, Behar D.J, Scheinowitz M, Rabin A.M. A new Mechanical Device for Declotting of Hemodialysis Access Grafts: First Clinical Experience. J Endovasc Ther 12:215-223, 2005
2. Kravchick, S, **Yoffe B**, Cytron S. Modified perianal/pericapsular anaesthesia for transrectal biopsy of the prostate in patients with anal rectal problems. Urology 69:139-41, 2007
3. **Yoffe B**, Vaysbeyn I, Urin Y, Waysbeyn I, Zubkova O, Chernyavskiy V, Ben-Dor D. Experimental study of a novel suture-less aortic anastomotic device. Eur J Vasc Endovasc Surg. 34, 79-86 (2007).
4. Nahlieli O, Bar-Droma E, Zagury A, Turner D.M, **Yoffe B**, Shacham R, Bar,T Endoscopic Intraoral Plating of Orbital Floor Fractures. J Oral & Maxillofacial Surgery. September 2007 (Vol. 65, Issue 9, Pages 1751-1757)
5. Nahlieli O, Shacham R Zagury, A, Bar T, **Yoffe B**. The Ductal Stretching Technique- Endoscopic Assisted Technique for Submandibular Stones. The Laryngoscope. Volume 117, Issue 6, Date: June 2007 Pages: 1031-1035.
6. **Yoffe B**, Levy B, Ben-Alon D. Baruchin O, Baruchin AM. Intra-arterial infusion of nitric oxide (NO)-first animal trial. Vascular Pharmacology (47) 57-62 (2007).

7. Yoffe B, Sapojnikov S, Margolin L, Butenko S. Early experience of transanal endoscopic microsurgery. *Techniques in Coloproctology* (2008)12:363-364

B- Case Reports

1. Baruchin A.M., Scharf S, Baruchin O, Yoffe B. Resurfacing of fingertip following deep burns: the hypothenar skin graft. *Burns* 31: 243-244, 2005.
2. Uriev L, Maslovsky I, Vainshtein P, Yoffe B, Ben-Dor D. Malignant Phyllodes tumor with heterologous liposarcomatous differentiation and tubular adenoma-like epithelial component. *Int J Med Sci.* 3:130-134, 2006.

Active Participation in Scientific Meetings

A- Abstracts

1. Yoffe B, Waysbeyn I, Waysbeyn I, Urin Y. A sutureless aortic graft for abdominal aortic aneurysm. The 23rd International Cardiovascular Surgical Symposium in Zurs/Arlberg, Austria, February 26th – March 5th, 2005.
2. Yoffe B, Waysbeyn I, Urin Y. Sutureless aortic graft for abdominal aortic aneurysm. The 23rd International Cardiovascular Surgical Symposium in Zurs/Arlberg, Austria, February 26th – March 5th, 2005.
3. Yoffe B, Harah E, Levy B. Preliminary results of intra-arterial NO (Nitric Oxide) delivery in animal models. The 23rd International Cardiovascular Surgical Symposium in Zurs/Arlberg, Austria, February 26th – March 5th, 2005.
4. Yoffe B, Sapojnikov S, Mnuskin Y. Laparoscopic colectomy for malignant and benign diseases. The 13th International Congress of the European Association for Endoscopic Surgery in Venice, Italy on June, 2005.
5. Yoffe B, Sapojnikov S, Goldblum C. Use of simicol® (simethicone) in colonic preparation for laparoscopic colon operations. The 13th International Congress of the European Association for Endoscopic Surgery in Venice, Italy on June, 2005.
6. Yoffe B, Ben-Alon D, Levy B Endovascular Delivery of NO (Nitric oxide) in animal trials. MEET 2005 in Cannes, France on June, 2005. The 13th International Congress of the European Association for Endoscopic Surgery in Venice, Italy on June, 2005.
7. Yoffe B, Sapojnikov S. Laparoscopic approach during Mirizzi Syndrome. The Israeli Society for Endoscopic Surgery, Tel-Ha'shomer, on September, 2005. The 13th International Congress of the European Association for Endoscopic Surgery in Venice, Italy on June, 2005.

8. Harah E, Yavnel L, **Yoffe B**. Comparison between loop and straight A-V shunt for hemodialysis-late term results. Israeli Vascular Society meeting during the Israeli Vascular Society Conference in The Dead sea, on June 29-July 1, 2005.
9. **Yoffe B**, Ben-Alon D, Levy B. Endovascular Delivery of NO (Nitric oxide) in animal trials. Israeli Vascular Society meeting during the Israeli Vascular Society Conference in The Dead sea, on June 29-July 1, 2005.
10. Rifman V, Goldblum C, Sapojnikov S, Gurvich D, **Yoffe B**. Ischemic Colitis. The Israeli Society for Colo-Rectal Surgery. Ramat-Gan, on March, 2006.
11. **Yoffe B**, Urin Y, Vaysbeyn I, Vaysbeyn I. First Clinical Experience with Sutureless Aortic Graft. 24th Annual Meeting of the Association of International Vascular Surgeons, Davos, Switzerland, on March 2006
12. **Yoffe B**, Urin Y, Vaysbeyn I, Vaysbeyn I. Laparoscopic aortic surgery with sutureless graft. The 22nd World Congress of the International Union of Angiology. Lisbon, Portugal, June 24-28, 2006.
13. **Yoffe B**, Harah E, Levy B. Endovascular delivery of nitric oxide in animal trials. The 22nd World Congress of the International Union of Angiology. Lisbon, Portugal, June 24-28, 2006.
14. **Yoffe B**, Harah E, Levy B. Endovascular delivery of nitric oxide in animal trials. The 35th World Congress of the International College of Surgeons. Pattaya, Thailand, 25-29 October, 2006.
15. **Yoffe B**, Urin Y, Vaysbeyn I, Vaysbeyn I. Laparoscopic Aortic Surgery with Sutureless Graft. The 35th World Congress of the International College of Surgeons. Pattaya, Thailand, 25-29 October, 2006.
16. **Yoffe B**, Urin Y, Vaysbeyn I, Vaysbeyn I. Laparoscopic Aortic Surgery with Sutureless Graft. The 3rd Meeting of the Israeli Society for Endoscopic Surgery. Eilat, Israel, November-December 2006
17. Rifman V, Sinelnikov Y, Ben-Michael S, Mnouskin Y, **Yoffe B**. Laparoscopic Appendectomy for Acute Gangrenous Appendicitis with Peritonitis. The 3rd Meeting of the Israeli Society for Endoscopic Surgery. Eilat, Israel, November-December 2006
18. Yosefy C, Be'eri R, Gilon D, Oren S, **Yoffe B**, Katz A. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in white Coat Hypertension Using Combined Evaluation with 3-D echocardiography and Carotid Intima-Media Thickness. 21st Scientific Meeting of International Society of Hypertension. Fukuoka, Japan, 15-19 October, 2006
19. **Yoffe B**, Leonty Y. Open transcervical approach for carotid artery stenting AIVS 2007, 25th Annual Meeting, and 11-18 March, 2007.
20. Yosefy C, **Yoffe B**, Magen E, Katz A, Oren S. Abnormalities in Carotids Intima-Media Thickness, left Ventricular Stiffness and Arterial Compliance in white Coat Hypertension. Are they innocent? The 54th Annual conference of the Israel heart society together with the Israel society of cardiothoracic surgery. Tel-Aviv, Israel 18-19 April, 2007.

21. Yosefy C, Be'eri R, Gilon D, Oren S, Yoffe B, Katz A. The Comprehensive Non Invasive Approach for Early Recognition of Hypertensive Cardiovascular Disease in white Coat Hypertension Using Combined Evaluation with 3-D Echocardiography and Carotid Intima-Media Thickness. The 54th Annual conference of the Israel heart society together with the Israel society of cardiothoracic surgery. Tel-Aviv, Israel 18-19 April, 2007.
22. Sapojnikov S, Margolin L, Butanko S, Yoffe B. FACS, Early experience of transanal endoscopic microsurgery. The Annual Meeting of the Israeli Society of Colon and Rectal Surgeons. Caesarea, Israel 11-12 September 2008
23. Yoffe B., Mnouskin Y. Livshits I. Interactive discussion: The most difficult case. Congress of the Israeli trauma association. Tel Aviv, Israel, 17 November 2008
24. Butanko S, Sapojnikov S, Margolin L, Mnouskin Y, Yoffe B. FACS, Laparoscopic vs open hemicolectomy and anterior resection for colorectal Cancer. Presented at the Annual congress of The Israeli Society for Endoscopic Surgery, Ramot, and 20-22 November, 2008.
25. Yoffe B, Bass A, Kobzantsev Z, Akinfiyev V, Kavounovski I The HDH device for suture-less vascular anastomosis: the novel surgical technique. Natural Orifice Surgery and other innovations a NESA meeting promoting excellence in surgery Naples, 21-22 November 2008 Italy
26. Yoffe B, Y.Urin, I.Vaysbeyn. Bass A. A novel suture-less device (HDH) For vascular anastomosis- clinical study. Presented at the 27th International cardiovascular surgical symposium, Zurs/Arlberg, Austria, February 28- March 7, 2009.
27. Yoffe B, Hospital under Attack. World Congress for the advancement of surgery, november1-4, 2009 Jerusalem, ISRAEL

B- Lecture & Presentations

1. Endovascular delivery of nitric oxide in animal trials. Stuff meeting in Hilel - Yafe Hospital, June 2005, Israel.

New Technologies Used For Pulmonary Evaluation

1. Method and Device for Sutureless Vascular Anastomosis. Barzilai Medical Center & HDH Medical.LTD.
2. Nitric oxide (NO) participates in vascular wall homeostasis Barzilai Medical Center & Ashkelon Technological Industries, Ashkelon, Israel.
3. A standard planned closure of trocar wounds plaque returning & microembolies occasion between a standard carotid stent and a sleeve wrapped carotid stent
4. Multi gene vascular systems.MGVS, Barzilai Medical Center & TEVA. margin probe device the breast lump after lumpectomy Barzilai Medical Center and DUNE medical
5. Articulated laparoscopic devices for tacks insertion and resection. Barzilai Medical Center & Novo Lap Medical.
6. Evaluation of NiTi Compression Anastomosis Clip (HandCAC) for Compression Anastomosis. Multicenter Study, Israel.
7. CardioFit™ for Heart Failure-Clinical Study. BIO Control Medical LTD& Barzilai Medical Center.

UROLOGY DEPARTMENT



Head of Department

Dr Shmuel Cytron, MD

Senior Lecturer of Medicine Ben-Gurion University

shmuelc@barzi.health.gov.il

Medical Team:

- | | |
|-------------------------------|---|
| ▪ Dr Kravchick Sergey, MD | <i>Assistant professor of Medicine
at Ben Gurion University</i> |
| ▪ Dr. David Kisari, MD | <i>Lecture of Medicine at BG University</i> |
| ▪ Dr. Dimitry Shumalinsky, MD | <i>Lecture of Medicine at BG University</i> |
| ▪ Dr. Adrian Paz, MD | <i>Lecture of Medicine at BG University</i> |
| ▪ Dr. Leonid Lobic, MD | <i>Lecture of Medicine at BG University</i> |
| ▪ Yevgeny Stepnov, MD | Urologist |
| ▪ Yevgeny Yulish, MD | Urologist |
| ▪ Uri Goralic, MD | Urologist |
| ▪ Igor Bunkin, MD | Resident |
| ▪ Leonid Loifman, MD | |
| ▪ David Bron, MD | |
| ▪ Imanuel Chotz, MD | |
| ▪ Michael Meloshevitzer, MD | |

Description

The Urology department includes 20 beds with the capacity of 25 beds (when needed). 12 Urologists are the medical staff, some of them in partial position.

The Urology department in the Barzilai Medical Center deals with all the Urological aspects such as: General Urology, Oncology, Pediatric Urology, Urodynamics studies, Female urology, Andrology, Endo-urology, Laparoscopic surgery, Cryoablation of tumors and organs, TRUS imagine and TRUS guided prostate biopsies, Cystosopy and biopsies, Bladder chemotherapy irrigation and Out patient clinic for diagnosis and follow-up.

Shmuel Cytron, MD

Urology Department

✪✪✪✪✪✪



✪✪✪✪✪✪

Main Fields of Research Activities

Experimental

- Comparison MMC level in blood and urine in two groups of patients who underwent TUR-BT followed by intravesical installation of MMC.
- Preliminary study in bladder cancer patient with disposable device thus preventing draining of the medicine out of the urinary bladder after mode of affective replication accompanied aneuploidy in pripherd blood lymphocytes of prostate cancer patient.
- 3-D record of trans-rectal Prostatic biopsies medical device – "Navigo". combination trans rectal ultrasound / magnetic resonance imaging system for evaluation prostate tissue a clinical feasibility study.one-arm, single-center, prospective study to assess the safety and efficacy of BioProtect biodegradable implantable balloon in prostate cancer subjects undergoing radiotherapy.

List of Publications

Refereed articles in scientific journals

A-Original Article

2. S. Kravchick, R. Peled, D. Ben-Dor, D. Dorfman, D. Kesari, **S. Cytron**. Comparison of different local anesthesia techniques during TRUS-Biopsies: Prospective pilot study. *Urology*, 65: 109-113, 2005.
3. S. Kravchick, I. Bunkin, E. Stepnov, R. Peled, L. Agulansky, **S. Cytron**. Emergency Extracorporeal Shock Wave Lithotripsy (ESWL) for acute renal colic due to upper Urinary Tract Stones. *J. Endourology*. 19: 1-4, 2005
4. S. Kravchick, D. Shumalinsky, M. Jeshurun-Koren, E. Stepnov, **S. Cytron**. Filling cystoureterography facilitates stone visualization in patients with previously inserted double-J ureteral stents. *Urol Res*. 33(3): 203-5. Epub May 14, 2005
5. .A. Machlenkin, A. Paz, E. Bar Haim, O. Goldberger, E. Finkel, B. Tirosh, I. Volovitz, E. Vadai, G. Lugassy, **S. Cytron**, F. Lemonnier, E. Tzehoval, L Eisenbach. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembran epithelial antigen of prostate-3 as candidates for prostate cancer Immonotherapy. *Cancer Res*. Jul 15; 65(14)6435-42, 2005.
6. S. Kravchick, R. Peled, D. Dorfman, L. Agulansky, D. Ben-Dor, **S. Cytron**. Predictive criteria for prostate cancer detection in man with serum PSA concentration of 2.0 to 4.0 ng/ml. *Urology*. Sep; 66(3):542-6, 2005.
7. S. Kravchick, E. Stepnov, V. Lebedev, L. Linov, O. Leibovici, CL. Ben-Horin, L. Trejo, R. Peled, **S. Cytron**. Non-contrast computerized tomography (NCCT) and dynamic renal scintigraphy (DRS) in the patients with refractory renal colic. *Eur J Radiol*. May 58(2):301-6. E pub Nov 28, 2005.
8. A. Tsivian, M. Neuman, E. Yulish, A. Shtricker, S. Levin, **S. Cytron**, AA. Sidi. Redo midurathral synthetic sling for female stress urinary incontinence. *Int Urogynecology Pelvic Floor Dysfnct*. Jan; 18(1):23-6. Epub Apr 1, 2006.
9. S. Kravchick, B. Yoffe, **S. Cytron**. Modified perianal/pericapsular anesthesia for transrectal biopsy of prostate in patients with anal rectal problems. *Urology* Jan;69(1):139-41, 2007

10. S. Kravchick, I. Bunkin, R. Peled, E. Yulish, D. Ben-Dor, Y. Kravchenko, **S. Cytron**. Patients with Elevated serum PSA and Indwelling Catheter after Acute Urinary Retention. Prospective Study of 63 Patients with 7 year Follow-Up. *J. Endourol.* October 21 (10) 1203-6, 2007.
11. **S Kravchick, Cytron S**, Mamonov A, Peled R, Linov L: Effect of short-term Dutasteride therapy on prostate vascularity in patients with BPH: A pilot study. *Urology*, 73(6):1274-8; 2009. *Impact factor 2.242*
12. **S Kravchick**, Stepnov E, **Cytron S**, Beb-Dor D, Kravchenko Y, Peled R: 7-10 years follow-up of 573 patients with elevated PSA (>4 ng/ml) or/and suspected PRexam: Biopsies protocol and follow-up guides. *J. Endourol*, 23(6):1007-13; 2009. *Impact factor 1.8*
13. **Cytron S**, Greene D, Witzsch U, Nylund P, Bjerklund Johansen TE. Cryoablation of the prostate: technical recommendations. *Prostate Cancer Prostatic Dis.* 2009; 12(4):339-46.
14. Kravchick S, Peled R, **Cytron S**. Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up. *Pathol Oncol Res.* 2011 Jun 8.
15. Grinberg-Rashi H, **Cytron S**, Gelman-Kohan Z, Litmanovitch T, Avivi L. Replication timing aberrations and aneuploidy in peripheral blood lymphocytes of breast cancer patients. *Neoplasia.* 2010 Aug; 12(8):668-74.
16. Nagler A, **Cytron S**, Mashevich M, Korenstein-Ilan A, Avivi L. The aberrant asynchronous replication - characterizing lymphocytes of cancer patients - is erased following stem cell transplantation. *BMC Cancer.* 2010 May 24; 10:230.

Active Participation in Scientific Meetings

A- Abstracts

1. L. Lobic, M. Hassan, D. Shumalinsky, D. Kesari, A. Paz, S. Kravchick, **S. Cytron**. Patient preferences in treatment of Erectile Dysfunction after Cryoablation of Prostate for Prostate cancer. The 9th Congress of the European Society for Sexual Medicine. Vienna, Austria, December 3-6, 2006.
2. A. Paz, D. Shumalinsky, L. Lobic, **S. Cytron**. Suture-less Anastomosis between Bladder Neck and Urethra during Laparoscopic Radical Prostatectomy. The 26th National Congress of Israeli Urological Association. Eilat, Israel, 2006.
3. A. Paz, D. Shumalinsky, L. Lobic, **S. Cytron**. En-Block Closure of Renal Artery and Vein with Endo-GIA during Laparoscopic Nephrectomy. The 26th National Congress of Israeli Urological Association. Eilat, Israel, 2006.
4. L. Lobic, **S. Cytron**, I. Nissenkorn. The use of Prostatic stent in patients with indwelling catheter and high risk for surgery. The 26th National Congress of Israeli Urological Association. Eilat, Israel, 2006.
5. S. Kravchick, Y. Raichlin, L. Gerber, A.B Sela, **S. Cytron**, A. Katzir. Fiberoptic Infrared (FT-IR) Spectroscopy on the Flattened Silver Halides Fiber. A Universal Technique for the Analysis of Urinary Stones Composition in Dry and Liquid Substances. American Urological Association (AUA) Annual Meeting, San Antonio, USA, May 21-26, 2005
6. S. Kravchick, I. Bunkin, E. Stepnov, Z. Bezer, **S. Cytron**. Percutaneous Suprapubic Cystolithotripsy (PCCL): Our approach through a 12 French Suprapubic access. The 23rd World Congress of Endourology. Amsterdam, Netherlands, August 23-26, 2005.
7. S. Kravchick, Y. Rachlin, D. Ben-Dor, A. Katzir, **S. Cytron**. Fiberoptic Infrared (FT-IR) Spectroscopy as a tool for discrimination between normal Urothelium and Transitional Cell Carcinoma (TCC) of different grade; Pilot Study, the 21st Annual EAU Congress, Paris, France, April 5-8, 2006.
8. S. Kravchick, E. Stepnov, V. Lebedev, **S. Cytron**. Non-Contrast Computerized Tomography (NCCT) and Dynamic Renal Scintigraphy (DRS) in the patients with refractory renal colic. The 24th World Congress of Endourology. Cleveland, USA, August 17-20, 2006
9. S. Kravchick, E. Stepnov, V. Lebedev, **S. Cytron**. Retrograde Reno-Ureteroscopy through a Mini-Perc in the supine position. Procedure of choice for selected patients with Cardiopulmonary problems. The 24th World Congress of Endourology, Cleveland, USA, August 17-20, 2006
10. S. Kravchick, E. Yulish, E. Stepnov, **S. Cytron**. Long-Term results of Intravesical DMSO/Lidocaine for Idiopathic Overactive Bladder; Prospective pilot study. The 24th World Congress of Endourology, Cleveland, USA, August 17-20, 2006
11. S. Kravchick, R. Peled, **S. Cytron**. Effect of short-term Dutasteride Therapy on prostate vascularity in patients with BPH; A pilot study. The 22nd Annual EAU Congress, Berlin, Germany, March 21-24, 2007.

12. S. Kravchick, I. Bonkin, R. Peled, **S. Cytron**. Patients with elevated PSA and indwelling Catheter after Acute Urinary Retention; A prospective study of 63 patients with 7 years Follow-Up. The 22nd Annual EAU Congress, Berlin, Germany, March 21-24, 2007.
13. S. Kravchick, R. Peled, E. Yulish, E. Stepnov, D. Ben-Dor, **S. Cytron**. 7-10 Years Follow-Up of 573 patients with elevated PSA (>4ng/ml) or/and suspected PR exam. Part 2: Follow-Up guides, American Urological Association (AUA). Annual Meeting, Orlando, USA, May 17-22, 2008

DEPARTMENT OF OPHTHALMOLOGY



Head of Department

Dr Shmuel Levartovsky, MD

Senior Lecturer of Medicine Ben-Gurion University

shmuell@barzi.health.gov.il

Medical Team:

- Igor Kaiserman MD, MSc, MHA
Vice Chair of Ophthalmology
Department, Head of Cornea
& external eye disease service
*Associated Professor of Medicine
Ben Gurion University*

- David Hauser, MD
*Lecturer of Medicine
Ben Gurion University*

- Ms. Dalia Levi
Head Nurse

Description

The department in Barzilai Medical Center deals with all fields of Ophthalmology aspects both surgical and medical

Shmuel Levartovsky, MD

Head of Ophthalmology

ՅԼՅԼՅԼՅԼ



ՅԼՅԼՅԼՅԼ

List of Publications

A-Original Articles

1. CE Traverso, F. De Feo, A. Messas-Kaplan, P. Denis, **S. Levartovsky**, E. Sellem, F. Badala, Z. Zagorsky, A. Bron and M. Belkin: Long term effect on IOP of stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification. Br J Ophthalmol. 89:425-9,2005
2. G. Sholohov, **S. Levartovsky**: Retained ophthalmic viscosurgical device material in the capsular bag 6 months after phacoemulsification. J Cataract Refract Surg 31:627-9,2005
3. **S. Levartovsky**, A. Springer, H. Leiba, AL Markovich, A. Pollack. Homologous scleral graft for corneal perforation in a child. Cornea 27:230-1,2008
4. Joel Hanhart, Shlomo Vinker, Arie Nemet, **Shmuel Levartovsky**, and Igor Kaiserman: Prevalence of epilepsy among cataract patients. Curr. Eye Res 35: 487-491, 2010

☆ Active Participation in Scientific Meetings

A- Abstracts

1. **S. Levartovsky**, R. Pokroy and S. Levinger: 2005; Intacs in keratoconus. World Cornea Congress V, Washington DC, USA 2005
2. **S. Levartovsky**, G. Sholohov, E. Levinger, S. Levinger, H. Leiba: 2006; Binocular functions following monovision correction with excimer laser surgery. American Society of Cataract and Refractive Surgery Meeting. San Francisco, USA
3. H. Leiba, G. Sholohov, E. Levinger. S. Levinger, **S. Levartovsky**: 2008; the effect of monovision LASIK or PRK correction on binocular functions in presbyopic patients. Annual meeting of American Association for Pediatric Ophthalmology and Starbismus. Washington DC, USA (poster)
4. **S. Levartovsky**. Unpleasant experience with ReSTOR: 2008; American Society of Cataract and Refractive Surgery Meeting. Chicago, USA
5. Kaiserman, A. Y Nemet, I. Bahar, S. **Levartovsky** S. Vinker 2009: Prevalence of chronic conditions among keratoconus patients. American Academy of Ophthalmology, San Francisco, USA
6. **S. Levartovsky**, M. Vershinin, I. Kaiserman, G. Kleinmann, O. Mahler, A. Pollack, A.L. Marcovich 2009: The effect of intracameral injection of vancomycin versus cefuroxime on corneal endothelium. ESCRS, Barcelona, Spain

Igor Kaiserman, MD, MSc, MHA

Vice Chair of Ophthalmology Department

Head of Cornea & External Eye Disease Service

නරඹනුයේ



නරඹනුයේ

Head of Department

Prof Igor Kaizerman, MD, MSc, MHA

Associated Professor of Medicine Ben-Gurion University

igork10@gmail.com

Main Fields of Research Activities

Experimental

1. The effects of corneal collagen cross-linking on IOP measurement in rabbit eyes
2. Harvesting donor corneas with OVD

Current clinical studies

1. Prognostic factors in Acanthameba Keratitis.
2. Improving the nomograms in PRK and LASIK
3. Evaluating the risk factors for cataract in a large cohort
4. The effect of donor age on corneal graft survival
5. IOL calculations after refractive surgery with Pentacam EKR
6. The association of blepharitis and keratoconus
7. Internal astigmatism after cataract surgery

8. Evaluation of the Gallilei Scheimflug camera
9. Evaluation of the results of pterygium surgery with glued conjunctival autograft
10. Treating viral conjunctivitis with Iodine solution

New Technologies

1. Developed a new technique for corneal transplantation – the half top hat technique.
2. Developed a new chopper for cataract surgery – the viscochopper.
3. Developed a new technique for pterygium surgery – the visco-dissection of pterygium.

List of Publications

A-Original Articles

1. Filho PA, Hazarbassanov RM, Grisolia AB, Pazos HB, **KaisermanI**, Gomes JÁ. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol. 2011 Jun;95(6):893-5.
2. Mashor RS, Bahar I, **KaisermanI**, Berg AL, Slomovic A, Rootman DS. Combined penetrating keratoplasty and implantation of iris prosthesis intraocular lenses after ocular trauma. J Cataract Refract Surg. 2011 Mar; 37(3):582-7.
3. **KaisermanI**, Sela T, Domniz Y, Visokovsky M, Suhodrev Y, Munzer G. Flap thickness using the moria one use-plus and moria m2 microkeratomes, J Refract Surg. 2011 Feb; 27(2):89. doi: 10.3928/1081597X-20110105-02.
4. Nemet AY, Vinker S, **KaisermanI**. Associated Morbidity of Blepharitis. Ophthalmology. 2011 Jan 26. [Epub ahead of print]
5. Hendler K, Pe'er J, **Kaiserman I**, Baruch R, Kalickman I, Barak V, Frenkel S. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res. 2011 Jan; 31(1):351-7.
6. Barak V, **Kaiserman I**, Frenkel S, Hendler K, Kalickman I, Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res. 2011 Jan; 31(1):345-9.

7. Bahar I, **Kaiserman I**, Livny E, Slomovic A, Slomovic A. Changes in corneal curvatures and anterior segment parameters after descemet stripping automated endothelial keratoplasty. *Curr Eye Res.* 2010 Nov; 35(11):961-6.
8. Nemet AY, Vinker S, Bahar I, **Kaiserman I**. The association of keratoconus with immune disorders. *Cornea.* 2010 Nov; 29(11):1261-4.
9. Mashor RS, **Kaiserman I**, Kumar N, Sansanayudh W, Rootman D. The effect of successful rebubbling after descemet stripping automated endothelial keratoplasty on endothelial cell counts. *Cornea.* 2010 Aug; 29(8):878-82.
10. Hanhart J, Vinker S, Nemet A, Levartovsky S, **Kaiserman I**. Prevalence of Epilepsy among Cataract Patients. *Curr Eye Res.* 2010 Jun; 35(6):487-91.
11. Nemet AY, Vinker S, Levartovsky S, **Kaiserman I**. Is cataract associated with cardiovascular morbidity? *Eye (Lond).* 2010 Aug; 24(8):1352-8. Epub 2010 Mar 26
12. Bahar I, **Kaiserman I**, Mashor RS, McAllum P, Slomovic A, Rootman D. Femtosecond LASIK combined with astigmatic keratotomy for the correction of refractive errors after penetrating keratoplasty. *Ophthalmic Surg Lasers Imaging.* 2010 Mar-Apr; 41(2):242-9. doi: 10.3928/15428877-20100303-14.
13. Mashor RS, **Kaiserman I**, Kumar NL, Sansanayudh W, Rootman DS. Deep lamellar endothelial keratoplasty: up to 5-year follow-up. *Ophthalmology.* 2010 Apr; 117(4):680-6. Epub 2010 Mar 2.
14. Kumar NL, **Kaiserman I**, Shehadeh-Mashor R, Sansanayudh W, Ritenour R, Rootman DS. IntraLase-enabled astigmatic keratotomy for post-keratoplasty astigmatism: on-axis vector analysis. *Ophthalmology.* 2010 Jun; 117(6):1228-1235.e1. Epub 2010 Feb 16.
15. **Kaiserman I**, Bahar I, Slomovic AR, Rootman DS. Half top hat wound configuration for penetrating keratoplasty: 1-year results. *Br J Ophthalmol.* 2009 Dec; 93(12):1629-33.
16. **Kaiserman I**, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients-is it safe? *Curr Eye Res.* 2009 Jul; 34(7):517-22.

17. KaisermanN, **Kaiserman I**, Hendler K, Frenkel S, Pe'er J. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas. *Br J Ophthalmol*. 2009 Sep; 93(9):1167-71. Epub 2009 Jun 30.
18. Bahar I, **Kaiserman I**, Levinger E, Sansanayudh W, Slomovic AR, Rootman DS. Retrospective contralateral study comparing descemet stripping automated endothelial keratoplasty with penetrating keratoplasty. *Cornea*. 2009 Jun;28(5):485-8
19. KaisermanN, Vinker S, **Kaiserman I**. Statins do not decrease the risk for wet age-related macular degeneration. *Curr Eye Res*. 2009 Apr; 34(4):304-10.
20. McAllum P, Bahar I, **Kaiserman I**, Srinivasan S, Slomovic A, Rootman D. Temporal and seasonal trends in *Acanthamoeba* keratitis. *Cornea*. 2009 Jan; 28(1):7-10.
21. Bahar I, Sansanayudh W, Levinger E, **Kaiserman I**, Srinivasan S, Rootman D. Posterior lamellar keratoplasty--comparison of deep lamellar endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty in the same patients: a patient's perspective. *Br J Ophthalmol*. 2009 Feb; 93(2):186-90. Epub 2008 Nov 19.
22. Bahar I, **Kaiserman I**, Lange AP, Slomovic A, Levinger E, Sansanayudh W, Slomovic AR. The effect of mitomycin C on corneal endothelium in pterygium surgery. *Am J Ophthalmol*. 2009 Mar; 147(3):447-452.e1. Epub 2008 Nov 7.
23. Bahar I, **Kaiserman I**, Sansanayudh W, Levinger E, Rootman DS. Busin Guide vs Forceps for the Insertion of the Donor Lenticule in Descemet Stripping Automated Endothelial Keratoplasty. *Am J Ophthalmol*. 2009 Feb; 147(2):220-226.e1. Epub 2008 Oct 18.
24. Bahar I, **Kaiserman I**, Lange AP, Levinger E, Sansanayudh W, Singal N, Slomovic AR, Rootman DS. Femtosecond laser versus manual dissection for top hat penetrating keratoplasty. *Br J Ophthalmol* 2009 Jan; 93(1):73-8. Epub 2008 Oct 16.
25. Bahar I, Levinger E, **Kaiserman I**, Sansanayudh W, Rootman DS. IntraLase-enabled astigmatic keratotomy for postkeratoplasty astigmatism. *Am J Ophthalmol*. 2008 Dec; 146(6):897-904.e1. Epub 2008 Aug 30.

26. Bahar I, **Kaiserman I**, Srinivasan S, Ya-Ping J, Slomovic AR, Rootman DS.
Comparison of three different techniques of corneal transplantation for keratoconus.
Am J Ophthalmol. 2008 Dec;146(6):905-12.e1. Epub 2008 Aug 23.
27. **Kaiserman I**, Bahar I, Rootman DS. Corneal wound malapposition after penetrating
keratoplasty: an optical coherence tomography study. Br J Ophthalmol. 2008 Aug;
92(8):1103-7.
28. Bahar I, **Kaiserman I**, Weisbrod M, McAllum P, Slomovic A. Extensive versus
limited pterygium excision with conjunctival autograft: outcomes and recurrence
rates. Curr Eye Res. 2008 May; 33(5):435-40.
29. McAllum P, **Kaiserman I**, Bahar I, Rootman D. Femtosecond laser top hat
penetrating keratoplasty: wound burst pressures of incomplete cuts. Arch
Ophthalmol. 2008 Jun; 126(6):822-5.
30. Bahar I, **Kaiserman I**, Srinivasan S, Berger Y, McAllum P, Slomovic A, Rootman D
Manual top hat wound configuration for penetrating keratoplasty. Cornea. 2008 Jun;
27(5):521-6..
31. Vinker S, Alkalay A, Hoffman RD, Elhayany A, **Kaiserman I**, Kitai E. Long-term
adherence to antihypertensive therapy: a survey in four primary care clinics. Expert
Opin Pharmacother. 2008 Jun;9(8):1271-7
32. Bahar I, **Kaiserman I**, McAllum P, Slomovic A, Rootman D. Comparison of posterior
lamellar keratoplasty techniques to penetrating keratoplasty. Ophthalmology. 2008
Sep; 115(9):1525-33. Epub 2008 Apr 28.
33. **Kaiserman I**, Bahar I, Rootman DS. Optical coherence tomography provides insight
into the effect of intacs in keratoconus. Arch Ophthalmol. 2008 Apr; 126(4):571-2.
34. **Kaiserman I**, Bahar I, McAllum P, Slomovic AR, Rootman DS. Suture-assisted vs
forceps-assisted insertion of the donor lenticula during Descemet stripping
automated endothelial keratoplasty. Am J Ophthalmol. 2008 Jun;145(6):986-990.
Epub 2008 Apr 9.

35. **Kaiserman I**, Maresky HS, Bahar I, Rootman DS. Incidence, possible risk factors, and potential effects of an opaque bubble layer created by a femtosecond laser. *J Cataract Refract Surg.* 2008 Mar; 34(3):417-23.
36. Bahar I, **Kaiserman I**, Buys Y, Rootman D. Descemet's stripping with endothelial keratoplasty in iridocorneal endothelial syndrome. *Ophthalmic Surg Lasers Imaging.* 2008 Jan-Feb; 39(1):54-6.
37. Bahar I, **Kaiserman I**, McAllum P, Rootman D. Femtosecond laser-assisted penetrating keratoplasty: stability evaluation of different wound configurations. *Cornea.* 2008 Feb; 27(2):209-11.
38. Bahar I, **Kaiserman I**, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. *Cornea.* 2008 Feb; 27(2):142-7.
39. Bahar I, **Kaiserman I**, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. *Curr Eye Res.* 2008 Jan; 33(1):23-8.
40. **Kaiserman I**, Bahar I, Rootman DS. Half-top-hat--a new wound configuration for penetrating keratoplasty. *Br J Ophthalmol.* 2008 Jan; 92(1):143-6.
41. Bahar I, **Kaiserman I**, Slomovic A, McAllum P, Rootman D. Fibrin glue for opposing wound edges in "Top Hat" penetrating keratoplasty: a laboratory study. *Cornea.* 2007 Dec; 26(10):1235-8. PubMed
42. Greenbaum A, **Kaiserman I**, Avni I. Long-term reversibility of epikeratophakia. *Cornea.* 2007 Dec; 26(10):1210-2.
43. Bahar I, **Kaiserman I**, Trope GE, Rootman D. Non-penetrating deep sclerectomy for glaucoma surgery using the femtosecond laser: a laboratory model. *Br J Ophthalmol.* 2007 Dec; 91(12):1713-4.
44. Bahar I, **Kaiserman I**, Rootman D. Cionni endocapsular ring implantation in Marfan's Syndrome. *Br J Ophthalmol.* 2007 Nov; 91(11):1477-80. Review. Retraction in: *Br J Ophthalmol.* 2010 Dec; 94(12):1695.

45. **Kaiserman I**, Bahar I, Rootman DS. Optical coherence tomography of Descemet membrane separation by the big bubble technique. *Cornea*. 2007 Oct; 26(9):1115-7.
46. Vinker S, Weinfass M, Kasinetz LM, Kitai E, **Kaiserman I**. Web-based question-answering service of a family physician - the characteristics of queries in a non-commercial open forum. *Med Inform Internet Med*. 2007 Jun; 32(2):123-9.
47. Frenkel S, Katz S, Horani A, **Kaiserman I**, Asleh SA, Blumenthal EZ. Estimating intraocular pressure using a glass rod. *Ann Ophthalmol (Skokie)*. 2006 Fall;38(3):195-9.
48. Vinker S, **Kaiserman I**, Karni A, Kitai E, Kasinetz LM, Elhayany A, Nakar S. Urgent referrals to a specialist by family physicians--is the "urgency" real: a prospective study. *Eur J Gen Pract*. 2007; 13(1):37-9.
49. **Kaiserman I**, KaisermanN, Elhayany A, Vinker S. Cataract surgery is associated with a higher rate of photodynamic therapy for age-related macular degeneration. *Ophthalmology*. 2007 Feb;114(2):278-82.
50. Vinker S, **Kaiserman I**, Waitman DA, Blackman S, Kitai E. Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: Does a central electronic medical record make a difference? *Clin Drug Investig*. 2006; 26(9):495-500.
51. **Kaiserman I**, KaisermanN, Elhayany A, Vinker S. Increased risk for herpetic eye disease in patients with allergic conjunctivitis. *Curr Eye Res*. 2006 Sep;31(9):721-5.
52. **Kaiserman I**, KaisermanN, Elhayany A, Vinker S. Risk factors for photodynamic therapy of predominantly classic choroidal neovascularization in age-related macular degeneration. *Am J Ophthalmol*. 2006 Sep; 142(3):441-7.
53. **Kaiserman I**, KaisermanN, Elhayany A, Vinker S. Topical beta-blockers are not associated with an increased risk of treatment for depression. *Ophthalmology*. 2006 Jul; 113(7):1077-80.

54. **Kaiserman I**, KaisermanN, Pe'er J. Long term ultrasonic follow up of choroidal naevi and their transformation to melanomas. *Br J Ophthalmol*. 2006 Aug; 90(8):994-8. Epub 2006 May 3.
55. **Kaiserman I**, KaisermanN, Nakar S, Vinker S. Herpetic eye disease in diabetic patients. *Ophthalmology*. 2005 Dec; 112(12):2184-8. Epub 2005 Oct 20.
56. **Kaiserman I**, Rosner M, Pe'er J. Forecasting the prognosis of choroidal melanoma with an artificial neural network. *Ophthalmology*. 2005 Sep; 112(9):1608.
57. **Kaiserman I**, Amer R, KaisermanN, Pe'er J. Ultrasonographic tissue characteristics of mushroom-shaped uveal melanoma. *Curr Eye Res*. 2005 Mar; 30(3):171-7.
58. **Kaiserman I**, KaisermanN, Nakar S, Vinker S. Dry eye in diabetic patients. *Am J Ophthalmol*. 2005 Mar; 139(3):498-503
59. **Kaiserman I**, KaisermanN, Nakar S, Vinker S. The effect of combination pharmacotherapy on the prescription trends of glaucoma medications. *J Glaucoma*. 2005 Apr; 14(2):157-60.
60. Hazarbassanov R, Ben-Haim O, Varssano D, Grinbaum A, **Kaiserman I**. Alcohol- vs hypertonic saline-assisted laser-assisted subepithelial keratectomy. *Arch Ophthalmol*. 2005 Feb; 123(2):171-6. Erratum in: *Arch Ophthalmol*. 2005 Apr; 123(4):499.

B-Case Reports

1. **Kaiserman I**, Or R. Laser Photocoagulation for Central Serous Retinopathy associated with Graft versus Host Disease. *Ocular Immunology and Inflammation*, 13(2-3): 249 - 256. 2005.
2. **Kaiserman I**, KaisermanN. Severe blepharoconjunctivitis induced by a peeling mask containing trichloroacetic acid. *Ocular Immunology and Inflammation*, 13(2-3): 257 - 259. 2005.
3. Bahar I, **Kaiserman I**, Buys, Y, Rootman D. Descemet's Stripping with Endothelial Keratoplasty in Iridocorneal Endothelial Syndrome. *Ophthalmic Surgery, Lasers &*

Imaging. 2008, 39(1):54-56.

4. **Kaiserman I**, Bahar I., Rootman DS. Optical coherence tomography provides insight into the effect of intacs in keratoconus. *Archives of Ophthalmology*. 126(4):571-2, 2008.
5. Lange AP, Bahar I, Sansanayudh W, **Kaiserman I**, Slomovic AR. Salzmann nodules -- a possible new ocular manifestation of Crohn's disease: a case report. *Cornea*. 2009 Jan; 28(1):85-6.

Active Participation in Scientific Meetings

A- Abstracts

1. Hazarbassanov R, Varssano D, Grinbaum A, **Kaiserman I**. Correlation Between Corneal and Total Wavefront Aberrations Measured at Various Optic Zones Pre- and Six Month Post-LASIK. Annual meeting of the association for research in vision and ophthalmology (ARVO). Fort Lauderdale, Florida USA. May 1-5, 2005
2. **Kaiserman I**, Kaiserman N, Nakar S, Vinker S. Increased prevalence of keratoconjunctivitis sicca in diabetes. Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 17-18, 2005.
3. **Kaiserman I**, Kaiserman N, Pe'er J. Transformation of choroidal nevi into choroidal melanoma. Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 17-18, 2005.
4. **Kaiserman I**, Kaiserman N, Pe'er J. Ruthenium-106 plaque brachytherapy for large choroidal melanomas. Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 17-18, 2005.
5. Lalazar G, **Kaiserman I**, Lalazar H, Frucht-pery J. Color contrast sensitivity after laser in situ keratomileusis. Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 17-18, 2005.
6. **Kaiserman I**, Kaiserman N, Varssano D, Grinbaum A, Hazarbassanov R. Long term effect of postoperative corneal steepness on hyperopic LASIK outcome. Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 17-18, 2005.
7. **Kaiserman I**, Kawar M, Rahamimoff R. Calcium based intercellular communication in damaged corneal keratocytes. 3rd international refractive and corneal surgery conference. Dead-Sea, Israel. May 18-21, 2005.
8. Varssano D, **Kaiserman I**, Grinbaum A, Hazarbassanov R. Correlation between corneal and total wavefront aberrations measured at various optic zones pre- and six month post- Wavefront guided LASIK. 3rd international refractive and corneal surgery conference. Dead-Sea, Israel. May 18-21, 2005.
9. Kawar M, Rahamimoff R, **Kaiserman I**. Calcium based communication in keratocytes. Visual function – insights from the revolution in biology at the molecular level. Tel-Aviv, Israel. June 15-17, 2005.
10. Varssano D, **Kaiserman I**, Schreiber L, Russ V., Sheinin Y. and Hazarbassanov R. Diluted Alcohol and Hypertonic Saline on the Corneal Epithelium: Light and Electron Microscopic Study. Annual meeting of the American Society of Cataract and Refractive Surgery & American Society Ophthalmic Administrators (ASCRS & ASOA). Washington, DC, USA. April 15- 20, 2005.
11. **Kaiserman I**, Kaiserman N, Elhayany A, Vinker S. Do topical beta-blockers increase the risk for depression in glaucoma patients? Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 9-10, 2006.
12. Hazarbassanov R, Grinbaum A, Varssano D. and **Kaiserman I**. Mean Changes and Correlation Between Corneal and Total Wavefront Aberrations at Various Optic Zones: Standard Versus Wavefront-Guided LASIK. Annual meeting of the American Society of Cataract and Refractive Surgery & American Society Ophthalmic Administrators (ASCRS & ASOA). San Francisco, CA, USA. April 17- 22,

- 2006.
13. **Kaiserman I**, Kaiserman N. Does Ocular Allergy Increase the Risk for Herpetic Eye Disease? Annual meeting of the American Academy of Ophthalmology and the Asia Pacific Academy of Ophthalmology. Las Vegas, Nevada, USA. November 11-14, 2006.
 14. Bahar I, **Kaiserman I**, McAllum P, Slomovic A.R, Rootman D.S. Fibrin Glue for Opposing Wound Edges in "Top Hat" Penetrating Keratoplasty: A Laboratory Study. Annual meeting of the association for research in vision and ophthalmology (ARVO). Fort Lauderdale, Florida USA. May 6-10, 2007.
 15. Bahar I, **Kaiserman I**, McAllum P, Rootman D.S, Slomovic A.R. Subconjunctival and Intrastromal Avastin injection for corneal neovascularization. Annual meeting of the Canadian Ophthalmological Society (COS). Montreal Québec, Canada. June 20-23, 2007.
 16. McAllum P, Srinivasan S, **Kaiserman I**, Bahar I, Slomovic A.R, Rootman D.S. Acanthamoeba Keratitis: A New Epidemic? Annual meeting of the Canadian Ophthalmological Society (COS). Montreal Québec, Canada. June 20-23, 2007.
 17. **Kaiserman I**, Maresky H.S, Bahar, I, Rootman, D.S. Incidence, risk factors and effects of opaque bubble layers created by the IntraLase femtosecond laser. Annual meeting of the Canadian Ophthalmological Society (COS). Montreal Québec, Canada. June 20-23, 2007.
 18. **Kaiserman I**, Maresky H.S, Bahar, I, Rootman, D.S. Incidence, risk factors and effects of opaque bubble layers created by the IntraLase femtosecond laser. Annual meeting of the Israel Refractive Surgery Society. Hertzelia, Israel. October 19, 2007.
 19. McAllum P., Bahar I., **Kaiserman I**, Slomovic A.R., Rootman D.S. PKP, DLEK, DSEK, and DSAEK for Corneal Endothelial Failure: How Do They Compare? Annual meeting of the American Academy of Ophthalmology and the Asia Pacific Academy of Ophthalmology. New Orleans, Louisiana, USA. November 10-13, 2007.
 20. Bahar I, **Kaiserman I**, McAllum P, Rootman D.S, Slomovic A.R. Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Annual meeting of the American Academy of Ophthalmology and the Asia Pacific Academy of Ophthalmology. New Orleans, Louisiana, USA. November 10-13, 2007.
 21. Bahar I, **Kaiserman I**, Srinivasan S, McAllum P, Slomovic A.R, Rootman D.S. Top Hat Wound Configuration for Penetrating Keratoplasty. Annual meeting of the American Academy of Ophthalmology and the Asia Pacific Academy of Ophthalmology. New Orleans, Louisiana, USA. November 10-13, 2007.
 22. **Kaiserman I**. OCT of the anterior segment. Meeting of the Israel Cornea Society. Tel-Aviv, Israel. November 30, 2007.
 23. **Kaiserman I**, Bahar I, Rootman DS. Cionni endocapsular ring implantation in Marfan's Syndrome. The ocular microsurgical meeting. Eilat, Israel. January 9-12, 2008.
 24. **Kaiserman I**, Bahar I, McAllum P, Slomovic A.R. Rootman DS. A prospective comparison of DLEK, DSEK, DSAEK and PKP. The ocular microsurgical meeting. Eilat, Israel. January 9-12, 2008.
 25. Barak V, **Kaiserman I**, Frenkel S, Hendler K, Kalickman I, Folberg R, Pe'er J. The Role of Serum Biomarkers In Predicting Metastatic Uveal Melanoma. 28th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 13-14, 2008.
 26. Hendler K, Frenkel S, Baruch R, **Kaiserman I**, Folberg R, Kalickman I, Barak V, Pe'er J. Serum Biomarkers Vs. Liver Function Tests In The Early Diagnosis Of Metastatic

- Uveal Melanoma. 28th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 13-14, 2008.
27. **Kaiserman I**, Bahar I, Rootman DS. Corneal Wound Malapposition After Penetrating Keratoplasty – An Optical Coherence Tomography Study. 28th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 13-14, 2008.
 28. **Kaiserman I**, Bahar I, Weisbrod M, McAllum P, Slomovic AR. Radical Versus Partial Subconjunctival Pterygium Excision With Conjunctival Autograft: Outcomes And Recurrence Rates. 28th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 13-14, 2008.
 29. **Kaiserman I**, Bahar I, Slomovic AR, McAllum P, Rootman DS. Fibrin Glue For Opposing Wound Edges In “Top Hat” Penetrating Keratoplasty. 28th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 13-14, 2008.
 30. Hendler K, Frenkel S, Baruch R, **Kaiserman I**, Folberg R, Kalickman I, Barak V, Pe'er J. Comparison of Serum Biomarkers and Liver Function Tests in the Early Diagnosis of Metastases From Uveal Melanoma. Annual meeting of the association for research in vision and ophthalmology (ARVO). Fort Lauderdale, Florida USA. April 27-May 1, 2008.
 31. Barak V, **Kaiserman I**, Frenkel S, Hendler K, Kalickman I, Folberg R, Pe'er J. The Dynamics of Serum Biomarkers and Their Role in Predicting Metastatic Uveal Melanoma. Annual meeting of the association for research in vision and ophthalmology (ARVO). Fort Lauderdale, Florida USA. April 27-May 1, 2008.
 32. Bahar I, **Kaiserman I**, Weisbrod M, McAllum P, Slomovic A. Extensive versus limited pterygium excision with conjunctival autograft: outcomes and recurrence rates. Canadian Ophthalmological Society Meeting, Whistler, BC Canada. June 11-14, 2008.
 33. Bahar I, **Kaiserman I**, Lange A, Slomovic A, Levinger E, Sansanayudh W, Slomovic A. The effect of mitomycin C on corneal endothelium in pterygium surgery. Canadian Ophthalmological Society Meeting, Whistler, BC Canada. June 11-14, 2008.
 34. Bahar I, **Kaiserman I**, Lange A, Levinger E, Sansanayudh W, Singal N, Slomovic A, Rootman D. Femtosecond laser versus manual dissection for top hat penetrating keratoplasty. Canadian Ophthalmological Society Meeting, Whistler, BC Canada. June 11-14, 2008.
 35. **Kaiserman I**, Bahar I, Slomovic A, Rootman D. Fine-tuning wavefront-guided myopic LASIK: should we aim for the wavefront refraction with the Visx Star S4? Canadian Ophthalmological Society Meeting, Whistler, BC Canada. June 11-14, 2008.
 36. Raskin E, **Kaiserman I**, Amer R. Fuchs' Heterochromic Iridocyclitis: Clinical Manifestations in 19 Patients. 7th International Symposium on Uveitis - International Uveitis Study Group. Constance, Germany. September 9 – 12. 2008.
 37. Hauser D, Mostovoy D. **Kaiserman I**. Laser Photocoagulation Following Intravitreal Bevacizumab for Central Vein Occlusion. American Society of Retina Surgeons annual meeting. Maui, HI USA. October 11 - 15, 2008.
 38. **Kaiserman I**, Nemet A, Levartovsky S, Vinker S. Prevalence of chronic diseases among patients undergoing cataract surgery. Annual meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology. Atlanta, Georgia, USA. November 8-11, 2008.
 39. Bahar I, Levinger E, **Kaiserman I**, Sansanayudh W, Rootman DS. IntraLase-Enabled

- Astigmatic Keratotomy for Postkeratoplasty Astigmatism. Annual meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology. Atlanta, Georgia, USA. November 8-11, 2008.
40. **Kaiserman I**. Variations in Big-Bubble deep anterior lamellar keratoplasty. The ocular microsurgical meeting. Eilat, Israel. February 9-12, 2009.
 41. Bahar I, **Kaiserman I**, Levinger E, Sansanayudh W, Slomovic AR. The effect of mitomycin c on corneal endothelium in pterygium surgery. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 42. **Kaiserman I**, Bahar I, McAllum P, Slomovic AR, Rootman DS. Prognostic factors in acanthamoeba keratitis. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 43. Bahar I, **Kaiserman I**, Sansanayudh W, Levinger E, Rootman DS. Busin guide versus forceps for the insertion of the donor lenticule in descemet stripping automated endothelial keratoplasty. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 44. **Kaiserman I**, Nemet A, Vinker S, Levartovsky S. Prevalence of chronic diseases among patients undergoing cataract surgery. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 45. Bahar I, Vinker S, **Kaiserman I**. The effect of topical steroids on blood glucose profile in diabetic patients. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 46. Kaiserman N, **Kaiserman I**, Hender K, Frenkel S, Peer J. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 47. Raskin E, **Kaiserman I**, Amer R. Long -term follow-up of fuchs' heterochromic iridocyclitis patients. 29th Annual meeting of the Israel Society for Vision & Eye Research. Neve-Ilan, Israel. March 12-13, 2009.
 48. Varshinin M, **Kaiserman I**, Kleinman G, Maler O, Levartovsky S, Polak A, Marcovitch A. The effect of intra-cameral Vancomycin and Ceforoxim injected after cataract surgery on corneal endothelial and thickness. Meeting of the Israel Ophthalmological Society. March 18, 2009 Ramat-Gan Israel.
 49. **Kaiserman I**, Bahar I., Slomovic A, Rootman D. Half-top-hat penetrating keratoplasty. Meeting of the Israel Ophthalmological Society. March 18, 2009 Ramat-Gan Israel.
 50. Bahar I, Levinger E, **Kaiserman I**, Sansanayudh W, Rootman DS. IntraLase-Enabled Astigmatic Keratotomy for Postkeratoplasty Astigmatism. Meeting of the Israel Ophthalmological Society. March 18, 2009 Ramat-Gan Israel.
 51. Kaiserman N, Frenkel S, Hender K, **Kaiserman I**, Pe'er J. Treating thick posterior uveal melanomas by Ru-106 brachytherapy. 35th Ophthalmic Oncology Group Meeting. April 1st - 4th, 2009. Jerusalem, Israel.
 52. Pe'er J, Frenkel S, Hender K, **Kaiserman I**, Kaiserman N. Ruthenium-106 Plaque Therapy for Posterior Uveal Melanomas Thicker Than 8 mm. Annual meeting of the association for research in vision and ophthalmology (ARVO). Fort Lauderdale, Florida USA. May 3-7, 2009.
 53. **Kaiserman I**, Nemet AY., Bahar I, Levartovsky S, Vinker S. Prevalence of Chronic Conditions Among Keratoconus Patients. Joint Meeting of the American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. San Francisco, CA, USA. October 24-27, 2009.

54. Bahar I, **Kaiserman I**, Vinker S. The Effect of Topical Steroids on Blood Glucose Profile in Diabetic Patients. Joint Meeting of the American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. San Francisco, CA, USA. October 24-27, 2009.
55. **Kaiserman I**, McAllum P, Bahar I, Srinivasan S, Slomovic AR, Rootman DS. Prognostic Factors in Acanthamoeba Keratitis. Joint Meeting of the American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. San Francisco, CA, USA. October 24-27, 2009.
56. **Kaiserman I**, Nemet AY, Bahar I, Levartovsky S, Vinker S. Prevalence of Systemin Disease Among Keratoconus Patients. . 30th Annual meeting of the Israel Society for Vision & Eye Research. Aveneu, Israel. March 11-12, 2010.
57. Bahar I, Vinker S, Livny E, **Kaiserman I**. Association Between Keratoconus And Renal Diseases. 30th Annual meeting of the Israel Society for Vision & Eye Research. Aveneu, Israel. March 11-12, 2010.
58. Bahar I, Shehadeh-Mashour R, **Kaiserman I**. Berg Amy L., Slomovic A., Rootman D. Prosthetic Iris Implantation For Traumatic Iris Deficiency. 30th Annual meeting of the Israel Society for Vision & Eye Research. Aveneu, Israel. March 11-12, 2010.
59. Bahar I, Bialer O, Weinberger D, **Kaiserman I**. Accuracy of Scheimpflug Holladay Equivalent Keratometry Readings After Corneal Refractive Surgery. 30th Annual meeting of the Israel Society for Vision & Eye Research. Aveneu, Israel. March 11-12, 2010.
60. Bahar I, **Kaiserman I**, Livny E, Slomovic A, Slomovic A. Changes in Corneal Curvatures and Anterior Segment Parameters After Descemet Stripping Automated Endothelial Keratoplasty. 30th Annual meeting of the Israel Society for Vision & Eye Research. Aveneu, Israel. March 11-12, 2010.
61. **Kaiserman I**, Zadok D, Lukovetsky S, Pokroy R, Levian L, Padova H, Assa A. Progression of Myopia And Astigmatism In Aircrew . 81st Annual meeting of the aerospace medical association. Phoenix, AZ, USA May 9-13, 2010.
62. Levian L, **Kaiserman I**, Lukovetsky S, Wand O, Padova H. Long -Term Change of The Refractive Error in Military Aviators Using The Integrated Helmet and Display Sighting System .Assa A. 81st Annual meeting of the aerospace medical association. Phoenix, AZ, USA May 9-13, 2010.

B- Invited plenary lectures at conferences/meetings

1. **Kaiserman I**. Refractive Surgery and combat military service. The 3rd International Refractive & Corneal Surgery Conference. Dead Sea Israel. May 18-21 2005.
2. **Kaiserman I**. Neural network predictive modeling for melanoma. ARVO ocular oncology collaborative research course. Ft. Lauderdale, FL. USA. April 30, 2005.
3. **Kaiserman I**. Topical beta-blockers are not associated with an increased risk of treatment for depression. The Editors' Choices Symposium of the Annual meeting of the American Academy of Ophthalmology and the Asia Pacific Academy of Ophthalmology. Las Vegas, Nevada USA. November 11-14, 2006.

DEPARTMENT OF PHARMACY SERVICES



Head of Department

Mgr Ahuva Lustig, MSc.Pharm.

ahuva@barzi.health.gov.il

Pharmacists Team:

- | | |
|------------------------------------|--|
| ▪ Rachel Sokol, BSc. | Deputy director |
| ▪ Shahar Aflalo, MSc.Pharm | Clinical pharmacist |
| ▪ Sigal Kerekesh Spirer, MSc.Pharm | Supervisor of Hemato-oncology service |
| ▪ Oliana Rubanov, MSc.Pharm | Supervisor of Centralized IV admixture service: |
| ▪ Nitzan Egozi, BSc.Pharm | Supervisor of services to Surgical Division |
| ▪ Ifat Telker, BSc.Pharm | Supervisor of services to Internal Diseases Division |

Additional Pharmacy team

- | | |
|----------------------|----------------------|
| ▪ Ms. Rita Kuniver | Assistant pharmacist |
| ▪ Ms. Lily Mil | Assistant pharmacist |
| ▪ Ms. Evgenia Fisher | Assistant pharmacist |

Additional logistic team

- Ms Edna Giassi
- Ms Dandy Izac
- Mr Levy Kapach

Description

The Department of Pharmacy Services is a service unit, which provides all pharmaceuticals required in the treatment of patients, teaching and research essential to the continued well being of patients.

The Head of Pharmacy Services, Mgr Ahuva Lustig is responsible for:

Management of personnel and financial resources; purchasing and inventory; handling of physical resources; administrative considerations of drug distribution and control systems; clinical and drug information services; quality assurance programs; development of safety and security procedures; participation in clinical and investigational drug trials.

Main Pharmacy Services focus in:

- *Drug Distribution* -The Pharmacy is the main logistical support for the distribution of pharmaceuticals for all inpatient patients and clinics. At present, all beds are covered by the traditional system (individual patient prescription and floor stock).
- *C.I.V.A. Services*- Provides a 36-hour supply of ready to use intravenous doses to all hospitalized patients.
- *T.P.N Service*- Provides consulting and monitoring services as well as aseptic preparations to all patients supported by T.P.N.
- *Ambulatory Care Pharmacy*- Prescription service is provided for soldiers, hospital employees and outpatients who require special medications.
- *Oncology Pharmacy*- Provides preparation of all parental cancer chemotherapy, drug information and monitoring of all patients receiving cancer therapy in hospital.
- *Perinatal Services*- Provides Unit Dose Distribution System to neonatal intensive care unit and pediatric department.
- *Drug Information Service*- Provides pharmaceutical, pharmacological and therapeutic information to all the medical staff of the Hospital.
- *Investigation Drug Service*- It is a Hospital mandated service, which provides support to clinical investigators involved in studies of drugs in humans. This includes acquisition, storage, preparation and dispensing of the drugs used in the study.
- *Tutorial Service*- Pharmacology lectures to nurses and other immigrant health care staff (physicians, microbiologists). Clinical instructors for pharmacy students at the "Ben- Gurion University of the Negev" Beer-Sheva, and the Hebrew University at Jerusalem. Instructors for internship over the sea pharmacy students

Mgr Ahuva Lustig, MSc.Pharm

Director of pharmacy services

תמונת מנהל



תמונת מנהל

Active Participation in Scientific Meetings

A-Abstract

5. **Lustig A**, Sokol R, Tesler J & Schneider R. "שימוש מונע בסגר אנטיביוטי" בהמודיאליזה". Annual meeting of the Israeli Society of Biopharmacy and Clinical Pharmacy Conference. Israel 2005.
6. **Lustig A**, Sokol R, Peled R. & David T: "Nurse's evaluation of pharmacist's services - a hospital survey" – 2005. Pharm World Sci .27: 290-295
7. **Lustig A**, Sokol R, Peled R & David T. "Nurses' evaluation of clinical pharmacists' services- a hospital survey". 2005 ASHP Boston, USA
8. **Lustig A**, & Sokol R.: "The role of pharmacist 'communication in patient safety and pharmacotherapy effectiveness", 2006 ESCP. Vienna, Austria.
9. **Lustig A**, Sokol R & Tesler J. "A multifaceted intervention program to reduce drug expenditure." 2007. EJHP. Maastricht, Netherlands.
10. **Lustig A**, Kerekesh S. "Evaluation of pharmacy input to prevent drug errors in Barzilai Medical Center". Info 2008 Annual Conference. Tel-Aviv, Israel.

11. **Lustig A.** & Cohen T. "פרדיגמה להקטנת עלויות תרופות בחדרי ניתוח" כנס השני לשיפור איכות השרות במדינת ישראל. ים המלח ישראל . 2008.
12. **Lustig A.** "Enhancement of Clinical Pharmacy Services in Israel" -2010. First National Meeting of clinically involved Pharmacists in Israel. Tel-Aviv, Israel
13. Aflalo S & **Lustig A.** "The pharmacist as initiator of a clinical study – from assembling a formulation to patient outcome TSCEM catheter lock in haemodialytic patients" 2010. First National Meeting of clinically involved Pharmacists in Israel. Tel-Aviv. Israel
14. **Lustig A.** & Kerekesh S. "An Optimization model to reduce tPA expenditure". 2011. EACPT. Budapest. Hungary.
15. **Lustig A.** "Benchmarking of pharmacy budget between two peripheral hospitals ". 2011. Israel's Health Economics meeting. Hedera .Israel
16. **Lustig A.**, Aflalo S & Egozi N. "Prevention of dialysis catheter complications with a new antimicrobial lock solution" 2011. FIP. Hyderabad, India.
17. **Lustig A.**, S Aflalo and A. Vexler. "Novel catheters lock solution in prevention of hemodialysis catheter complications- Pharmacy formulation". 2011. ACCP Congress.Chicago, USA

Competitive Research Grants

- 1993 Project: A cost effectiveness evaluation of antibiotic treatment in Community-acquired pneumonia. Awarded by the Chief Scientist of the Ministry of Health
Principal Investigators: Scharf S & Lustig A.
- 1994 Project: Antimicrobial treatment: drug prescribing patterns for Hospitalized patients. Awarded by the Chief Scientist of the Ministry of Health.
Principal Investigators : Enbon A & Lustig A.
- 1995 Project: Evaluation of an educational program to prevent Nosocomial methicillin resistant Staphylococcus Aeruginosa Infection. Awarded by the Chief Scientist of the Ministry of Health Principal Investigators: Mishal I. & Lustig A.
- 1998 Project: Prescribing errors of drugs in a general hospital in Israel. Awarded by the Chief Scientist of the Ministry of Health
Principal Investigators: Scharf S. & A Lustig

ALLERGY AND CLINICAL IMMUNOLOGY SERVICE

תורבות



תורבות

Head of Service

Dr Eli Magen, MD

Lecturer of Medicine Ben Gurion University

elima@barzi.health.gov.il

תורבות

Medical Team:

Yuri Zeldin, MD

Allergy & Clinical Immunology

Outpatient Clinic

Instructor of Medicine Ben Gurion University

Cohen Ziona, MSc

Clinical Immunology Laboratory

Description

The Allergy and Clinical Immunology Service offers consultation and referral for all patients with immunologic/allergic disorders. In addition to disorders such as allergic rhinitis (hay fever), asthma, sinusitis, insect allergy, food allergy, vasculitis syndromes, skin allergic and immunological disorders (special expertise in chronic urticaria and contact dermatitis), penicillin and other drug allergies, the staff has particular expertise in adult immunodeficiency disorders (including HIV/AIDS). In collaboration with the Clinical Immunology laboratory, children with suspected immunodeficiency are also evaluated and treated. Immunologic evaluation includes studies such as antibody and complement levels, IgG subclasses, lymphocyte and neutrophils function, and delayed hypersensitivity skin testing.

As a referral Immunology laboratory, we perform full complement tests, (C1 inhibitor, C2, C3, C4, C5-C9, a total complement activity (CH50 or CH100). Other complement components are also evaluated as needed to look for complement deficiencies. We carry out complement laboratory evaluation for all Israeli Medical centers in cases of recurrent microbial infections, autoimmune diseases, hereditary and acquired angioedema, and various types of kidney immune diseases.

Research Activity

Our research focus is multidisciplinary and spans basic immunologic studies and clinical trials. Translational research studies are aimed at uncovering the mechanisms of endothelial/mesenchymal progenitor cells and complement interaction in immune inflammation, on discovering pathophysiologic processes involved in the initiation and propagation of allergic responses in the lung (asthma), skin (eczema), upper respiratory tract (allergic rhinitis), and vascular immunopathology (especially in arterial hypertension).

Clinical research studies focus on uncovering clinical, epidemiologic and therapeutic principles concerning chronic idiopathic/autoimmune urticaria and skin allergic diseases. For this purpose we intend in the near future to establish allergic dermatology unit.

List of Publications

1. **Magen E**, Borkow G, Bentwich Z, Mishal J, Scharf S. Can worms defend our hearts? - Chronic helminthic Infections may attenuate the development of cardiovascular diseases. *Med Hypotheses*. 2005; 64(5):904-9.
2. **Magen E**, JR. Viskoper, J. Mishal, R. Priluk, D. London, C. Yosefy. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. *Journal of Human Hypertension*; 2005; (7), 1-7
3. J. Gabbay, J. Mishal, **Magen E**, R. Zatcoff, Y. Shemer-Avni and G. Borkow. Copper Oxide Impregnated Textiles with Potent Biocidal Activities. *Journal of Industrial Textiles*. 2005, 4; 78-83
4. Sthoeger Z, Neiman A, Elbirt D, Zinger H, **Magen E**, Burstein R, Eitan S, Abarbanel J, Mozes E. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. *Am J Med Sci*. 2006 Jan; 331(1):4-9.
5. **Magen E**, Yosefy C, Viskoper RJ, Mishal J. Treatment of allergic rhinitis can improve blood pressure control. *J Hum Hypertens*. 2006 Nov; 20(11):888-93.
6. **Magen E**, Mishal J, Schlesinger M. Sensitizations to allergens of TRUE test in 864 consecutive eczema patients in Israel. *Contact Dermatitis*. 2006 Dec;55(6):370-1.
7. **Magen E**, Mishal J, Schlesinger M, Scharf S. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. *Helicobacter*. 2007 Oct; 12(5):567-71. (IF - 2,47)
8. Mishal J, Embon A, Darawshe A, Kidon M, **Magen E**. Community acquired acute bacterial meningitis in children and adults: An 11-year survey in a community hospital in Israel. *European Journal of Internal Medicine* 2008 Oct; 19(6):421-6. (IF-1,045)
9. Zeldin Y, Weiler Z, Cohen A, Kalinin M, Schesinger M, Kidon M, **Magen E**. Efficacy of nasal Staphylococcus aerius eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. *Ann Allergy Asthma Immunol*. 2008 Jun; 100(6):608-11.

10. Zeldin Y, Kidon MI, **Magen E**, Bibi H, Cohen A, Waisel Y, Kivity S. Impact of specific allergen sensitization on the prevalence of asthma in patients with allergic rhinitis from adjacent distinct geographic areas. *Ann Allergy Asthma Immunol.* 2008 Jul; 101(1):30-4.
11. Vitkovsky Y, Kuznik B, Solpov A, **Magen E**. Status of platelet-lymphocyte subpopulations aggregation in circulating blood of patients with type 1 diabetes with and without diabetic nephropathy. *Isr Med Assoc J.* 2008 Oct;10(10):691-4 (IF-0,626)
12. **Magen E**, Mishal J, Paskin J, Glick Z, Zeldin Y, Viskoper R, Schlesinger M. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. *Journal of Clinical hypertension.* 2008 Sep;10(9):677-83.
13. Zeldin Y, Weiler Z, **Magen E**, Tiosano L, Kidon MI. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. *Isr Med Assoc J.* 2008 Dec;10(12):869-72.
14. **Magen E**, Agmon-Levin N, Elbirt D, Mishal J, Stoecker Z. Eradication of helicobacter pylori infection can facilitate immune reconstitution in patients with HIV-1 infection. *International Journal of Infectious diseases.* 2010 Apr;14(4):e322-7.
15. Members of the writing group for the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)-Evaluation of Subcutaneous Proleukin in a Randomized International Trial (**ESPRIT Study Group**) and the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) Scientific Committee. Interleukin-2 therapy in patients with HIV infection. *N Engl J Med.* 2009 Oct 15;361(16):1548-59.
16. Weiler Z, Zeldin Y, **Magen E**, Zamir D, Kidon MI. Pulmonary function correlates with arterial stiffness in asthmatic patients. *Respir Med.* 2010 Feb;104(2):197-203.
17. **Magen E**, Feldman A, Cohen Z, Ben Alon D, Minz E, Chernyavsky A, Linov L, Mishal J, Schlezinger M. Circulating Endothelial Progenitor Cells, Th1/Th2/Th17 Related Cytokines, Complement and Endothelial Dysfunction in Resistant Hypertension. *Am J Med Sci.* 2010 Feb;339(2):117-22.

18. Elbirt D, Asher I, Broda K, Werner B, Mahlev-Guri K, Gradstein S, Burke M, Cohen Y, Tadessa S, Radain-Sade S, **Magen E**, Sthoeger Z. Israeli-Migrants From Sub-Saharan Africa (Ethiopia) and HIV: Medical and Social Issues - The Experience of One Major HIV Center. *Int Public Health J* 2010; 2(3):329-347
19. **Magen E**, Feldman A, Cohen Z, Alon DB, Linov L, Mishal J, Schlezinger M. Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension. *Am J Med Sci.* 2010 May; 339(5):415-9. (IF- 1,355)
20. **Magen E**, Mishal J, Feldman VK, Kidon M, Schlesinger M, Sthoeger Z. Increased platelet volume and CRP in spontaneous chronic urticaria patients with a positive autologous serum skin test. *Am J Med Sci.* 2010 Jun;339(6):504-8.
21. **Magen E**, Mishal J, Schlesinger M. Impact of contact sensitization in chronic spontaneous urticaria. *Am J Med Sci.* 2011 Mar; 341(3):202-6.
22. **INSIGHT-ESPRIT Study Group**. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). *HIV Med.* 2011 Apr; 12(4):219-27. (IF- 1,355).
23. **Magen E**, Mishal J. L-Thyroxine treatment is not effective in patients with Chronic Idiopathic Urticaria and Thyroid Autoimmunity. *International Journal of Dermatology.* 2011 Mar; (Accepted). (IF- 1,177).
24. **Magen E**, Mishal J, Schlesinger M. Clinical and laboratory features of antihistamine resistant chronic spontaneous urticaria. *Ann Allergy Asthma Immunol.* 2011 Apr;(Accepted)
25. **Magen E**, Schlesinger M. Characteristics of chronic spontaneous urticaria in elderly. *International Journal of Dermatology.* 2011 Apr; (Accepted).

Case reports and reviews

1. **Magen E**, Elbirt D, Sthoeger Z. Cardiovascular disease prevention and treatment in HIV-patients. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus. *Isr Med Assoc J.* 2005 Apr; 7 (4):252-6.



Editor: **ORNIT COHEN** M.Med.Sc